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SUMMARY 
Introduction. Alzheimer’s disease is the most common neurodegenerative disease and 
leading cause of dementia globally, with an increasing prevalence especially in developing 
countries such as South Africa. Currently, no single disease modifying treatment exists.. 
Alzheimer’s disease has a complex pathophysiology with the main causative factor involving 
defective proteolytic pathways, including the process of macroautophagy, and toxic amyloid 
beta aggregation. In addition, metabolic perturbations as well as disrupted mitochondrial 
dynamics are implicated. These disruptions culminate in neuronal cell death. Recently, 
ketone bodies have shown beneficial effects in the context of neurodegenerative diseases 
including Alzheimer’s disease, indicating improvements in both molecular disruptions as 
well as cognition. However, although literature implicates a role for autophagy in alleviating 
protein accumulation, the mechanism of action remains largely unclear. 
Aims. The aim of this project was therefore assess the effects of the ketone body beta-
hydroxybutyrate in neuronal cells under basal conditions and in an injury model. We aimed 
to assess four parameters intimately linked to cellular survival in these two models: cellular 
viability, autophagic flux, mitochondrial network morphology and intracellular ATP supply. 
We hypothesized that ketone bodies will protect neurons from paraquat-induced 
neurotoxicity by increasing ATP levels through increasing autophagic flux. 
Methods. GT1-7 cells were cultured using DMEM supplemented with 10% FBS under 
standard conditions (5% CO2, 37 °C). To assess the role of ketone bodies under basal 
conditions, Western blot analysis of amyloid precursor protein (APP), amyloid beta (Aβ), 
beta site APP cleaving enzyme (BACE), p62 and LC3-II proteins was performed. Fluorescence 
microscopy was performed utilizing fluorochromes targeting APP, Aβ and BACE. 
Quantitative assessment of neuronal ATP was completed using a luciferase-based assay. 
Qualitative assessment of neuronal ATP distribution was performed by transfecting cells 
with a FRET-based ATP indicator, ATeam, and by capturing images with fluorescence 
microscopy. For all the experiments in the first model, treatment with the 
autophagosomal/lysosomal fusion inhibitor, bafilomycin A1, was included to assess 
autophagic flux. To assess the role of ketone bodies in response to injury, cells were 
exposed to the herbicide paraquat and Western blot analysis of LC3 and cleaved PARP, an 
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apoptotic protein, was performed. A WST-1 reductive capacity assay was completed and 
mitochondrial morphology assessed by means of the mitochondrial polarization-dependent 
fluorochrome, tetramethylrhodamine ethyl ester (TMRE), capturing and analysing images 
with ImageJ software. In addition transmission electron microscopy was performed to 
indicate neuronal ultrastructure, ATP quantification and qualitative assessment as well as 
flow cytometry to indicate reactive oxygen species (ROS) by using both dichlorofluorescein 
(DCF) to indicate general ROS and TMRE to assess mitochondrial polarization.  
Results. Under basal conditions, it was observed that the ATP distribution within cells 
changed to large areas of detected signal when treating cells with ketone bodies and 
bafilomycin. There were no significant differences in detected ATP levels between 
treatment groups. Western blot results revealed that bafilomycin treatment resulted in a 
strong trend towards increased protein levels of BACE and APP, and a significant decrease in 
Aβ levels. Decreased p62 protein expression was observed upon ketone body treatment as 
well as a strong trend for decreased LC3-II protein levels upon bafilomycin treatment. 
Fluorescence microscopy revealed that bafilomycin treatment caused accumulation of APP, 
BACE and Aβ, and increased nuclear signal of BACE and APP. For the injury-induced model 
the WST-1 assay results reveal that paraquat caused a significant decrease in reductive 
capacity, which ketone body supplementation rescued by significantly increasing reductive 
capacity. Western blot analysis revealed a strong trend for decreased LC3-II protein 
expression upon bafilomycin treatment. No differences between groups were observed for 
cleaved PARP.  
Mitochondrial morphological assessment indicated a highly fused network in the control 
and ketone body group, and a highly fragmented state upon paraquat treatment, which was 
improved to a more fused state upon ketone body co-treatment. No significant differences 
were observed in the flow cytometry data, however a similar trend for increased 
fluorescence intensity upon ketone body and paraquat co-treatment was present in cells 
stained with DCF and TMRE. ATP concentration and distribution was severely affected by 
paraquat treatment, which decreased detected ATP levels and signal. Ketone body 
treatment caused a change in ATP distribution apparent as large ‘hotspots’, however, did 
not significantly increase ATP concentration in the co-treatment group. Transmission 
electron microscopy indicated intact, elongated mitochondria in the control and ketone 
Stellenbosch University  https://scholar.sun.ac.za
v 
 
body groups, as well as well-defined vacuolar structures. They were increased upon ketone 
body supplementation. Paraquat exposure caused mitochondrial disruption as indicated by 
swollen mitochondria with decreased integrity as well as less well defined vacuolar 
structures. Fewer vacuolar structures were observed in the co-treatment group.  
Discussion and conclusion. Our results suggest that ketone body exposure increases 
autophagic flux and decreases the presence of amyloid-associated proteins. In addition, 
ketone bodies confer protection from neurotoxicity and improve mitochondrial network 
connectivity. Our results further indicate a role for ketone bodies in localized ATP supply. 
Taken together, ketone body exposure may hold great potential as an adjuvant therapy in 
the context of neurodegeneration.  
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OPSOMMING  
Inleiding. Alzheimersiekte is die mees algemene neurodegeneratiewe siekte en wêreldwyd 
toemend die vernaamste oorsaak van demensie. Ontwikkelende lande soos Suid-Afrika sal 
veral beïnvloed word. Huidiglik bestaan daar geen enkele behandeling nie.  Die patologiese 
aspekte van die fisiologie van Alzheimersiekte is kompleks, maar die vernaamse oorsaaklike 
faktor behels foutiewe proteolitiese weë, insluitend makroautofagie, en toksiese amyloid 
beta opeenhoping. Daarbenewens word metaboliese versteurings sowel as ‘n ontwrigte 
mitochondriese dinamiek geïmpliseer. Hierdie versteurings veroorsaak uiteindelik die dood 
van neurone. Dit is onlangs bewys dat ketoonliggame voordelige gevolge het in die konteks 
van neurodegeneratiewe siektes, insluitend Alzheimersiekte waar verbeterings in beide 
molekulêre versteurings sowel as kognisie waargeneem is. Nieteenstaande die rol van 
autofagie om proteïn opeenhoping te verlig rapporteer in die literatuur, is die meganisme 
van aksie steeds onduidelik.  
Doel. Die doel van hierdie projek was dus om die uitwerking van die ketoonliggaam beta-
hidroksie butiraat te bepaal onder basis toestande en in ‘n beseringsmodel. Ons doel was 
om vier bepalers wat nou gekoppel is met sellulêre oorlewing in die twee modelle te 
assesseer: seloorlewing, autofagiese stroming, mitochondriese netwerk morfologie en 
intrasellulêre ATP verskaffing. Ons hipotese was dat ketoonliggame neurone sal beskerm 
van paraquat-induseerde neurotoksisiteit, deur ATP vlakke te vermeerder deur die toename 
van autofagiese stroming. 
Metodes. GT1-7 selle was deur middel van selkultuur geweek met behulp van DMEM verryk 
met 10% FBS onder standaard toestande (5% CO2, 37 °C). Western blot analise van APP, Aβ, 
BACE, p62 en LC3-II proteïnvlakke was onderneem om die effek van ketoonliggame onder 
basis toestande te bepaal. Fluoressensie-gebaseerde mikroskopie was onderneem deur 
fluorochrome te gebruik gerig aan APP, Aβ en BACE. Kwantitatiewe evaluering van 
neuronale ATP was voltooi met behulp van ‘n lusiferaas-baseerde toets. Kwalitaties 
evaluering van neuronale ATP verspreiding was uitgevoer deur selle met ‘n FRET-
gebaseerde ATP wyser, ATeam, te transfekteer en af te beeld met fluoresserende 
mikroskopie. Bafilomycin, ‘n inhibeerder van autofagosomale/lisosomale samesmelting, was 
gebruik om selle te behandel in alle eksperimente van die eerste model om die autofagiese 
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stroming te assesseer. Selle is blootgestel aan paraquat, ‘n onkruiddoder, om die effek van 
ketoonliggame te bepaal in reaksie tot skade, en dan is Western blot analise van LC3 en 
gekliefde PARP, ‘n apoptotiese proteïen, onderneem. ‘n WST-1 toets, wat reduktiewe 
kapasitieit aandui, is voltooi en mitochondriese morfologie is geassesseer deur die 
mitochondriese polarisasie-afhanklike fluorokroom, tetrametielrodamien etielester (TMRE) 
te gebruik, beelde te neem en te analiseer met behulp van ImageJ sagteware. Verder was 
transmissie elektron mikroskopie onderneem om neuronale ultrastruktuur aan te dui, sowel 
as ATP kwantifikase en kwalitatiewe assessering en vloeisitometrie om reaktiewe suurstof 
spesies (ROS) aan te dui deur gebruik van beide dichlorofluoresien (DCF) vir algemene ROS 
en TMRE as aanduiding van mitochondriese polarisasie.  
Resultate. Onder basis toestande is daar ‘n verskil in ATP verspreiding waargeneem, met 
ketoonliggaam en bafilomycin behandeling wat die ATP verspreiding tot groot areas binne 
selle verander het. Geen beduidende verskille in the ATP vlakke van die behandelings 
groepe was teenwoordig nie. Die Western blot metode het aangetoon dat bafilomycin 
behandeling ‘n sterk neiging tot toegenome proteïen vlakke van BACE en APP tot gevolg het, 
asook ‘n beduidende afname in Aβ vlakke.  Ketoonliggaam behandeling het ‘n sterk tendens 
tot die  afname in p62 proteïn uitdrukking tot gevolg gehad, en bafilomycin behandeling het 
verder ‘n sterk tendens tot die afname van LC3-II proteïnvlakke veroorsaak. Fluoressensie 
mikroskopie het uitgewys dat bafilomycin behandeling die opeenhoping van APP, BACE and 
Aβ veroorsaak en die selkern sein van BACE en APP verhoog. Die WST-1 toets resultate het 
aangedui data paraquat ‘n beduidende afname in reduktiewe vermoë tot gevolg het, wat 
ketoonliggaam aanvullings beredder het deur die reduktiewe kapasiteit weer beduidend te 
herstel. Western blot analise het ‘n sterk tendens vir die afname in LC3-II proteïen 
uitdrukking in reaksie op bafilomycin behandeling aangetoon. Daar is geen verskille tussen 
groepe vir gekliefde PARP waargeneem nie.   
Mitochondriale morfologiese assessering het ‘n hoogs geïntegreerde netwerk vir die 
kontrole  en ketoonliggaam groep uitgewys, en ook dat ‘n hoogs gefragmenteerde toestand 
voorkom in reaksie tot paraquat behandeling, wat tot ‘n meer geïntegreerde toestand 
verbeter het met ketoonliggaam mede-behandeling. Geen beduidende verskille is 
waargneem in die vloeisitometrie data nie, alhoewel dieselfde tendens vir hoë fluoressensie 
intensiteit in reaksie op gesamentlike ketoonliggaam en paraquat behandeling in selle wat 
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gekleur is met DCF en TMRE aangewys is. Paraquat behandeling het ATP konsentrasie en 
verspreiding beduidend beïnvloed, asook die ATP vlakke en sein verminder.   Ketoonliggaam 
behandeling het ‘n verandering in ATP verspreiding tot gevolg gehad wat voorkom het as 
groot ‘hotspots’.  Transmissie elektron mikroskopie het aangedui dat verlengde 
mitochondria, en goed gedefinieerde vakuoolstrukture in die kontrole en ketoonliggaam 
groepe voorgekom het. Hierdie strukture het vermeerder nadat ketoonliggame toegedien is.  
Paraquat blootstelling het mitochondriale disrupsie tot gevolg gehad, soos aangedui is deur 
geswelde mitochondria met afgenome integriteit en swakker gedefinieerde vakuool 
strukture.  Minder vakuool strukture is waargeneem in die gesamentlike behandeling groep.  
Bespreking en gevolgtrekking. Die resultate verskaf ‘n aanduiding dat ketoonliggame ‘n 
toename in autofagiese stroming veroorsaak en ‘n afname in die voorkoms van spesifieke 
amyloid-geassosieerde proteïene. Verder verleen ketoonliggame ook beskerming teen 
neurotoksisiteit en verbeter mitochondriale netwerk verbindingsstatus. Ons dui verder 
daarop dat ketoonliggame ‘n rol speel in plaaslike ATP beskikbaarheid. Om saam te vat; 
ketoonliggame het beduidende potensiaal as ‘n toegevoegde terapie in die konteks van 
neurodegenerasie.  
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GAPDH  Glyceraldehyde 3-phosphate dehydrogenase  
GFP   Green fluorescent protein 
GSK3   Glycogen synthase kinase 3 
GTPase  Guanosinetriphosphatase 
HD   Huntington’s disease 
HRP   Horse radish peroxidase 
IDE   Insulin degrading enzyme 
IGF-1   Insulin-like growth factor-1 
IgG   Immunoglobulin G 
IP3   Inositol triphosphate 
IRS-1   Insulin receptor substrate-1 
JNK1   c-Jun N-terminal kinase 1 
KB   Ketone bodies 
KD   Ketogenic diet 
LDH   Lactate dehydrogenase 
LSDs   Lysosomal storage diseases 
LUT   Lookup table                                      
MAP1-LC3  Microtubule-associated protein 1 light chain 3 
MCI   Mild cognitive impairment 
MCTs   Monocarboxylate transporters 
Mfn   Mitofusin protein 
MMSE   Mini-mental-state examination 
mRNA   Messenger ribonucleic acid 
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mPTP   Mitochondrial permeability transition pore 
mTOR   Mammalian target of rapamycin 
MTT   3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide 
Na+/ K+-ATPase Sodium-potassium adenosine triphosphatase 
Na3VO4  Sodium orthovanadate 
NADH   Nicotinamide adenine dinucleotide (reduced form) 
NADPH  Nicotinamide adenine dinucleotide phosphate (reduced form) 
NaF   Sodium fluoride 
NaOH   Sodium hydroxide 
NCD   Neurocognitive disorder 
NFT   Neurofibrillary tangle 
NINCDS/ADRDA National institute of neurological and communicative diseases and 
stroke/Alzheimer's disease and related disorders association 
NMDA   N-methyl-D-aspartate  
NOS   Nitric oxide synthase  
Opa1   Optic atrophy 1 
OxPhos  Oxidative phosphorylation 
p70S6K  Phosphorylated p70S6 kinase 
PBS   Phosphate-buffered saline 
PD   Parkinson’s disease 
PDH   Pyruvate dehydrogenase  
PDK1   3-phosphoinositide-dependent protein kinase-1 
PE   Phosphatidylethanolamine 
PET   Positron emission tomography 
PFK   Phosphofructokinase-1 
PFKFB3  6-phosphofructose-2-kinase/fructose-2,6-bisphosphatase-3 
PGC-1α  Peroxisome proliferator-activated receptor-c coactivator 1α 
PI   Propidium iodide 
PIB   Pittsburgh compound B 
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PI3K   Phosphatidylinositol 3-kinase 
PI-3-P   Phosphatidylinositol-3-phosphate 
PIP3   Phosphatidylinositol (3,4,5)-trisphosphate 
PKA   Protein kinase A 
PMSF   Phenylmethylsulfonyl fluoride 
PMT   Photomultiplier tube 
PONR                             Point-of-no-return 
PPP   Pentose phosphate pathway 
PSEN   Presenilin 
PTEN   Phosphatase and tensin homologue deleted from chromosome 10 
PVDF   Polyvinydilene difluoride 
RIPA   Radioimmunoprecipitation assay buffer 
RIPK1/RIP1  Receptor-interacting protein kinase 1 
RNA   Ribonuclein acid 
ROS   Reactive oxygen species 
sAPPα   Soluble peptide APPα 
SDS-PAGE  Sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis 
SQSTM1  Sequestome 1 (p62) 
T2DM   Type 2 diabetes mellitus 
TBS-T   Tris-buffered saline-Tween 
TCA   Tricarboxylic acid  
TEM   Transmission electron microscopy 
TMRE   Tetramethylrhodamine ethyl ester 
TNF   Tumour necrosis factor 
TNFR   TNF receptor 1 
Tris-HCl  Trisaminomethane hydrochloride 
TSC   Tuberous sclerosis complex  
ULK-1   Unc-51 like autophagy activating kinase 1 
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v-ATPase  Vacuolar H+-ATPase 
WST-1   Water soluble tetrazolium salt 1  
YFP   Yellow fluorescent protein 
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Units of measurement 
%  percentage 
°C  degrees Celcius 
µM  micromolar 
µmol  micromole 
µg  microgram 
µl  microlitre 
µm  micrometre 
cm  centimetre 
h  hour 
hrs  hours 
l  litre 
min  minute(s) 
ml  millilitre 
mm  millimetre 
mM  millimolar 
ng  nanogram 
nM  nanomolar 
nm  nanometre 
pM  picomolar 
rpm  rotations per minute 
sec  second(s) 
V   volt 
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MOTIVATION FOR STUDY 
Alzheimer’s disease is the most prevalent neurodegenerative disease and the greatest 
contributor towards dementia.  Its prevalence is increasing, and it is predicted that the 
global number of patients will rise to 106.8 million by 2050 (Brookmeyer et al., 2007). 
Furthermore, low and medium income countries will be especially adversely affected, thus 
South Africa is substantially implicated in the disease burden (Wortmann, 2012). 
Researchers face the challenge of a multifaceted disease pathology. The identification of the 
major molecular disruptions involved, as well as identifying early events in the pathogenesis 
are crucial in order to prevent neurodegeneration. Currently no single disease modifying 
treatment exists. Mitochondria are present in high numbers in neurons and are essential for 
ATP synthesis. However, during Alzheimer’s disease their functioning is impaired (Pagani 
and Eckert, 2011) and it is becoming increasingly clear that the dysfunction in ATP 
production is central in the disease pathogenesis. Macroautophagy,also referred to as 
autophagy is a major protein degradation system that plays an important role in cellular 
survival, likely through supplying metabolic substrates. Dysregulated autophagy has been 
identified in Alzheimer’s disease (Nixon and Yang, 2011). Ketone bodies, a major alternative 
to glucose for fuelling the brain, have shown promising results in reducing the 
pathophysiological changes associated with Alzheimer’s disease both molecularly and 
functionally (Van der Auwera et al., 2005; Henderson et al., 2009). However, the underlying 
molecular mechanisms that connect ketone bodies, amyloid aggregation, autophagy and 
ATP availability remain unclear. Therefore, in order to fully understand the efficacy of 
ketone bodies as a potential therapeutic strategy for Alzheimer’s disease, it is necessary to 
understand their effects on the mechanisms that govern neuronal survival.  
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Chapter 1: LITERATURE REVIEW 
1.1 Introduction 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, and the greatest 
contributor towards dementia. The global prevalence is increasing and it is estimated that 
the global number of AD patients will rise to 107 million by 2050 (Brookmeyer et al., 2007). 
It is predicted that low and medium income countries will  especially be adversely affected, 
placing South Africa at a greater risk for the number of people suffering from AD 
(Wortmann, 2012). High rates of dementia have a great economic impact as well; the total 
global societal cost of dementia in 2009 alone was estimated at $422 billion (Wimo et al., 
2010). There is currently no cure for AD, and the growing burden of disease makes finding 
an effective treatment for it a high priority. No single cause for the disease has been 
established thus far, however aging is likely the most important risk factor for developing 
AD (Saido, 2013). Moreover, pathological changes take place in the brains of aging patients 
years before overt AD manifests, thus illustrating the long disease progression (Chong and 
Sahadevan, 2005).  
 
 
 
 
 
 
 
 
 
South Africa is a newly developing nation, with high levels of unemployment and poverty, 
and income inequality remains a major national challenge (Leibbrandt et al., 2012). A 
polarized burden on health persists as well; non-communicable diseases are on the 
increase, while infectious diseases and maternal and child mortality still persists (Chopra et 
al., 2009). In South Africa, an increase in age, together with illiteracy or lack of education, 
depressive illness, low fibre diet and vascular disease have been identified as factors 
increasing the risk for developing dementia, AD or vascular dementia (Kalaria et al., 2008). 
Figure 1.1: The prevalence rates of Alzheimer’s disease according to disease state. (Brookmeyer et al., 
2007). 
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This presents a unique set of risk factors that increases the likelihood for developing 
dementia in this country (Kalaria et al., 2008). Thus it is necessary to explore the link 
between the risk factors of aging, diet, metabolism and AD, and accordingly these will be 
discussed in this review.  
 
In order to understand the underlying molecular mechanisms that drive the process of 
disease progression in AD, we have to turn our attention to physiological neuronal 
metabolism, their metabolic demands and protein degradative pathways first and then 
summarise the pathological changes characteristic of AD. 
1.2 Overview of cerebral functioning 
a. Neuronal metabolism 
AD is an illness affecting primarily neuronal cells which have specific metabolic 
requirements. A brief overview of neuronal metabolism is necessary to understand neuronal 
cell death which occurs during AD.  
 
The brain consists of primarily two cell types – neurons and astrocytes (glial cells or glia). 
These two cell types are highly interconnected and form functional networks through their 
spatial organization.  Their metabolic profiles also reflects this co-dependency, by their 
utilization of different but complementary pathways (Bélanger et al., 2011).   
  
The brain contains sparse energy reserves, yet neurons have a high energy demand. Thus, a 
constant supply of energy substrates from the circulation is necessary. Glucose is considered 
the essential substrate but other metabolites derived from glucose such as pyruvate, 
lactate, and glutamate as well as alternative fuel sources such as ketone bodies (KB) can also 
be catabolized. Phosphorylated glucose, or glucose-6-phospate (glucose-6P), can enter one 
of three metabolic pathways to produce adenosine triphosphate (ATP). The first is glycolysis, 
which generates pyruvate, two ATP molecules and the reducing equivalent NADH (Bélanger 
et al., 2011). Pyruvate can be further metabolised in the tricarboxylic acid (TCA) cycle and 
oxidative phosphorylation (OxPhos) in the mitochondria. Oxygen is required as an electron 
acceptor to generate the final products of 30-34 molecules of ATP and CO2 in this route. An 
alternative use of pyruvate is its reduction to lactate by lactate dehydrogenase (LDH) in the 
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cytosol (Bélanger et al., 2011). The second pathway to utilize glucose-6P is the pentose 
phosphate pathway (PPP) where the reducing equivalent NADPH is produced. A third 
avenue, possible in astrocytes, is glycogenesis where glucose-6P units are stored as 
glycogen. Indeed, astrocytes are the main site of glycogen storage in the adult brain 
(Bélanger et al., 2011). 
 
Astrocytes can be distinguished from neurons by their functional qualities. The definition of 
mature astrocytes includes the features of nonexcitability i.e. astrocytes cannot generate 
action potentials, measure of glycogen granules present, and close proximity and 
interactions with blood vessels through astrocytic processes (Kimelberg, 2010). These 
features provide a clue to the overarching function of astrocytes – to support neuronal 
activity. Astrocytes are much more than the static support network of cells previously 
thought, however. Evidence suggests that they are also ‘excitable’ in the sense that they are 
capable of releasing a host of molecules, so-called ‘gliotransmitters’, in response to internal 
or external stimuli (Volterra and Maldolesi, 2005). An example is the release of glutamate 
from astrocytes and subsequent neuronal activation in response to increased intracellular 
calcium.  Other functions of astrocytes include neuronal synchronization, by their 
involvement in stimulating postsynaptic neuronal excitability, and the regulation of cerebral 
blood flow by calcium-dependent gliotransmission, which facilitates changes in arteriolar 
tone (Volterra and Maldolesi, 2005). Astrocytes also form a close association with synapses 
and actively control synaptic transmission through their role in synapse formation, function 
and elimination (Chung et al., 2015). In addition to these functions, it has been 
demonstrated that astrocytes occupy discrete regions without overlap, i.e. neighbouring 
astrocytes do not share the same underlying neuropil (Bushong et al., 2002). In addition, 
Halassa et al. (2007) reported that a single astrocyte contacts 300-600 dendrites to form 
‘synaptic islands’. These findings illustrate the high dependence of neurons on glia.    
 
Astrocytes play a key role in coupling synaptic activity to glucose metabolism. They are 
stellate cells with multiple processes that form a close interaction with capillaries and 
synaptic contacts, which are rich in neurotransmitter receptors, including glutamate 
receptors (Magistretti and Pellerin, 1999). These features make astrocytes ideally suited to 
their coupling role. Glutamate is the cerebral cortex’s primary excitatory neurotransmitter. 
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The activation of afferent pathways triggers glutamate release from activated synaptic 
terminals, which affects the excitability of target neurons by binding to its receptors. 
Glutamate is swiftly taken up again by astrocytic processes which terminates its actions on 
postsynaptic neurons, a reaction dependent on the electrochemical gradient of sodium 
(Magistretti and Pellerin, 1999). Following re-uptake into astrocytes, glutamate is converted 
into glutamine which is released and taken up by neurons to replenish their glutamate 
reserves (Figure 1.2). Glutamate uptake by astrocytes also has a metabolic effect – it 
stimulates glucose utilization and lactate production via aerobic processes in affected cells. 
This process operates independently of glutamate receptors, but the activation of the 
Na+/K+ -ATPase pump is a central event. Intracellular sodium levels rise concomitantly with 
glutamate uptake which activates the Na+/K+-ATPase and in this way stimulates glucose 
uptake and glycolysis (Magistretti and Pellerin, 1999). 
 
 
 
 
Astrocytes rely predominantly on the biochemical pathway of glycolysis as opposed 
toOxPhos, and freely take up glucose to convert it to lactate for ATP synthesis (Bélanger et 
al., 2011).  The preference for lactate as fuel substrate, as opposed to pyruvate, is a result of 
gene expression patterns in astrocytes. Specific enzymes are synthesized in accordance with 
these patterns, for example 6-phosphofructose-2-kinase/fructose-2,6-bisphosphatase-3 
(PFKFB3), which activates the glycolytic enzyme phosphofructokinase-1 (PFK), is highly 
expressed. Low expression levels of the aspartate/glutamate carrier (AGC)  are present and 
the conversion of pyruvate to lactate is favoured by inactivation and/or low expression of 
Figure 1.2:  Neuron-glia metabolic coupling and glutamate shuttling (from Magistretti, 2006). 
 
Stellenbosch University  https://scholar.sun.ac.za
6 
 
pyruvate dehydrogenase (PDH) resulting in less pyruvate entering the TCA cycle (Bélanger et 
al., 2011). This is important since the enzyme profile in this context dictates local availability 
of ATP (De Bock et al., 2013).  
 
Neurons are characterized by high energy demands, due to the high levels of 
macromolecule synthesis; a process which consumes the most ATP within cells (Buttgereit 
and Brand, 1995). They are mainly dependent on the OxPhos of substrates; a logical 
situation when one considers that OxPhos produces about 15 times more ATP than 
glycolysis (Bélanger et al., 2011). The specific molecular features of neurons are responsible 
for their distinct metabolic profile. The glycolytic enzyme PFKFB3 is virtually non-existent in 
neurons due to its constant degradation, in contrast to the situation in astrocytes (Bélanger 
et al., 2011). As a result there is a far lower rate of glycolysis. Experimental upregulation of 
glycolysis is not metabolically favourable and in fact detrimental to neurons, as it leads to 
apoptosis and oxidative stress (Herrero-Mendez et al., 2009). This is thought to occur as a 
result of decreased flux through the PPP and thus diminished production of NADPH – an 
important antioxidant. An alternative fuel source utilized by neurons is lactate. It has been 
demonstrated that lactate is a preferred substrate above glucose (Smith et al., 2003). 
Ketone bodies also have the ability to support basal energy needs, given that they are 
present at a sufficient concentration to saturate metabolism. It has recently been shown 
that they provide approximately as much as half of neurons’ oxidative needs during activity 
(Chowdhury et al., 2014). This matter deserves further attention in order to elucidate the 
extent of reliance on ketone bodies as an energetic substrate. 
 
An increase in ketone metabolism represents a return to an early developmental pathway of 
substrate utilization, not usually relied upon for energy production in adulthood (Prins, 
2008). Utilization of ketone bodies is an adaptive response to provide energy. It has very 
different properties to glucose metabolism that are relatively new and promising  for 
example it has been shown to confer neuroprotection, which will form a focus point of this 
thesis. These properties mostly have the net effect of increased energy efficiency and 
antioxidant capacity (Prins, 2008). Its metabolism leads to specific beneficial outcomes 
which include: (i) areduction of the nicotinimide adenine dinucleotide (NAD) couple, (ii) a 
decrease in reduced Co-enzyme Q (translating to less superoxide formation), and (iii) a 
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reduction in the number of biochemical reactions required to enter the TCA cycle (Prins, 
2008). 
 
Different methods that assess brain metabolism have revealed tight coupling between 
energy demand and supply in the brain. Magnetic resonance imaging (MRI) is a tool widely 
used in diagnostic medicine to generate not only structural images of the organs but also 
data on the vascularization, perfusion and physico-chemical state of tissues (Logothetis, 
2008). Functional MRI (fMRI) further enhances the scope of MRI as it enables the 
measurement of hemodynamic changes after enhanced neural activity. It is frequently used 
to demonstrate which areas of the brain are activated in response to execution of a specific 
task. The blood-oxygen-level-dependent (BOLD) contrast mechanism is routinely used to 
generate images of the human brain (Logothetis, 2008). Positron emission tomography 
(PET) is a technique where positron emitting radioisotopes are used to tag biologically active 
molecules. A positron-labelled probe is administered intravenously and a PET-scan is 
performed to determine the tissue concentration of the probe and labelled products over a 
certain period. An example of such a probe is 2-[F-18]fluoro-2-deoxy-D-glucose (FDG). FDG 
is an F-18-labelled glucose analog which is used to investigate the facilitated transport and 
phosphorylation of glucose. It is commonly used to study altered metabolic states which 
occur in disease states of the brain (Phelps, 2000). Pittsburgh compound B (PIB) is used to 
tag deposits of amyloid beta (Aβ) peptide, an important protein in AD pathology, present in 
neuronal tissue (Forsberg et al., 2008). 
 
b. The role of mitochondria in metabolism 
Mitochondria are crucial for ATP generation, as well as for monitoring cellular functions 
such as the activation of cell death pathways and calcium regulation. They generate energy 
via the biochemical processes of the TCA cycle and OxPhos. Mitochondria are present in 
especially high numbers in the perikarya and the synapses (Pagani and Eckert, 2011), areas 
of high energy demand in functioning neurons. 
Mitochondria exist as an interconnected network which is subject to dynamics of two 
opposing events: mitochondrial fission and fusion. Mitochondria are continuously moving 
along intracellular tubulin network structures and can present as fused with other 
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mitochondria (fusion) or as fragmented from the network to produce distinct rod or sphere 
shaped mitochondria (fission). In healthy neurons fission and fusion is in a state of 
equilibrium and facilitates intracellular movement of mitochondria. Mitochondrial networks 
comprised of fused mitochondria are beneficial to metabolically active cells, as this 
conformation favours ATP distribution. Fission in contrast is observed more often in 
quiescent cells (Westermann, 2010). Furthermore, fission is linked to cell death, as a result 
of defective mitochondria produced by fragmentation, while fusion is important for 
maintaining mitochondrial function and a healthy mitochondrial pool (Chan, 2006). 
These dynamic events are controlled by different proteins belonging to the dynamin family. 
Dynamin related protein (Drp1) and fission protein (Fis1) are primarily responsible for fission 
(Reddy, 2009). Fis1 is localized on the outer mitochondrial membrane while Drp1 is mostly 
cytosplasmic, but a small fraction associates with the outer mitochondrial membrane which 
promotes mitochondrial fragmentation. Free radicals activate Fis1 to induce fission. Three 
major proteins are primarily responsible for controlling fusion. These are the mitofusin 
proteins Mfn1 and Mfn2, present on the outer mitochondrial membrane, and Opa1, 
localized on the inner mitochondrial membrane. Mfn1 allows fusion by mediating an 
oligomerization reaction between Mfn molecules of adjacent mitochondria (Reddy, 2009).  
During apoptosis, fragmentation of the mitochondrial network occurs.  Cells with Fis1 
deficiency display increased fusion as well as resistance to apoptotic cell death. Opa1 
depletion has shown the opposite effect – mitochondria in these cells are extensively 
fragmented and cells have an increased vulnerability to cell death (Lee et al., 2004). The 
network state of mitochondria is sensitive to metabolic perturbations and can adapt to 
metabolic pertubations such as. a high fat diet or starvation by favouring fission or fusion 
(Hoppins, 2014). However, it has to be noted that the elucidated response is cell-type 
specific (Dietrich et al., 2013). Furthermore it has been demonstrated that AMP-activated 
kinase (AMPK), a cardinal metabolic sensor, is activated when even mild disturbances in 
cellular ATP occur and in this way it acts as a primary sensor of mitochondrial function 
(Green et al., 2014).  
Mitochondria are responsible for cellular energy production and as such, are vital to 
maintaining cellular function. The next section will discuss ATP, the chief energy molecule 
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produced by mitochondria and utilized by cells in a hierarchy of ATP consuming processes 
(Buttgereit and Brand, 1995).  
c. ATP and neuronal metabolism 
The brain has high energy demands and although it competes with several other organs in 
terms of energy metabolism, its metabolic rate is nine times higher than the average mass-
specific metabolic rate of the human body as a whole (Aiello and Wheeler, 1995). It 
metabolizes 50% of total body glucose, but constitutes only 2% of the body mass (Fehm et 
al., 2006). ATP is the energetic ‘currency’ to which metabolic substrates such as glucose are 
broken down to, and is important for providing energy in order for cells to function. Dzeja 
and Terzic (2003) provide evidence that demonstrates the precisely controlled coupling 
between ATP demand and supply by an enzymatic network. This coupling is tightly 
regulated so that fluctuations in intracellular adenine nucleotide concentrations are rarely 
observed, even with increased metabolic flux (Dzeja and Terzic, 2003).  
Synapses are heavily dependent on local ATP synthesis on functioning mitochondria, 
because of the great distance between neuronal cell soma and synaptic terminals. Electrical 
signalling processes and synaptic transmission consume the most ATP in the brain, based on 
a breakdown of activities that this entails, including ion pumping and vesicle recycling 
(Harris et al., 2012). This is supported by Buttgereit and Brand (1995) who demonstrated 
that sodium and calcium cycling was the second greatest ATP-consuming process in cells. 
ATP is provided by the numerous mitochondria which occur here, precisely to generate ATP 
that can meet neuronal energy demands. The relationship between ATP demand and its 
localization is demonstrated by the fact that synaptic activity contributes significantly to ATP 
consumption and that it, in turn, fuels ATP production (Harris et al., 2012). Despite evidence 
of ATP localizing at the synapses of neurons, there are few studies focusing on the 
localization of intracellular ATP, however some studies illustrate the strength of emerging 
techniques that focus on ATP localization in cells.  
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Figure 1.3: Schematic drawing of FRET-based ATP probe ATeam, AT1.03 which allows ATP 
localization studies  (Imamura et al., 2009). 
 
There has been an increasing trend of monitoring ATP in single living cells using imaging and 
videoing techniques. These techniques become more accessible to researchers with the 
development and availability of advanced techniques such as super-resolution microscopy. 
Imamura et al. (2009) laid the groundwork for a live cell imaging method with an ATeam 
construct which labels intracellular ATP, targeted to particular regions.  A Förster resonance 
energy transfer (FRET)-based ATP indicator was developed that consists of cyan and yellow 
fluorescent proteins (CFP and YFP) situated on either side of the ε subunit of bacterial FoF1-
ATPase. Conformational changes are induced upon ATP binding and result in increased FRET 
efficiency (Figure 1.3). This type of assay provides an advantage compared to the ubiquitous 
luminescence assay as chemiluminescence is affected by other substrates, intracellular 
oxygen and pH, and its imaging is labour-intensive (Imamura et al., 2009).  
ATP visualization in live cells allows assessment, in real time, of its association with other 
cell components. In addition, it has the advantage of providing high spatial and temporal 
resolution. Another study utilizes a novel method to visualize ATP and demonstrates the 
experimental power of monitoring ATP in cells. The authors used a genetically encoded 
reporter of synaptic ATP to demonstrate the link between energy demand and availability. 
In that manner it was revealed that electrical activity places significant demands on ATP 
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production particularly in presynaptic terminals, and also drives ATP synthesis (Rangaraju et 
al., 2014). De Bock et al. (2013) visualized ATP ‘hotspots’ by using the biosensor GO-ATeam. 
Large amounts of ATP are required for the contraction and protrusion of cellular extensions 
(lamellipodia and filopodia) of the cell tips, as they rely on remodelling of the actin 
cytoskeleton. Endothelial cell motile structures are situated far from mitochondria and thus 
rely on glycolysis for local ATP production. The authors describe high ATP concentrations in 
lamellipodia, and furthermore reveal that silencing PFKFB3, the glycolytic enzyme previously 
explained,, abolished this localization. Thus ATP is not uniformly distributed in the cell and 
metabolic demands determine where ATP is localized. This has thus far been confirmed in 
endothelial cells, and it can be speculated that this is also the case in neurons based on the 
high ATP levels present at synapses. Results such as these strongly suggest that it is possible, 
and highly informative, to deduce cellular ATP demands from the intracellular localization of 
ATP. Moreover, the subcellular localization of ATP is not routinely assessed, and research 
into neuronal ATP localization patterns is lacking.  In addition, the localization of ATP in the 
presence of ketone bodies or during autophagy dysfunction remains largely unclear. 
As we shall see, the protein degradation pathway of macroautophagy plays a particularly 
central role in neuronal metabolism and pathology, as it provides another means of 
contributing ATP under stress conditions. 
d. Autophagy and lysosomes in the context of cellular metabolism 
In 1955 De Duve and colleagues  discovered a pattern in rat liver enzyme distribution which 
lead to the identification of lysosomes and the birth of autophagy research. The seminal 
work of the Yoshimori lab (Kabeya et al., 2000) identified LC3-I and LC3-II, the first 
mammalian proteins associated with autophagosomes to be identified. Since then, a vast 
body of research has expanded our knowledge of the molecular factors involved in the 
process of autophagy. Autophagy is vitally important for survival, as demonstrated by the 
finding that mice in which autophagy is downregulated by deleting Atg3 die within a day of 
birth (Sou et al., 2008). In addition, autophagy inhibition leads to neurodegeneration, as 
demonstrated by mouse models with Atg5 and Atg7 knockouts (Hara et al. 2006; Komatsu 
et al. 2005).   
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Autophagic machinery 
Macroautophagy (from here onwards referred to as ‘autophagy’), microautophagy and 
chaperone mediated autophagy represent one of two main protein catabolic pathways 
together with the ubiquitin-proteasome system (Nedelsky et al., 2008). Autophagy is a 
dynamic process during which double-membraned sequestering vesicles, termed 
autophagosomes, encapsulate part of the cytosol and damaged organelles, fuse with 
lysosomes which contain acidic hydrolases, thereby degrading macromolecules into their 
constituents e.g. amino acids. The process of autophagy is characterized by discrete steps 
(Klionsky, 2005): (1) induction, (2) cargo selection, (3) nucleation of vesicle formation, (4) 
vesicle expansion and completion, (5) retrieval, (6) targeting, docking and fusion of the 
vesicle with the lysosome/vacuole and (7) breakdown of the intraluminal vesicle. It is 
possible for multiple lysosomes to fuse with a single autophagosome. Once 
autophagosomes have released their digested cargo back into the cytosol, lysosomes are 
reformed to enter the autophagic cycle again. Increased mammalian target of rapamycin 
(mTOR) activity drives the process of lysosome reformation, by generating proto-lysosomal 
structures that extrude from autophagolysosomes and mature to supplement the lysosomal 
pool and maintain lysosomal homeostasis (Yu et al., 2010). Amino acids that are produced 
during autophagy-driven proteolysis exit autophagolysosomes through the vacuolar 
effluxers Atg22, Avt3, and Avt4 which transport them across the autophagolysosomal 
membrane into the cytosol (Yang et al., 2006).   
Lysosomes play a vital role in the process of autophagy, as they enable the degradation of 
various substrates. They are comprised of a single-lipid bilayer membrane which 
encapsulates several types of hydrolases (Settembre et al., 2013). Transport proteins in the 
membrane facilitate the transport of both intra- and extracellular proteins as well as 
acidification of the lumen and fusion with other structures. Apart from their established role 
in clearing substrates, lysosomes have other functions including activities related to 
lysosomal exocytosis and signalling pathways involving nutrient sensing, metabolism and 
cell growth (Settembre et al., 2013). However, research regarding these alternative roles of 
lysosomes is still in its early phases. The importance of functioning lysosomes is 
demonstrated by lysosomal storage diseases (LSDs). LSDs are inherited metabolic 
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dysfunctions which are caused by mutations in genes encoding proteins that are necessary 
for lysosomal function e.g. lysosomal membrane or lumen proteins (Settembre et al., 2013). 
As a result individuals with these disorders display the progressive accumulation of material 
destined for lysosomal degradation. More than 60 LSDs have been identified, with 
classification based on which material accumulates in lysosomes. Patients with LSDs 
frequently display neurodegeneration as well as cognitive decline, suggesting a particularly 
high neuronal reliance on functional lysosomal clearance (Settembre et al., 2013).  The link 
between disrupted cellular clearance methods and neurodegeneration will be discussed 
later.  
There are more than 30 known genes regulating autophagy in yeast, many with mammalian 
orthologs (Ravikumar et al., 2010). Atg proteins drive the different processes of autophagy 
(Mizushima et al., 2010). The autophagosomal membrane is thought to form from 
intracellular membranous structures such as the endoplasmic reticulum (ER), mitochondria 
and the Golgi body upon induction by the Beclin-Vps34 complex. Following induction, 
elongation is facilitated by the actions of two ubiquitin-like reactions (Ravikumar et al., 
2010). First, activated Atg12 forms a covalent bond with Atg5, after which the Atg12-Atg5 
complex conjugates with Atg16L1. In the second reaction microtubule-associated protein 1 
light chain 3 (MAP1-LC3 or LC3) is cleaved to form LC3-I in the cytosol. LC3-I is then 
conjugated to phosphatidylethanolamine (PE) to form LC3-II via the actions of Atg3 and 
Atg7. LC3-II is the only known Atg protein to remain associated with the autophagosomal 
membrane, and as such is a valuable molecular marker for autophagy (Ravikumar et al., 
2010). Sequestome 1 (SQSTM1), or p62 is another protein used in this regard, as it is 
involved in the targeting of poly-ubiquitinated proteins towards autophagolyosomes for 
degradation (Barth et al., 2010). 
Control of autophagy induction and its link to metabolism 
Autophagy is tightly linked to cellular metabolism, energy sensing and mitochondrial 
function. Several different signalling pathways in mammals are involved in regulating 
autophagy in this context. The first of these is the mTOR pathway, which is the most widely 
studied (Ravikumar et al., 2010). Many different pathways affect autophagy via their actions 
on the mTOR complex 1 (mTORC1) consisting of various different proteins (Figure 1.4). 
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Importantly, it negatively regulates autophagy by phosphorylating ULK-1. Rapamycin 
binding strengthens the association of mTOR with Raptor, another mTORC1 protein, and 
inhibits the mTOR kinase activity. On the one hand, the phosphatidylinositol 3-kinase (PI3K) 
pathway, triggered by insulin binding to its cell surface receptor, acts on mTOR, in the 
process eithersuppressing autophagy  (Ravikumar et al., 2010). Theclass I PI3K product PIP3 
activates Akt, thereby inhibiting autophagy. Akt phosphorylates and inactivates the 
tuberous sclerosis complex (TSC) 1/2, which will lead to mTOR activation. In addition, it 
inhibits the transcription of autophagy genes. The class III PI3K product, PI-3-P, in contrast  
stimulates autophagy when its levels increase. Phosphatase and tensin homologue deleted 
from chromosome 10 (PTEN) stimulates autophagy by inhibiting the PI3K pathway upstream 
of mTOR (Ravikumar et al., 2010). 
Amino acids suppress autophagy through the mTORC1 pathway. Influx of essential amino 
acids causes their binding to and stimulation of Rag GTPases present on the lysosome 
associated protein, Ragulator. This recruits mTORC1 to the lysosomal surface and 
suppresses autophagy (Sarkar, 2013). The phenomenon of macrolipophagy, the regulatory 
function of autophagy on intracellular lipid stores is another example of substrate-driven 
control of autophagy. Lipid metabolism and autophagy both provide nutrients during times 
of nutrient deprivation and share further similarities in their function and regulation (Singh 
et al., 2009). Autophagy is crucial for lipid droplet breakdown and its inhibition increases 
lipid storage. Autophagic pathway components facilitate lipid metabolism by associating 
with lipid droplets during starvation (Singh et al., 2009).   
AMPK is a cellular energy sensor which detects changes in the intracellular ATP/AMP ratio. It 
activates TSC2 directly through phosphorylation, priming it for phosphorylation by glycogen 
synthase kinase 3 (GSK3) effectively inhibiting mTORC1 (Ravikumar et al., 2010). 
Regulation of autophagy can also occur in an mTOR-independent fashion. Several signalling 
cascades are involved here (Sarkar, 2013). Adenylate cyclase mediates the increase of cyclic 
AMP (cAMP) by converting ATP activating the PKAsignalling pathway. In turn phospholipase 
C leads to the the production of inositol triphosphate (IP3) and diacylglycerol 
(DAG)suppressing autophagy by the release of calcium from the ER and influx through 
calcium channels. This prevents fusion of lysosomes and autophagosomes, and thus the 
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maturation of autophagosomes. In addition, PKA can directly phosphorylate and thus 
modulate the activity of calcium channels, illustrating crosstalk between these two 
pathways (Marx et al., 2000). Increased calcium also activates calpain, which inhibits 
autophagy (Sarkar, 2013). Inhibition of nitric oxide synthase (NOS) stimulates autophagy by 
inhibiting c-Jun N-terminal kinase 1 (JNK1) and its downstream effects. Starvation, in turn, 
activates JNK1 and autophagy by disrupting the interaction of Bcl-2 and Beclin-2, which 
normally suppresses autophagy. Pharmaceutical drugs targeting specific proteins in these 
pathways can be used to induce or inhibit autophagy (Sarkar, 2013). 
Recently, acetyl-coenzyme A (AcCoA), a major metabolite generated by fatty acid, protein 
and carbohydrate catabolism, was identified as an important regulator of autophagy. It has 
been demonstrated that increasing cytosolic AcCoA inhibits autophagy and decreasing levels 
induces it (Mariño et al., 2014). The authors found that depleting AcCoA reduced the activity 
of E1A binding protein p300 (EP300), an acetyltransferase which is required for the 
suppression of autophagy when high levels of AcCoA are present. They surmise that the 
acetylation of Atg proteins by EP300 is the mechanism of its action, yet further investigation 
is required to eliminate other targets of EP300. These data further indicate the strong 
integration of the autophagy pathway and cellular metabolism.  
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The brain is uniquely sensitive to stresses that upregulate autophagy. This may be achieved 
by different conditions including starvation, exercise and treatment with pharmacological 
agents such as rapamycin (He et al., 2012a; Kuma et al., 2004; Ravikumar et al., 2004). 
Neurons treated with 5 nM rapamycin for 1 h demonstrate rapidly induced autophagy as 
evidenced by a decrease in phosphorylated p70S6 kinase (p70S6K) activation mediated by 
mTOR when compared to controls (Boland et al., 2008). Decreased mTOR activity was 
sustained after 6 h and 24 h treatment with rapamycin at the same concentration, with LC3-
II levels increased at both measured time points. Majumder et al. (2011) elegantly revealed 
that administering rapamycin (14 mg/kg) in chow to two month old transgenic AD mice 
across their lifespan induces autophagy in the brain as indicated by decreased p70S6K 
protein levels. Moreover, autophagy is also induced in transgenic mice that were fed the 
rapamycin-containing diet for three months from the age of 15 months (Majumder et al., 
2011). Exercise is a potent inducer of autophagy in the brain. Rats performing an acute bout 
of exercise (95 min of treadmill exercise) had significantly increased autophagy markers as 
assessed by Western blot analysis and GFP-LC3 puncta count in brain slices (He et al., 
2012a).  Mice subjected to 1 h of treadmill exercise demonstrated a significant upregulation 
in the conversion of LC3-I to LC3-II as indicated by Western blot analysis as well as increased 
Figure 1.4: Autophagy generates metabolic substrates through continuously recycling lysosomes. 
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GFP-LC3 puncta visible in skeletal muscle, compared to non-exercised littermates (Grumati 
et al., 2011).  
Starvation is a well-documented inducer of autophagy. Kuma et al. (2004) demonstrated in 
a mouse model that autophagy is induced during the early neonatal starvation period, 
occurring when pups are deprived of the nutrients supplied across the placenta and before 
they are suckled. The authors analysed primarily GPF-LC3 punctae and amino acid levels in 
different tissues and identified a marked plasma decrease of amino acids. These data 
indicate the major physiological role of functional autophagy. Brain tissue levels were not 
analysed by this group (Kuma et al., 2004). Neurons exposed to serum starvation, grown in 
glucose containing-medium without amino acids and other growth factors, display 
autophagy induction as indicated by increased LC3-II protein levels in the presence of the 
lysosomal inhibitor leupeptin, as well as increased presence of autophagolysosomes (Boland 
et al., 2008).  
Measuring autophagic flux 
Different tissues express autophagic activation to different degrees. Mizushima et al. (2004) 
generated a GFP-LC3 mouse to monitor the induction of autophagy in different organs in 
response to starvation, which allows visualization of autophagic vacuoles (AV). Interestingly, 
the brain did not show autophagy induction even after 48 h starvation. An important 
consideration relating to this finding is that purely measuring cellular levels of LC3 is not 
sufficient to make deductions about autophagy levels as autophagosomal cargo is 
continuously degraded. It has therefore been proposed that lysosomal turnover be used as 
marker instead (Tanida et al., 2005; Barth et al., 2010). It has been suggested that the 
apparent absence of autophagy induction in brain tissue may simply be the expression of an 
efficient turnover of AV, which will result in the rapid degradation of LC3-II. An example to 
illustrate the pitfalls of a static measure of autophagy is provided: LC3-II levels will increase 
either in the case of increased autophagosome synthesis, or if LC3-II degradation is blocked 
at any stage of autophagy after autophagosome formation (Rubinsztein et al., 2009). Thus, 
the utilization of lysosomal fusion inhibitors is crucial in order to interpret results related to 
autophagy activity (Rubinsztein et al., 2009).  
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Autophagic flux is defined by the extent of autophagic degradation activity, and thus by the 
rate of measured autophagic degradation (Loos et al., 2014). Various methods for 
measuring ‘autophagy’ exist, but only some of them consider changes in autophagosomal 
numbers over time (Klionsky et al., 2012). Transmission electron microscopy, GFP-LC3 
fluorescence microscopy and LC3 detection and quantification are examples of frequently 
used methods to measure autophagy, most often in vitro. In vivo methods to measure the 
autophagic flux of organs is a poorly developed area of research currently, yet it is of great 
importance as basal autophagy levels, the time course of autophagy induction and the 
bioavailability of drugs that induce and inhibit autophagy are likely tissue specific. Great 
care needs to be taken when interpreting autophagy markers (Klionsky et al., 2012). LC3 is 
the most widely monitored autophagy-related protein and different methods utilize its 
detection. Western blotting can be performed to detect the ratio of LC3-I to LC3-II, which 
provides an indication of how efficiently the conversion from LC3-I to LC3-II occurs.  
However, the pattern of this conversion seems to be cell specific, and related to the type of 
stress cells are exposed to. Autophagic flux can more accurately be inferred by measuring 
the difference in LC3-II levels between samples in the presence and absence of autophagy 
inhibitors (Mizushima and Yoshimori, 2007). Inhibitors include lysosomal protease inhibitors 
E64d and pepstatin A, as well as bafilomycin A1 which inhibits the fusion of autophagosomes 
and lysosomes (Mizushima and Yoshimori, 2007). 
It is clear that autophagy is a crucial evolutionary conserved pathway to maintain 
homeostasis in conditions of nutrient stress, with a particular role in neuronal metabolism. 
Now that the high ATP demands, substrate preference and metabolic pathways of the brain 
have been highlighted, the focus will shift to the perturbations in these parameters 
observed in Alzheimer’s disease.  
1.3 The Alzheimer’s disease brain 
In this section the molecular disruptions observed in AD will be discussed first, followed by a 
summary of how AD and dementia are diagnosed, thirdly the different cell death modes by 
which neuronal loss occurs will be highlighted, fourthly the role of mitochondrial function in 
AD followed by disrupted autophagy in AD and finally altered neuronal metabolism in AD 
will be discussed. 
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a. Molecular disruptions present in Alzheimer’s disease  
 
Defective autophagy is a feature of numerous neurodegenerative diseases including AD. The 
exact nature of the observed dysfunction will be discussed in section 1.3d. The focus will 
now move to the underlying cause of neurotoxicity in AD. Neurodegenerative diseases 
include AD, Parkinson’s disease (PD) and Huntington’s disease (HD). They are each 
characterized by the accumulation of specific abnormal proteins, such as Aβ and tau in AD, 
α-synuclein in PD and huntingtin protein in HD, each affecting particular brain regions. 
Despite the differences in the aetiology of these diseases, they share the symptom of 
protein aggregation (Swart et al., 2014). Protein aggregation is the association of two or 
more non-native protein molecules. Aggregation most often occurs with partially folded or 
misfolded states of proteins (Hartl and Hayer-Hartl, 2009). The Aβ1-42 peptide, the 
predominant peptide present in amyloid plaques, aggregates and forms oligomers, 
protofibrils and fibrils before being deposited to form plaques (Ahmed et al., 2010). 
However, this process is not a one-way reaction – fibrils represent a dynamic state of 
constant breakdown to recycle their composite units to be reassembled (Carulla et al, 2005). 
The histopathological and molecular presentation of AD will be discussed first before 
delving deeper into the nature of the aggregates observed.  
 
Two overt hallmarks have been identified post-mortem in AD brains; extracellular senile 
plaques and intracellular neurofibrillary tangles (NFTs). They were first described in the 
seminal work of German neuropathologist Aloïs Alzheimer more than a century ago 
(Alzheimer, 1911). NFTs contain hyperphosporylated tau (Grundke-Iqbal et al., 1986), a 
protein which functions to stabilize tubulin while senile plaques are comprised largely by 
amyloid-β (Aβ) peptide (Roher et al., 1996). 
 
Tau is a neutral or slightly basic protein which forms part of the microtubule associated 
protein (MAP) family (Cleveland et al., 1977). It is a hydrophilic protein which appears as a 
random coiled structure in solution. It mainly occurs in neurons and functions to stabilize 
microtubules (Avila et al., 2004). Alternative splicing of exons two, three and ten generates 
six different isoforms in the central nervous system. AD is classified as the most common of 
the tauopathies - conditions resulting from abnormal tau levels, processing or mutations 
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(Avila et al., 2004). Tau is hyperphosphorylated in AD, a reaction catalysed mainly by GSK3 
(mainly GSK3β) at the amino acid residues threonine-231, serine-396 or -404. In 
nonpathological conditions, kinase-mediated phosphorylation of tau causes it to detach 
from microtubules, which allows for effective axonal transport (Ballatore et al., 2007). 
Hyperphosphorylation causes tau to dissociate from microtubules and to form aggregated 
NFTs in the cytosol (Grundke-Iqbal et al., 1986). Tau knockout mice have a deficiency in tau 
protein which partially delays neurodegeneration as indicated by dentate gyrus volume (De 
Barreda et al., 2010). GSK3 overexpression is toxic to mice, but tau knockout ameliorates 
this effect, demonstrating the importance of tau in the pathology of neurodegeneration (De 
Barreda et al., 2010).  
 
Braak and Del Tredici (2012) delineate AD progression by using a staging model, important 
for determining disease severity. It encompasses both pre-tangle formation and NFT stages 
I-VI, each characterized by the extent to which NFTs are present. Immunostaining for 
abnormal tau (using AT8 antibody) reveals that a variety of brain regions are systematically 
affected. Vulnerable neurons in the locus coeruleus are affected first, followed by lesions in 
the entorhinal region of the temporal lobe, with cortical involvement seen only in NFT 
stages V and VI.  
 
 
 
 
 
 
 
 
The second major AD lesion, amyloid plaques, is comprised of Aβ peptide. Aβ is a 
physiologically occurring peptide derived from the processing of the membrane-spanning 
amyloid precursor protein (APP) which is present ubiquitously in the plasma and organelle 
membranes (Sambamurti et al., 1992). The Aβ peptide plays an important role in synaptic 
physiology; however the precise role of APP is still largely unclear although it is known to be 
expressed in neurons (O’Brien and Wong, 2011). There are various pathways of APP 
Figure 1.5: Tau hyperphosphorylation leads to neurofibrillary tangle formation. 
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processing, and not all of them generate Aβ. APP is synthesized in the ER and Golgi 
apparatus and then transported along the axon toward the synaptic terminal’s cell surface 
through the trans-Golgi network, where it inserts. The exact intracellular locus of APP 
processing is an important factor determining whether or not Aβ is produced. APP can be 
proteolyzed at the cell surface by α-secretase and γ-secretase, which produces an APP 
ectodomain (sAPPα) which diffuses rapidly. Alternatively, APP can re-enter the cell by being 
taken up into clathrin-coated pits and transported to endosomes which contain γ-secretase 
and beta-site APP-cleaving enzyme (BACE), produces the ectodomain sAPPβ, the APP 
protein intracellular domain (AICD) as well as Aβ. These peptides are released into the 
extracellular space by endosomes that translocate to the cell surface or are degraded in 
lysosomes (O’Brien and Wong, 2011). The enzymes governing APP processing have been 
identified. BACE1 is a transmembrane aspartic protease that cleaves APP at two sites. It is 
the neuronal β-secretase. Following BACE1 cleavage of APP, its C-terminal fragment (APP-
CTF) is cleaved by the γ-secretase complex at one of many sites, situated at residue 40-44 to 
produce Aβ peptides. The γ-secretase complex is comprised of four proteins, of which one is 
presenilin 1 (PSEN1) or presenilin 2 (PSEN2). PSEN1 and PSEN2 contain two aspartyl residues 
which are crucial for intramembranous cleavage, an important function of the γ-secretase 
complex (O’Brien and Wong, 2011). Cells in which PSEN1 are deleted are characterized by a 
near complete abolition of autophagy, demonstrating an important function of PSEN1 in the 
autophagosomal/lysosomal degradation pathway. The PSEN1 holoprotein acts as a 
chaperone in the ER to facilitate maturation and targeting of the v-ATPase V0a1 subunit to 
lysosomes (Lee et al., 2010). This subunit is essential for lysosome acidification and the 
activation of proteases, without which substrates cannot be degraded. These same 
functions are affected in patients with familial AD caused by PSEN1 mutation, though to a 
lesser degree.  
 
There has been a change regarding the consensus of which form of the amyloid peptide 
aggregates, i.e. formation driven by oligomers or fibrillar plaques, and it is not clear which of 
these is the main agent causing neurotoxicity (Benilova et al., 2012). Even though the exact 
aetiology of AD remains unknown, aberrant processing of APP and Aβ are unifying factors 
among different theories (Di Carlo et al., 2010). Recent findings suggest Aβ being 
responsible for AD-related tau hyperphosphorylation, as the addition of soluble Aβ or 
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aqueous extract from AD brains stimulates tau phosphorylation at epitopes characteristic of 
AD in vitro (De Felice et al., 2008; Jin et al., 2011). This emphasizes the central role of Aβ in 
AD. However, it has to be remembered that tau and amyloid proteins are functionally linked 
as the transport of autophagosomes to lysosomes is dependent on a stable microtubule 
network (Swart et al., 2014). Additional considerations in Alzheimer’s research, apart from 
proteolytic cleavage pathways involved, are the rate of Aβ production, its removal rate and 
rate of fibril formation from soluble proteins (Shoji et al., 1992). The rates of protein 
degradation pathways, such as autophagy, will here play an important role. It is important 
to identify the level of functioning of these parameters as it will determine neuronal health 
and thus resistance to cell death.  
 
Oligomers and amyloid fibrils are toxic to cells and contribute to neurodegeneration (Hartl 
and Hayer-Hartl, 2009). However, literature suggests different sources of toxicity, i.e. either 
oligomers or fibrils present in amyloid plaques as the main agent responsible for 
neurodegeneration. Xie et al. (2013) demonstrated that plaques cause surrounding 
oxidative stress and contribute to toxicity and neuronal death in AD.  However, the fibril-rich 
plaques appear not to be a direct cause of AD-associated dementia, rather the increased 
production of a toxic version of Aβ, the peptide Aβ42, is central in the disease progression 
(Saido, 2013). It has been shown that neuronal cell loss is correlated with oligomeric Aβ 
load, and not with fibrillar amyloid plaque burden (DaRocha-Souto et al., 2011). In this case 
‘Aβ load’ (oligomers) refers to the percentage the cortex covered by immunostained 
amyloid deposits and ‘amyloid plaque burden’ refers to the area occupied by dense plaques 
staining positive for thioflavin S. Similarly, it has been found that Aβ42 oligomers are more 
toxic than fibrils in vitro (Ahmed et al., 2010).  
 
Indeed, various studies have shown that oligomers are more potent inducers of disrupted 
synaptic function and neural networks than aggregates (Palop and Mucke, 2010). Synaptic 
function can be measured by the synaptic transmission strength and plasticity, while 
excitatory synapse transmission can be assessed by monitoring the expression levels of cell 
surface receptors such as the N-methyl-D-aspartate (NMDA) and A-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors.  It is also significant to note that AD 
transgenic mice exhibit altered physiology and neurites prior to plaque deposition 
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(Capetillo-Zarate et al., 2006; Gillardon et al., 2007). Furthermore, Gillardon et al. (2007) 
suggest that the Aβ-induced neurodegeneration is not caused by a simple increase in Aβ 
levels or plaques but rather the transition of Aβ protein to soluble oligomers or fibrils. 
 
It has been elegantly demonstrated by the Finkbeiner lab (Arrasate et al., 2004) that protein 
aggregation per se is not associated with cell death. In fact, the cells that survived the 
longest upon mutant huntingtin protein presence were those that also displayed protein 
aggregates or inclusion bodies. Ross and Poirier (2005) use many lines of evidence to 
support the theory that aggregates represent a cellular protective mechanism. However, the 
amount of Aβ deposit in the brains of transgenic mice is correlated to neuronal loss in the 
CA1 hippocampal subfield. Thus the presence of Aβ, regardless of its form (soluble or 
aggregated), is considered to be detrimental to neuronal cells (DaRocha-Souto et al., 2011).  
AD is classified as either familial or sporadic AD. Familial AD occurs primarily as a result of 
genetic mutations on chromosomes 1, 14 or 21 (Götz et al., 2011; Hoyer, 2000). These 
mutations cause autosomal dominant AD that presents early and usually severely. There are 
 
 
 
 
 
 
 
 
 
 
 
 
32 mutations in genes encoding APP, 179 mutations in PSEN1 and 14 in PSEN2. APP 
mutations occur around the γ-secretase cleavage site, but it should be noted that the most 
frequently observed APP mutation occurs adjacent to the BACE1 cleavage site. PSEN 
mutations cause alternated expression of amino acids in their transmembrane regions 
Figure 1.6: Amyloid beta is produced from amyloid precursor protein (APP) and forms toxic 
aggregates. 
Stellenbosch University  https://scholar.sun.ac.za
24 
 
(O’Brien and Wong, 2011). These mutations lead to an important outcome – increased 
production of Aβ42 relative to Aβ40. Aβ42 is the less soluble and more toxic Aβ species. Only 
about 1% of AD cases are familial, however. The rest are classified as ‘sporadic AD’, of which 
50-70% are estimated to have a genetic component, however the cause is mostly unknown.  
Susceptibility genes for sporadic AD include the apolipoprotein E allele (ApoE).  The ApoE 
allele occurs as three variants that encode the proteins ApoE2, ApoE3 and ApoE4. The 
ApoE4 allele significantly increases the risk of developing AD, with increasing risk for 
homozygous individuals. ApoE4 binds Aβ less strongly than the other two ApoE proteins, 
and in individuals with the ApoE4 allele it shows a strong correlation with increased Aβ 
deposition in the brain (O’Brien and Wong, 2011).  In addition to the APP, PSEN1, PSEN2 and 
ApoE gene mutations or expression patterns discussed, two potential AD susceptibility 
genes have recently been identified. The function of IGHV1-67 (chromosome 14) is unknown 
but is most likely involved in immunoglobulin G (IgG) VDJ-type recombinations during 
lymphocyte maturations. The TP53INP1 gene on chromosome eight encodes a protein that 
facilitates autophagy-dependent apoptosis via phosphorylating p53 and is involved in cell 
migration and extracellular matrix adhesion (Escott-Price et al., 2014). Thus disrupted 
autophagy in the context of apoptotic cell death is implicated in AD. Despite the genetic 
alterations observed in familial AD, it is impossible to macroscopically distinguish a sporadic 
from a familial AD brain as both present a similar set of characteristics (Götz et al., 2011). 
These will now be discussed. 
 
AD researchers face the challenge of multifaceted disease pathology, yet the biggest hurdle 
is the length of time, often a matter of decades, that separates its cause from functional 
defects (Saido, 2013). Aging is the main risk factor for developing AD, complicating the 
process of unravelling its aetiology, as aging is also associated with molecular disruptions 
that are implicated in AD e.g. oxidative stress, inflammation and mitochondrial damage 
(Gouras et al., 2010). In aging, there is a loss of brain volume, but the extent is less severe 
than observed in AD, especially in the hippocampus (Resnick et al., 2003; Frisoni et al., 
2010). The free radical theory of aging states that reactive oxygen (ROS) species are 
responsible for damaging proteins, which accumulate over time (Harman, 1956). Aged cells 
are less proficient at clearing defective proteins by proteolytic pathways and as a result 
proteins accumulate and aggregate intracellularly (Martinez-Vicente et al., 2005).  
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The theme of proteostasis, homeostasis of protein degradation, is hence central and will be 
discussed in more detail below. The divide between apparent cognitive decline and the 
molecular disruptions remains a large problem, however, and the means by which AD is 
currently diagnosed remains challenging and will be investigated first.  
b. Dementia and Alzheimer’s disease diagnosis 
Perhaps the most well-known clinically manifest hallmark of AD is the memory loss 
associated with dementia. The definition of dementia is the development of cognitive 
deficits which manifests as memory impairment and disturbances in language use, motor 
activity, cognition of objects and executive function (Chertkow, 2008). The term ‘mild 
cognitive impairment’ (MCI) was created to identify cognitive deficiency in the stage 
between normal aging and dementia. MCI as separate diagnostic category is seen as a 
valuable tool because of the possibility to intervene before AD (or other dementia-
associated diseases) manifests in the transition from MCI to dementia (Petersen et al., 
2014). MCI is not always a precursor to more serious conditions, but it is very often the case, 
with a rate of conversion to dementia of 50% within five years (Petersen et al., 1999). 
Recently, the American Psychiatric Association has published a new set of criteria for 
dementia which includes pre-dementia in the Diagnostic and Statistical Manual for Mental 
Disorders (DSM-5). Here the stage of cognitive impairment is termed ‘mild neurocognitive 
disorder’ (NCD). It shares many features with MCI but includes more expanded criteria that 
allow clinicians to distinguish subtle features that are present in NCD, but absent in normal 
aging and dementia. Some characteristics of NCD include ‘preserved independence in 
functional abilities’ and ‘objective cognitive impairment’. It is implied that 
neuropsychological testing can be a helpful diagnostic tool. NCD can further be classified as 
mild or major, and its aetiology can be determined, such as arising from AD, frontotemporal 
degeneration or Lewy body disorders (Petersen et al., 2014).  
AD dementia can be distinguished from so-called ‘all-cause dementia’ by specific features, 
outlined by the National Institute on Ageing and the Alzheimer’s Association (McKhann et 
al., 2011). Here it is recommended that AD dementia be subdivided into ‘(1) Probable AD 
dementia, (2) Possible AD dementia, and (3) Probable or possible AD dementia with 
evidence of the AD pathophysiological process’. ‘Probable dementia’ includes insidious 
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onset  from months to years, a history of worsening cognition, impaired learning and 
information recall as well as a range of non-amnestic presentations such as impaired 
executive function. The certainty of diagnosis increases to ‘possible AD dementia’ with 
evidence of progressive cognitive decline as reflected by formal neuropsychological tests, 
and with the presence of genetic mutations in the APP, PSEN1 or PSEN2 genes. Evidence of 
pathophysiological processes adds another level of certainty. This evidence is based on 
various biomarkers characteristic of AD, such as Aβ and tau proteins. The focus of this 
review will hence be on the pathophysiological changes observed in AD. It is important to 
consider when in the disease pathogenesis the molecular underpinning of these symptoms 
appear and how cognitive decline correlates with molecular events. Dementia symptoms 
are observed only late in AD disease progression, during Braak stage V, when clinical 
diagnosis usually takes place. Thus there is an extended time, possibly decades, during 
which pathogenic changes take place before diagnosis (Braak and Del Tredici, 2012). 
 
Diagnosing AD can be confusing when one considers the long ‘pre-clinical’ stage of the 
disease in which no AD dementia is diagnosable. Sperling et al. (2011) developed a model of 
AD disease progression where the phases of AD are characterized sequentially from ‘pre-
clinical’, ‘MCI’, and ‘dementia’ with biomarker presence increasing the risk of developing 
AD, but not guaranteeing progression to the clinical phases. A particularly powerful model 
has been proposed by Jack et al. (2010) and expanded by Sperling et al. (2011) and includes 
preclinical AD, where the most important biomarkers of AD pathophysiology are shown to 
increase to abnormal levels in a predictable order until a ceiling is reached.  These 
biomarkers present as reduced presence of Aβ42 in the cerebrospinal fluid (CSF) and as 
increased amyloid tracer retention in PET imaging. Both indicate brain Aβ amyloidosis. PET 
can also be used to identify decreased FDG uptake with an AD-typical pattern of 
temporoparietal hypometabolism, a marker for synaptic dysfunction. MRI is used to detect 
brain atrophy that presents in a specific pattern of neurodegeneration in AD involving the 
medial temporal lobes, paralimbic and temporoparietal cortices (Sperling et al., 2011). 
 
It is beneficial in a clinical setting to distinguish between stages of severity of AD dementia 
in order to govern decision-making for treatment. The Clinical Dementia Rating (CDR) has 
become a standard measure for dementia staging internationally, and evaluates patients’ 
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impairment in six domains: memory, orientation, judgement and problem-solving, 
community affairs, home and hobbies and personal care, to yield a score that indicates one 
of five categories (Perneczky et al., 2006). These are: 0 (no dementia), 0.5 (questionably 
dementia), 1 (mild dementia), 2 (moderate dementia) and 3 (severe dementia). Caregivers 
are relied upon to provide substantial information necessary to make a diagnosis with CDR, 
and brief assessment tools, such as the Mini-Mental-State Examination (MMSE) may be 
more useful in clinical practice. The MMSE involves the patient having to complete tasks and 
questions such as the time and place that reveal his/her state of cognitive functioning. It 
usually takes about 10-15 minutes to complete. The final score of the patient will indicate 
dementia severity, with a score of 30 indicating the best cognitive function, and a score of 
zero the worst (Perneczky et al., 2006). 
 
As the loss of brain volume and neuronal cell death is responsible for AD dementia, the 
processes governing cell death and their molecular link with the autophagic machinery will 
be discussed now.  
 
c. Cell death modalities  
Magnetic resonance imaging reveals macroscopic changes present in the AD brain. These 
typically include an atrophied hippocampus and widened ventricles (Apostolova et al., 
2012). Neuronal and synaptic loss occur in parallel with the ‘positive’ features of protein 
aggregation, and more recently early changes such as injured dendrites and synapses have 
expanded the traditional hypothesis of the events leading to AD (Serrano-Pozo, 2011). An 
overview of cell death mechanisms and their molecular regulation is necessary in order to 
better contextualize its contribution to neuronal tissue atrophy. 
 
Cell death categorization 
Early cell death research used morphological features to identify different cell death modes, 
as biochemical research methods were less available then (Galluzzi et al., 2012). However, 
subsequent research has provided evidence that using morphotypes of cell death may hide 
a great degree of heterogeneity. Nonetheless this approach was favoured by the scientific 
community until recently, despite the availability of powerful biochemical methods to 
assess cell death.  A ‘dead’ cell displays either irreversible plasma membrane 
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permeabilization or has suffered complete fragmentation. Cell death can occur by activation 
of one of three death modes: apoptosis, necrosis and cell death by autophagy. However, 
recent developments recommend to move away from this, primarily morphology based, 
restrictive categorization since a large degree of molecular overlap exists (Galluzzi et al., 
2015). Instead, cell death can be classified into two main categories for functional purposes 
– ‘accidental’ and ‘regulated’ cell death. Accidental cell death usually occurs when cells are 
exposed to severe conditions, usually over a short period of time and probably does not 
involve a specific molecular machinery (Galluzzi et al., 2015). However, for the purpose of 
this literature review we will refer to both factors that control cell death, as well as 
morphological features in order to better connect with previous literature. 
 
Traditional cell death modalities 
‘Programmed cell death’ refers to an established series of events that lead to cell death, 
such as observed during apoptotic cell death. Apoptosis can be identified morphologically 
by cell shrinkage, membrane blebbing, nuclear fragmentation and chromatin margination 
(Lockshin and Zakeri, 2004). It is dependent on a cascade of molecular events, and can be 
subdivided into the intrinsic and extrinsic apoptotic pathway that culminates in the same 
execution pathway. The execution pathway is initiated by caspase-3 cleavage which results 
in DNA fragmentation, cell protein degradation, protein cross-linking, formation of 
apoptotic bodies and uptake by phagocytic cells following the expression of phagocytic cell 
receptor ligands. In the extrinsic pathway, transmembrane receptors or death receptors of 
the tumour necrosis factor (TNF) receptor gene superfamily transmit death signals from the 
cell surface to intracellular signalling pathways (Elmore, 2007). Death receptors bind their 
ligands and form cluster interactions with one another. A death-inducing signalling complex 
(DISC) is formed which triggers the autocatalytic activation of pro-caspase 8, to form active 
caspase-8. Caspase-8 triggers the execution pathway. The intrinsic apoptotic pathway is 
triggered by a diverse range of intracellular stimuli that do not act via receptors, but through 
mitochondria. Signals can act in a negative fashion in the absence of growth factors, 
hormones and cytokines where there is a loss of apoptosis suppression. Positive signals 
include toxins, hypoxia, hyperthermia, viral infections, and free radicals. Intrinsic stimuli 
cause changes in the mitochondrial inner membrane, which triggers the opening of the 
mitochondrial permeability transition pore (mPTP) and loss of the mitochondrial 
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transmembrane potential. Two groups of pro-apoptotic proteins, normally sequestered in 
the intermembrane space, are then released into the cytosol. The first group activates the 
caspase-dependent mitochondrial pathway and consists of cytochrome c, Smac/DIABLO, 
and Htr/Omi (Elmore, 2007). Cytochrome c binds and activates apoptotic protease 
activating factor 1 (Apaf-1) and pro-caspase 9, which forms an apoptosome and in turn 
activates caspase-9. The second group of proteins is released from mitochondria during 
apoptosis – a late event in the apoptotic cascade – and consists of apoptosis-inducing factor 
(AIF), endonuclease G and caspase-activated DNase (CAD). Both AIF and endonuclease G act 
in a caspase-independent manner and cause changes in DNA such as fragmentation and 
condensation. CAD is released from mitochondria and translocates to the nucleus. Caspase-
3 cleaves and activates CAD which in turn causes DNA fragmentation and advanced 
chromatin condensation (Elmore, 2007). Poly (ADP-ribose) polymerase (PARP) is also 
cleaved during apoptosis, to form an 85 kDa protein (Tewari et al., 1995). Apoptotic 
mitochondrial events are controlled and regulated by members of the Bcl-2 family of 
proteins, and the tumour suppressing protein p53 also plays an important regulatory role 
(Elmore, 2007).  
Necrosis, in contrast, most often operates in a less controlled fashion where cells swell, leak 
cytoplasmic contents into the extracellular environment and cause an inflammatory 
response (Lockshin and Zakeri, 2004). In addition, it was traditionally defined by the absence 
of apoptosis and autophagic morphological traits. However, more recently, it has emerged 
that necrosis is less accidental and can occur in a regulated fashion (Galluzzi et al., 2012). 
Triggers that may induce regulated necrosis include alkylating DNA damage, excitotoxins 
and death receptor ligation.  TNFα binding to the TNF receptor 1 (TNFR) recruits five 
proteins, including receptor-interacting protein kinase 1 (RIPK1 or RIP1) to its cytoplasmic 
tails, which provides a docking station for three other proteins. Under certain conditions 
such as caspase-8 absence, deubiquinated RIP1 can engage with its homolog, RIP3 which 
activates the execution of necrotic cell death (Galluzzi et al., 2012).  
 
Autophagic cell death is caspase-independent, and cells display many large AV, and an 
externalization of phosphatidylserine (Lockshin and Zakeri, 2004). However, the existence of 
this type of cell death has been questioned, and suggested that increased autophagy 
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preceding cell death may rather represent a futile attempt to escape death (Shen et al., 
2012). The loss of ATP is a striking feature distinguishing apoptosis and necrosis, as only 
necrosis is marked by a large decrease in the amount of ATP (Lockshin and Zakeri, 2004).  
 
Recent literature now recommends to rather focus on the factors that control cell death 
than on characterizing the different cell death modalities. Cellular metabolism is a major 
role player in determining cellular fate. There is evidence of ‘metabolic checkpoints’, 
molecular mechanisms regulating cellular functions in response to metabolic stimuli, that 
detect changes in the major metabolites, such as the ratios of ATP/ADP and AcCoA/CoA, and 
that interact with these metabolic signals to initiate downstream events (Green et al., 2014). 
The effectors of these events are metabolites and metabolic by-products, as well as various 
enzymes involved in metabolic circuits. Signal transducers are activated in this way, 
including those involved in initiating cell death. Examples of checkpoints include the 
mitochondrial checkpoint, the autophagy checkpoint (comprehensively interconnected with 
other checkpoints), the AcCoA/CoA checkpoint and the p53 checkpoint (Green et al., 2014).  
 
Cell death dynamics 
Cellular dynamics is at the heart of cell death decision-making. The point-of-no-return 
(PONR) is a powerful concept here. A cell’s ability to respond to an insult will determine the 
subsequent cell death mode, with the metabolic state of the cell playing a key role (Loos 
and Engelbrecht, 2009). The PONR for autophagy occurs earlier in time than that for 
apoptosis since autophagy induction, above basal levels of autophagy, is the first stress 
response initiated. Cells have to be most stressed for necrosis to occur. The three death 
modes are connected ATP-dependently, and autophagy plays both a direct and indirect role 
in delaying apoptosis and necrosis onset as it can generate ATP (Loos and Engelbrecht, 
2009).  
 
Apoptosis is the main cell death pathway involved in AD and neurons treated with Aβ 
peptide trigger apoptosis in vitro (Loo et al., 1993).  Moreover, the activation of apoptosis by 
both the intrinsic and extrinsic pathways, possibly dependent on the form of Aβ protein 
involved, has been described (Di Carlo, 2010). However, based on the here described 
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molecular overlap between cell death modalities, it has to be considered in the particular 
context of a cellular stress response. 
 
d. The role of dysfunctional mitochondria in Alzheimer’s disease 
Mitochondrial dysfunction is a prominent feature of AD (Reddy, 2009). It constitutes a host 
of factors such as respiratory chain uncoupling, superoxide radical production, and calcium 
leakage (Kroemer et al., 1998). It can also be a cause of neuronal death. Mitochondrial 
dysfunction can lead to cell death in two distinct ways. The first is characterized by 
activation of the permeability complex, which occurs when environmental factors trigger an 
increase in mitochondrial membrane permeability. This activates apoptosis by releasing 
mitochondrial proteins such as cytochrome c and dispersion of the electrochemical gradient 
present on the inner mitochondrial membrane. The second way is characterized by a 
bioenergetic state of distress which disrupts cellular function to such an extent that 
apoptosis or necrosis is triggered (Kroemer et al., 1998). 
Aβ and APP can associate with various mitochondrial compartments, including the inner and 
outer mitochondrial membrane, the intermembrane space and the matrix which may 
explain the mitochondrial dysfunction observed (Pagani and Eckert, 2011). Aβ may affect 
components of the electron transport chain (ETC) present on the inner membrane, and TCA 
cycle enzymes present in the mitochondrial matrix, disrupting normal metabolic as well as 
antioxidant function. Aβ may also bind to cyclophilin D (CypD), a component of the mPTP 
which promotes its opening and thus apoptosis. The activity of fission protein Fis1, present 
on the outer mitochondrial membrane, is enhanced by Aβ, resulting in increased 
mitochondrial fragmentation (Pagani and Eckert, 2011).   
 
Significant impairment in four functional parameters of mitochondria, i.e. reductive 
capacity, mitochondrial membrane permeability, ROS and ATP levels, occurs after exposing 
hippocampal cells to mitochondrial-targeted Aβ (Cha et al., 2012). These detrimental 
changes are a direct cause of cell death. Aβ’s association with mitochondria causes harmful 
changes in both morphology and function. Morphologically apoptotic features are observed, 
such as fragmentation, cristae disruption, and mitochondrial swelling (Cha et al., 2012). 
Stellenbosch University  https://scholar.sun.ac.za
32 
 
Calkins and Reddy (2011) exposed hippocampal neurons to Aβ peptide and observed 
decreased mitochondrial motility as well as fragmented mitochondria (Figure 1.7). 
 
Animal models of AD reveal similar results. In a study of transgenic mice, Robinson et al. 
(2014) demonstrated that deficiency in PSEN1/2 or AICD affects mitochondrial function. 
Here, PSEN1 regulated peroxisome proliferator-activated receptor-c coactivator 1α (PGC-
1α), important for expression of mitochondrial proteins, causing disrupted mitochondrial 
energy metabolism when mutated.  
Multiple researchers have shown that Aβ disrupts mitochondrial dynamics, which causes 
the equilibrium between fission and fusion to shift and favour fission (Calkins et al., 2011). 
Protein levels of Drp1, Opa1, Mfn1 and Mfn2 are significantly reduced in AD neurons, while 
Fis1 protein levels are significantly increased. Although the changes in Opa1, Mfn1 Mfn2 
and Fis1 expression are associated with increased fission, Drp1 reduction is linked with 
mitochondrial elongation, which could lead to an uncertain outcome in mitochondrial 
dynamics in AD.  Furthermore, soluble amyloid oligomers have a detrimental effect on 
mitochondria – there is an increased mitochondrial fragmentation and altered 
mitochondrial distribution to a state where the majority of mitochondria are localized in the 
soma and very few present in the neuronal processes (Wang et al., 2009). This is 
understandable in light of the fact that fission/fusion proteins control not only 
mitochondrial morphology but also their intracellular distribution. The same group also 
identified that overexpressing Drp1 prevented the oligomer-induced synaptic loss, 
indicating the important role of abnormal mitochondrial dynamics in the process of synapse 
loss. This finding is of interest as Drp1 overexpression causes predominantly fragmented 
mitochondria, a condition that seems to be present in AD, but was found to rescue neurons 
from the abnormal pattern of mitochondrial distribution. This may be understood better 
when one considers that there is both an abnormal expression pattern of fission and fusion 
proteins in AD, and that both of these processes occur at a slower rate in AD neurons 
compared to healthy neurons. Mitochondria spend more time in a state of fission in amyloid 
oligomer treated cells, which may indicate the reason for the increased fission observed in 
AD (Wang et al., 2009). These results suggest a dynamic assessment of fission and fusion 
rate, in order to dissect the mitochondrial function in the context of protein levels.  
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The focus will now shift from altered mitochondrial network features often observed in 
neurons derived from AD patients to autophagy, which is another crucial intracellular 
system that is involved in metabolic homeostasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e. The role of disrupted autophagy in Alzheimer’s disease 
Autophagy, a major protein degradation pathway, is usually activated as a first stress 
response in cells during e.g. nutrient deprivation, but it also serves important homeostatic 
functions, such as the breakdown of non-functional structures e.g. peroxisomes (Klionsky, 
2005). It is also the mechanism by which long-lived proteins are degraded (Nixon and Yang, 
2011), an important role in light of the fact that 99% of all cellular proteins are long-lived 
(Schworer et al., 1981). Disrupted autophagy has been identified as a key factor in 
neurodegenerative diseases such as PD, HD and AD. In HD, autophagy malfunction occurs as 
a result of AV not being able to recognize cytosolic cargo, resulting in failure to engulf cargo 
as demonstrated by studies on a HD mouse model and human HD cells where mutant 
huntingtin protein (Martinez-Vicente et al., 2010). In PD mutant α-synuclein binds to 
Figure 1.7: Aβ associates with mitochondria and results in increased mitochondrial fission. 
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lysosomal membrane receptors, probably impairing the uptake and degradation of both α-
synuclein and other substrates, thereby contributing to their accumulation (Pan et al., 
2008). Elucidating the exact nature of autophagy disruption in AD is complicated as there is 
conflicting evidence regarding altered autophagy induction (Nixon and Yang, 2011). We will 
present the major characteristics of this dysfunction below. 
Autophagy has become a major focus of current AD research.  Disrupted autophagy is 
recognized as an important event that leads to the characteristic AV accumulation observed 
in dystrophic neurites (Nixon and Yang, 2011). Fascinating work by Hara et al. (2006) 
demonstrates that the suppression of basal autophagy in mice by preventing Atg5 
expression leads to neurodegeneration, and suppression of Atg7 leads to multiple cellular 
abnormalities (Komatsu et al., 2005). This finding places enormous importance on 
autophagic dysfunction as a factor in the disease pathogenesis of neurodegeneration, if one 
considers that neurodegeneration occurs in the absence of mutated proteins in these 
studies. The authors demonstrate that a loss of autophagy first leads to the accumulation of 
diffuse abnormal proteins, and then to inclusion body formation in later stages, suggesting 
that autophagy is primarily responsible for the turnover of diffuse cytosolic proteins under 
normal conditions (Hara et al., 2006).  This validates the theory that inclusion body 
formation is an adaptive response which occurs when diffuse abnormal proteins overwhelm 
the process of autophagic clearance.  
The implications of defective autophagy are dire; the fact that it is a feature of so many 
neurodegenerative diseases is not surprising. The autophagic machinery is connected to 
three major pathways of energy sensing, i.e. the AMPK, mTOR, and protein kinase A (PKA) 
pathways, which are vital for maintaining cellular energy levels, and thus susceptibility to 
cell death (Loos et al., 2013).   
He et al. (2012a) generated mice with a knock-in BCL2 deficit, which resulted in blocked 
induction of autophagy but not basal levels of autophagy. They identified that mutant mice 
had an impaired increase in muscle glucose metabolism and also decreased exercise 
endurance. The metabolic effects of the BCL2 mutation could illuminate these findings; 
there was a blunted decrease in serum glucose and insulin levels.  Thus induced autophagy 
is necessary for sufficient glucose supply, indicating its profound integration in metabolism.  
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AD is characterised by severe changes in autophagy. Neurons in the brains of AD patients 
exhibit swollen neuritic processes - dystrophic neurites - which are filled with AV (Nixon et 
al., 2005).  These represent the various intermediate stages of autophagic degradation and 
include autophagosomes and endosomes fused with autophagosomes. AV accumulation has 
been attributed to impaired clearance of AV rather than strong autophagy induction (Boland 
et al., 2008). Yet upregulated autophagy initiation has been observed in the early stages of 
AD (Cataldo et al., 1995; Ginsberg et al., 2010). These apparently contradictory scenarios 
may be understood in terms of disease progression – early in the disease progression 
increased autophagy induction may represent a compensatory mechanism, but during the 
later stages, neurons’ degradative capacity decrease (Lipinski et al., 2010). It has also been 
demonstrated that the defect in autophagy is localized at the level of lysosomal 
degradation, and not in the early steps of autophagosome or autolysosome formation 
(Nixon and Yang, 2011). PSEN1 mutations, which cause early-onset AD, result in disrupted 
lysosome acidification, which provides strong evidence for defective proteolysis in AD 
(Nixon and Yang, 2011).  
Genomic analysis has revealed the underlying mechanisms governing the disrupted 
autophagy characteristics of AD (Lipinski et al., 2010). Specifically, ROS are identified as 
mediators of the type III PI3 kinase activity – an important upstream regulator of autophagy 
initiation. Lysosomal dysfunction caused by Aβ is independent of ROS, however. Proteomics 
has revealed that PSEN1 and nicastrin are found in the lysosomal membrane. These proteins 
both form part of the γ-secretase complex and are involved in intramembrane proteinolysis 
and are associated with AD (Schröder et al., 2010). This provides additional evidence for 
lysosomal autophagy dysfunction in AD.  
The molecular connection between autophagy and Aβ peptides is of vital importance in 
understanding disrupted autophagy in AD. Tian et al. (2013) demonstrated that an LC3-
receptor mediated reaction is responsible for the shuttling of the APP-CTF from the 
endocytic pathway to autophagosomes for degradation via autophagy. They identified that 
adaptor protein 2 complex which plays a role in chlathrin-mediated endocytosis functions as 
an LC3 receptor and is likely required for APP-CTF degradation by autophagy (Tian et al., 
2013).  This result supports the concept of targeted elimination of cargo by autophagy, an 
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emerging theme in recent research, and, more specifically identifies a possible mechanism 
by which autophagy degrades Aβ.  
Amyloid homeostasis may be greatly dependent on autophagy. Beclin-1 levels are reduced 
in the brains of AD patients and result in reduced neuronal autophagy (Pickford et al., 2008). 
Beclin-1 plays an important role in autophagy as it binds with and promotes the activity of 
Vps34 (Pickford et al., 2008), a class III PI3 kinase imperative for autophagosome formation 
(Jaber et al., 2012). Beclin-1 deficiency disrupts autophagy, modulates APP metabolism and 
leads to both intra- and extracellular Aβ deposits in mice (Pickford et al., 2008). 
Furthermore, the reduction in beclin-1 observed in the AD brain seems to be correlated with 
disease severity – patients with amnestic MCI (which could be considered early, prodromal 
AD) had a 30% reduction in beclin-1 levels compared to age-matched controls, while 
patients with severe AD had a 70% reduction in beclin-1 levels compared to control 
(Pickford et al., 2008). Thus beclin appears to be involved in the gradual autophagic failure 
associated with AD progression. Aβ accumulation may overwhelm the autophagic system 
which plays a ‘clean-up’ role in this situation and may clarify the many AV observed 
histologically (Cataldo et al., 1995). However, autophagy also plays a direct role in the 
production of Aβ as AV contain APP and amyloid producing enzymes, as demonstrated using 
APP transgenic mice (Yu et al., 2004). Indeed, autophagy and the endocytic pathway are 
heavily involved in the processing of APP and Aβ generation. The combination of increased 
formation of vacuoles containing Aβ, combined with the reduced clearance facilitates Aβ 
accumulation observed in AD (Nixon, 2007). Autophagy regulates Aβ peptide levels 
(Vingtdeux et al., 2011; Spilman et al., 2010), and it has been demonstrated that inducing 
autophagy can slow AD progression in mice models (Yang et al., 2011; Spilman et al., 2010). 
Thus, increasing autophagy holds promise as a therapeutic target. 
Activating autophagy can reduce both Aβ levels and AD occurrence in vivo, demonstrating 
its validity as a therapeutic target (Spilman et al., 2010). However, timing is a crucial 
component when considering the manipulation of autophagic flux as a therapeutic strategy. 
It would be optimal to increase autophagy at early stages of the disease, when the 
degradative capacity of cells is more likely to be intact. This would aid the inherent 
machinery in cells that clear defective proteins. Enhancing autophagy later in disease could 
be not only counter-productive, but also dangerous as this period is characterized by 
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reduced proteolytic abilities and extensive AV accumulation. Doing so could potentially 
exacerbate the AV load and may accelerate neuronal cell death. It is hence very important 
to characterize autophagic flux and autophagy status in in vitro and in vivo models. It would 
be most useful to determine the level of autophagic flux in AD patients. The scientific tools 
to achieve this are still lacking, yet the importance of an ‘autophagometer’ has been 
outlined (Rubinsztein et al., 2009).  If implemented, decreased autophagic flux could 
potentially be identified even before dementia manifests. The deficit could then be treated 
according to flux deviation in patients. Currently, major neuronal loss precedes the onset of 
disease manifestation. This emphasizes the therapeutic focus on prevention, as opposed to 
the mere management of symptoms. 
f. Altered neuronal metabolism in Alzheimer’s disease 
The fact that cellular energetics and survival are closely linked warrants a closer assessment 
of the metabolic changes that occur in the AD brain and how metabolism influences AD 
susceptibility. Energetic substrates are inextricably linked to cellular functioning. Indeed, it is 
not only a lack of a balanced supply of substrates which may be detrimental to cells, but also 
the type of substrate being metabolized. 
 
There is disrupted energetic substrate supply in AD and cerebral glucose metabolism is 
reduced by 20-40% in sporadic AD (Hoyer, 2000). Moreover, decreased hippocampal 
glucose metabolism in AD mice has been observed, which occurs concomitantly with 
impaired spatial memory and neuronal cell loss (Sadowski et al., 2004).  Decreased glucose 
transport may cause this decrease, and it is an widely observed effect found in both normal 
and triple transgenic (3xTg-AD) mouse brains which harbour mutations in PSEN, APP and tau 
(Ding et al., 2013). 
In patients with MCI, brain volume loss due to AD can be detected in the hippocampus, 
entorhinal cortex and parahippocampal gyrus (Mosconi, 2005). Structural MRI studies have 
revealed that the medial temporal lobe is the earliest affected brain region in AD. 
Furthermore, the transition to dementia can be predicted by changes in the lateral temporal 
lobe. FDG-PET imaging has demonstrated that reduced glucose metabolism in the parieto-
temporal, frontal and posterior cingulate cortices is indicative of AD (Mosconi, 2005). This 
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method has 90% sensitivity in identifying AD, although it is not able to differentiate AD from 
other dementias.  
Metabolomics has revealed that 154 metabolites in plasma and 150 metabolites in CSF were 
significantly altered in AD patients compared to control subjects (Trushina et al., 2013). In 
addition, 40 canonical pathways in plasma and 30 in CSF were significantly altered in the AD 
subjects. Cholesterol and sphingolipid transport was the most affected pathway in both CSF 
and plasma samples, and in the CSF aspartate and aspargine metabolism as well as the TCA 
cycle were among the top four altered pathways. Not surprisingly, the number of affected 
pathways was found to increase with disease severity, emphasising the importance of 
healthy metabolism for delaying disease progression.  
A poor diet and lack of physical exercise increases the risk of developing AD. In contrast, it 
has been demonstrated that elders without dementia who followed a Mediterranean-type 
diet, i.e. a diet rich in cereals, legumes, fish, fruits and vegetables as well as 
monounsaturated fats, had a decreased risk for developing AD over a mean period of 5.4 
years of follow-up. Their odds improved even further when physically active, with more 
physical activity being associated with a lowered risk for developing AD. When the factors of 
diet and physical exercise were considered together in the same model, a statistically 
significant association with AD incidence was found (Scarmeas et al., 2009). 
 
Longitudinal (Janson et al., 2004) and epidemiological studies (Peia et al., 2002) support the 
relationship between AD risk and glucose metabolism disorders. Type 2 diabetes mellitus 
(T2DM) has been identified as a risk factor for developing AD (Vagelatos and Eslick, 2013) 
and altered brain metabolism is observed in AD patients soon after clinical symptoms 
manifest, alterations which have features reminiscent of T2DM such as impairments in 
glucose handling and energy metabolism (Bosco et al., 2011). Furthermore, these changes 
are proposed to occur before symptoms manifest, casting AD as a particular type of ‘brain 
diabetes’. Insulin and insulin-like growth factor-1 (IGF-1) can bind to receptors expressed 
ubiquitously, including in the brain. Binding to their respective receptors in the brain 
facilitates important functions such as neuronal survival, energy homeostasis and memory 
(Bosco et al., 2011). The insulin signalling pathway is initiated by insulin binding the insulin 
receptor in the plasma membrane, which causes its autophosphorylation, in the process 
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activating its tyrosine kinase activity (Liu et al., 2011). This causes the recruitment and 
phosphorylation of a variety of substrates including insulin receptor substrate-1 (IRS-1). IRS-
1 also binds various substrates, notably PI3K, which leads to the phosphorylation and 
activation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) which in turn activates 
Akt.  Insulin induces the upregulation of the insulin degrading enzyme (IDE) which acts in a 
feedback mechanism in hippocampal neurons to control insulin signalling (Zhao et al., 
2004). IDE levels and activity are decreased in AD and are associated with increased levels of 
Aβ, demonstrating the importance of insulin signalling control in preventing AD (Figure 
1.89). It is important to note that Akt phosphorylates GSK3β, thereby deactivating its 
activity. Thus a decrease in insulin signalling contributes to exacerbated tau 
hyperphosphorylation via GSK3β activity (Liu et al., 2011).  
 
Brain glucose uptake occurs at specific regions such as the hippocampus through the actions 
of glucose transporters. It has been shown, however, that there is a reduced uptake of 
glucose in the brains of animals with T2DM. A similar theme emerges with AD. Insulin levels 
are lower in the CSF of AD patients and IGF-1 receptor expression is diminished dependent 
on disease severity. IGF-1 resistance seems likely, as an increase in serum IGF-1 is seen in 
early AD, but IGF-1 mRNA levels are reduced in severe AD (Bosco et al., 2011). Moloney et 
al. (2010) describes similar results: despite increased expression of IGF-1 receptor levels in 
AD, a significantly reduced number of neurons expressed the receptor. The insulin receptor 
also reflects this pattern, as despite increased expression levels, the receptors were found 
to be concentrated intracellularly in AD neurons as opposed to distributed throughout the 
soma and dendrites. Amyloid may be the causative factor of these disruptions - Aβ was 
found to target the insulin receptor, to interfere with its signalling and to alter its 
responsiveness (Townsend et al., 2007; Lee et al., 2009).  
 
Other research supports the notion that a diabetic milieu causes AD pathophysiology. 
Trudeau et al. (2010) has shown that cells grown in high glucose (30 mmol/L) medium were 
characterized by mitochondria with disrupted morphology. 3xTg-AD mice and sucrose-fed 
mice presented similar mitochondrial disruptions, reflecting the link between T2DM and AD, 
and highlighting the risks of a high sugar diet (Carvalho et al., 2012).  Moreover, altered 
insulin signalling is implicated in Aβ-mediated tau hyperphosphorylation via GSK3β 
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(Tokutake et al., 2013; Hong and Lee, 1997). The exact mechanisms involved are not yet 
clearly understood, however.   
 
Modern diets have protected most members of urbanized communities from starvation, yet 
the resulting overnutrition is increasing the burden of health globally, and is leading to the 
development of not only obesity, diabetes and cardiovascular disease (Chopra et al., 2002) 
but is also associated with the risk of developing AD, due to the inflammatory milieu that 
exists in obesity (Businaro et al., 2012). In sharp contrast, dietary restriction is one of the 
few interventions that extend lifespan in model organisms including primates (Fontana et 
al., 2010; Colman et al., 2014). This may be the result of the resistance to oxidative stress, 
reduction in molecular damage, reduced occurrence of cancer and cardiovascular disease 
(Fontana et al., 2010).  Caloric restriction leads to an increase in circulating ketone body 
levels (Knopp et al., 1991), demonstrating the physiological impact of nutrient deprivation 
and ketone bodies. This deserved further attention and will form part of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.8: Decreased insulin signalling leads to tau 
hyperphosphorylation. 
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g. Experimental models in Alzheimer’s disease research 
Genetically altered mouse strains often serve as powerful animal models of AD. Knowledge 
of susceptibility and causative genes has allowed for the generation of different mouse 
strains with AD symptoms. Commonly used systems include the Tg2576 strain which 
overproduces APP and 3xTg-AD mice (Morrissette et al., 2009). 
The use of transgenic mice offers the valuable opportunity to gather information about the 
physiological and in vivo function of expressed genes and their gene-products. This aspect is 
especially powerful for investigating of early pathogenic changes at the molecular level, as 
only late stages of the disease are accessible in humans due to post mortem tissue analysis 
(Van Leuven, 2000). A major limitation of these mice models, however, is that they only 
mimic the rare familial forms of AD; and not sporadic AD which accounts for most cases 
(Morrissette et al., 2009). 
It is also possible to move beyond amyloid-based manipulation in AD models. The physical 
conditions present during neurodegeneration can be represented in both in vivo and in vitro 
models. It is known that inflammation occurs in the AD brain as the result of amyloid 
plaques. Microglia and other inflammatory cells are found in abundance in plaque-rich areas 
as well as high levels of ROS which damages neurons and leads to oxidative stress 
(Johnstone et al., 1999). Paraquat (1,1’-dimethyl-4,4’-bi-pyridinium) is a broad-spectrum 
herbicide used in the field of neurodegeneration research to induce neuronal cell death as it 
causes oxidative stress (McCormack et al., 2005). Although paraquat results in selective 
neurodegeneration in the substantia nigra, it has a host of effects on neurons that makes it 
suitable for neurodegeneration research in general. Its toxic effects are attributed to its 
redox cycling abilities, producing superoxide radicals and depleting reducing equivalents 
such as NADH, which can induce lipid peroxidation (Bus and Gibson, 1984).  This mechanism 
of action is supported by McCormack et al. (2005) who observed that ferritin transgenic 
mice, able to prevent iron-catalyzed oxidative reactions,  were protected from paraquat-
induced cell death and had unchanged levels of lipid peroxidation, as evidenced by 4-HNE 
staining. McCarthy et al. (2004) demonstrated that apoptosis is probably the cell death 
mode involved as indicated by morphological and biochemical changes in human 
neuroblastoma cells treated with paraquat. In addition, paraquat causes a decrease in ATP 
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production, which indicates impaired mitochondrial functioning, as well as an increase in 
the mitochondrial ROS generation. Gliosis occurs as a result of paraquat exposure, as 
indicated by the microglial and astrocytic activation (McCormack et al., 2002). Thus, the 
oxidative stress caused by damaged neurons can effectively be mimicked in vitro by treating 
cells with the herbicide paraquat.  
1.4 Therapeutic interventions 
a. Current treatment interventions and trends in research 
Despite major efforts in research into AD, no effective disease modifying intervention to 
treat it exists. There are treatment options available to ameliorate symptoms, however, and 
new treatment avenues are being explored. 
AD patients are commonly treated with drugs to control behavioural changes such as 
depression or psychosis. The use of these drugs has associated risks, including increased 
mortality in elders with dementia (Honig and Boyd, 2013). Here, we provide a brief overview 
of the therapies currently available, and thereby indicate the disconnect between treatment 
intervention and cellular pathology. This pathology eventually leads to neuronal cell death 
and outwardly manifests as first MCI and then AD dementia (Apostolova et al., 2012). 
Neurotransmitter based therapies are primarily aimed at addressing the cholinergic defect, 
the loss of cholinergic neurons present in AD (Whitehouse et al., 1982). Four 
acetylcholinesterase inhibitor drugs were approved in the United States of America 
between 1993 and 2001, however since then the use of the first acetylcholinesterase 
inhibitor, tacrine hydrochloride, has declined due to its side effect of hepatic toxicity. 
Donepezil hydrochloride is commonly prescribed, and is used in a once daily dose. Newer 
approved acetylcholinesterase inhibitors are rivastigmine tartrate and galantamine 
hydrobromide. Memantine hydrochloride functions as an NMDA antagonist to reduce 
excessive excitatory activity (Honig and Boyd, 2013). Excitotoxicity, the excessive exposure 
to the neurotransmitter glutamate or overactivation of its receptor (one of which is the 
NMDA-type receptor) results in excessive calcium influx which can injure neurons and 
contributes to neuronal death (Lipton, 2004). Despite the fact that these drugs have 
resulted in cognitive, behavioural and functional improvements, the beneficial effects are 
limited. Furthermore, they are only symptomatic treatment and may cause a variety of side 
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effects (Honig and Boyd, 2013). Neurotransmitter-based pharmacological agents are the 
only drugs being prescribed to patients today (Chou, 2014). However, many other 
therapeutic interventions are being tested on the grounds of encouraging preliminary 
results.  
Immunotherapy refers to applying a vaccine approach to reduce amyloid depositions. This 
treatment method has received attention since 1999 when reduced amyloid deposition was 
described in transgenic mice overproducing APP (Schenk et al., 1999). Early human clinical 
trials generated conflicting results, with some patients displaying autoimmune reactions, 
while others exhibited improved cognition and amyloid clearance (Morgan, 2011). Passive 
immunotherapy investigations showed a similar trend of increased amyloid clearance, but 
with the side effect of micro-haemorrhages and increased vascular amyloid deposition. 
Later, cases of vasogenic oedema were reported. Several clinical trials have reached phase 
three testing, however the adverse effects prevent its use as a treatment in the near future 
(Morgan, 2011).  
Physical exercise exerts beneficial effects in AD transgenic mice. This includes behavioural 
improvements such as ameliorated cognitive impairment as well as a protective effect 
against synaptic changes and oxidative stress (García-Mesa et al., 2011). Rats exposed to 
long-term exercise in the form of 30 min treadmill exercise per day demonstrated decreased 
tau and GSK3β activation in the hippocampus (Bayod et al., 2011). Recently, it was found 
that acute exercise causes a two-fold increase in GFP-LC3 positive puncta in wild-type mice 
(He et al., 2012a), highlighting the role of autophagy in glucose regulation, and its 
importance for mediating some of the benefits of exercise.  
Rapamycin is an antibiotic that can be used to induce autophagy in the brain by inhibiting 
mTOR. mTOR hyperactivation parallels amyloid an tau pathology in transgenic AD mice 
(Caccamo et al., 2010), while rapamycin administration decreases brain levels of amyloid 
deposition and defective tau (Caccamo et al., 2010; Spilman et al., 2010). The benefits of 
rapamycin extended to improved cognition in transgenic mice (Caccamo et al., 2010; 
Spilman et al., 2010). However, targeting mTOR has complications as its substrates control 
many cellular processes such as the regulation of protein synthesis, mitochondria and lipid 
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Table 1: Current and developing treatment interventions for Alzheimer’s disease 
metabolism (Bové et al., 2011). Rapamycin is also immunosuppressive and is even 
considered a classical drug used for this purpose (Matsue et al., 2011).  
 
  
Treatment Class/description Mechanism of 
action 
Status 
Donepezil 
hydrochloride 
Acetylcholinesterase 
inhibitor 
Reduces 
excitotoxicity 
Approved, used 
clinically (Honig and 
Boyd, 2010) 
Rivastigmine 
tartrate  
Acetylcholinesterase 
inhibitor 
Reduces 
excitotoxicity 
Approved, used 
clinically (Honig and 
Boyd, 2010) 
Galantamine 
hydrobromide 
Acetylcholinesterase 
inhibitor 
Reduces 
excitotoxicity 
Approved, used 
clinically (Honig and 
Boyd, 2010) 
Memantine 
hydrochloride 
NMDA receptor 
antagonist 
Reduces 
excitotoxicity 
Approved, used 
clinically (Honig and 
Boyd, 2010) 
Immunotherapy Aβ vaccine Targeted amyloid 
clearance 
Clinical trials (Morgan, 
2011) 
Physical 
exercise 
Behavioural 
intervention 
Upregulated 
autophagy 
Research (He et al., 
2012a;  García-Mesa et al., 
2011)  
Rapamycin mTOR inhibitor Upregulated 
autophagy 
Research                   
(Caccamo et al., 2010) 
Rilmenidine Unknown Upregulated 
autophagy 
Research (Rose et al., 
2010) 
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Rilmenidine was recently identified as a potential drug for the treatment of 
neurodegeneration by a screening of US Food and Drug Adminstration (FDA) approved 
drugs. This follows the finding that rilmenidine, a drug prescribed for hypertension, could 
attenuate toxicity in a mouse model of Huntington’s disease, possibly by activating 
autophagy in an mTOR-independent fashion (Rose et al., 2010). However, the research is 
still in its early phases, no results of rilmenidine-based intervention in an AD model exist yet.  
b. The ketogenic diet and neurodegenerative diseases  
Early reports indicate that specific diets increase the risk for developing AD. A study of a 
community’s fat intake revealed that high intake of saturated or trans-unsaturated fats 
increased the incidence of AD, while unsaturated fat intake served a protective role (Morris 
et al., 2003). In addition high energy and dietary saturated fat in old age are considered high 
risk factors for AD (Grant, 1999). The Rotterdam study, which aimed to assess the causes of 
disease incidence and progression in the elderly (people aged 55 to 106 years), is an 
example (Hofman et al., 1991). Kalmijn et al. (1997) investigated the relationship between 
dietary fat and cholesterol consumption and the risk of dementia in participants of the 
Rotterdam study. They suggest a borderline significant association between high saturated 
fat (p=0.66) and cholesterol (p=0.40) intake and the risk of dementia and refer to the fact 
that this type of diet is associated with cardiovascular disease, which increases the risk of 
developing dementia. Thus there is a definitive role for a high calorie diet and metabolic 
disruptions in AD pathogenesis. 
 
In contrast, evidence indicates that ketosis is protective against dementia, as will be 
discussed below. Prolonged fasting, diabetic ketoacidosis and following a ketogenic diet (KD) 
cause production of ketone bodies. KDs are characterised by very low carbohydrate content 
and increased fat and protein intake, with fat intake commonly providing 80% of dietary 
calories (Beckett et al., 2013). ‘Ketosis’ is indicated by an increase in measurable ketone 
bodies in circulation, specifically elevation of beta-hydroxybutyrate (β-OHB) and 
acetoacetate (Veech et al., 2001). Physiological ketosis (in contrast to pathological diabetic 
ketoacidosis) occurs after 3-4 days of no carbohydrate consumption, which leads to the 
overproduction of ketone bodies from fatty acids (Paoli et al., 2013). AcCoA is synthesised 
from ketone bodies as an energetic substrate which can enter the TCA cycle (Paoli et al., 
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2013). Humans are, as far as is known, the only species that reaches plasma β-OHB levels 
above 5 mM/L –possibly an evolutionary conserved mechanism of relying on ketone bodies 
for ‘brain fuel’ during times of starvation. Basal blood β-OHB levels range from 0.01-0.03 
mM (Grey et al., 1975) while the average plasma concentration of β-OHB in human adults is 
4-7 mM/L after two weeks of fasting (Cahill, 2006).  
 
Ketone bodies are produced by the liver. Three ketone bodies exist: acetone, acetoacetate, 
and β-hydroxybutyrate (Prins, 2008). Only β-OHB and acetoacetate are used as metabolic 
fuel sources, and are produced by the partial oxidation of fatty acids (Cahill, 2006). β-OHB is 
the primary circulating ketone body and increased concentrations are observed four to 
seven days after fasting (Grey et al., 1975). Plasma β-OHB levels can increase four- to 
fivefold after two days of fasting or following a KD, with a remarkable 13 fold increase in its 
cerebral uptake (Prins, 2008). Ketone bodies replace glucose as the brain’s main metabolite 
during ketosis (Owen et al., 1967). They cross the blood-brain barrier by using 
monocarboxylate transporters (MCTs), where they are metabolised by three enzymes and 
then enter the TCA cycle (Prins, 2008).  
 
In recent years, there have been increasing reports of KDs improving various disease 
conditions. Epilepsy was treated successfully with the KD for many decades, and is today an 
established part of an integrative approach to managing epilepsy, together with 
anticonvulsant drugs (Kossoff, 2011). The therapeutic use of the KD for epilepsy paved the 
way for research into other neurological diseases, and the KD has received increasing 
attention from researchers in the neurodegeneration field.  
 
Administering a KD (60% fat) was found to protect against motor neuron death in a mouse 
model of amyotrophic lateral sclerosis (ALS; Zhao et al., 2006). In addition, it was found that 
KB promotes ATP production in ALS mice – ATP concentration was increased in 
mitochondria isolated from mutant mice when treated with ketone bodies, with 
mitochondria showing an increased ATP synthesis rate compared to diseased controls (Zhao 
et al., 2006).  
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Cheng et al. (2009) induced PD in rats by administering 6-hydroxydopamine (6-OHDA) and 
investigated the effects of a KD (composed of 90,7% fat) on dopaminergic neurons. They 
revealed that the KD protected against 6-OHDA neurotoxicity and corrected the decreased 
dopamine levels and its metabolite dihydroxyphenylacetic acid found in PD rats. Levels of 
the antioxidant glutathione are decreased in PD rats, and administration of a KD inhibited 
this decrease. The authors conclude that this mechanism was responsible for the 
neuroprotective effects of the KD observed. In a human feasibility study, PD patients that 
followed a ‘hyperketogenic diet’ (4 parts fat to 1 part carbohydrate-protein mixture) for four 
weeks had improved Unified Parkinson’s Disease Rating Scale scores, however a placebo 
effect was not ruled out (VanItallie et al., 2005). 
 
In a study of HD mice fed a KD, researchers identified delayed onset of significant weight 
loss in KD fed mice. This is an important improvement, considering that higher body weight 
is correlated with slow HD progression (Ruskin et al., 2011). Taken together, the evidence 
presented here demonstrates the versatility and efficacy of using the KD, or KB to treat 
neurodegenerative diseases. AD is no exception, as will be discussed next.  
 
c. Ketone bodies as Alzheimer’s disease adjuvant therapy 
Differences may exist in the efficacy of utilizing ketone bodies under normal and diseased 
conditions. Indeed, there is a loss of utilization efficiency in AD. AD patients report a higher 
incidence of seizures (Palop and Mucke, 2009) possibly because the homeostasis of both 
neuronal circuits and mitochondrial functioning is affected (Kapogiannis et al., 2011). Thus it 
became feasible to use KD as a treatment for AD as it is also a neurodegenerative disease 
featuring disrupted synaptic transmission as a result of Aβ toxicity (Calkins and Reddy, 
2011).  
 
In the hippocampus of non-transgenic female mice KB were transported and utilized as an 
alternative fuel (Ding et al., 2013). In 3xTg-AD mice, however, only three month old mice 
showed a ketogenic phenotype, after which the use of ketone bodies declined, indicating 
that mice with advanced disease were not able to utilize ketone bodies, and thus were 
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denied the benefits of switching to ketone metabolism as an adaptive response (Ding et al., 
2013). 
 
Samoilova et al. (2010) demonstrated that exposing hippocampal cultures to a chronic 
concentration of 10 mmol/L of ketone bodies in conjunction with low glucose was 
neuroprotective, as indicated by attenuated cell death after ischemia and glucose 
deprivation, but not against the seizure-type hyperexcitability responsible for neuronal 
damage during metabolic insults. Arakawa et al. (1991) demonstrated that ketone body 
administration can act as a substitute energy source for glucose. They revelaed that ATP 
levels were significantly increased after two hours of treatment in brain slices treated with 
glucose-free medium and medium containing ketone bodies only.  
 
In a study of mice carrying the ‘London’ (APP/V717I) mutation, which leads to early and 
significantly increased brain Aβ levels, Van der Auwera and colleagues (2005) revealed 
decreased Aβ deposition in the brain after only 43 days following a KD. Beckett et al. (2013) 
did not find a decrease in Aβ levels in mice with knock-in mutations of the APP and PSEN1 
genes fed a KD for one month, despite motor improvements. Both of these groups used 
young mice (three and 1-2 months old, respectively) and fed the mice similar chow 
composed of 79% fat, hence these results are conflicting.  
 
Recently, C57/BL6 double transgenic mice, which exhibit age-dependent Aβ plaque 
aggregation, administered an esterified form of β-OHB for 2.5 months promoted spatial 
learning and working memory, as indicated by Morris water maze results (Zhang et al., 
2013). In addition to these cognitive improvements, the authors described a multitude of 
other beneficial effects. There was a decrease in Aβ deposition in the hippocampus which, 
remarkably, was more effective than the approved AD drug, donepezil. β-OHB 
administration decreased apoptotic cell death in glucose-deprived cells, possibly due to its 
protective effects on mitochondria; ketone body treated groups showed stabilized 
mitochondrial membrane potential, increased ATP levels and an increased reductive state 
(Zhang et al., 2013).  
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 A randomized double-blind placebo-controlled clinical trial in which mild-to-moderate AD 
patients were given an oral ketogenic substrate caused a significant improvement in 
cognitive performance (Henderson et al., 2009). Similarly, Reger et al. (2004) found that 
increasing serum β-OHB levels of patients suspected of having AD (as indicated by the 
National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's 
Disease and Related Disorders Association’s or NINCDS/ADRDA criteria and positive for the 
ApoE4 allele) by medium-chain triglyceride administration resulted in improved Alzheimer’s 
Disease Assessment Scale (ADAS-cog) scores, a test consisting of 11 subscales which 
measure various cognitive abilities including memory, language and praxis skills (Benge et 
al., 2009). Interestingly, the ameliorative effects of KB on AD symptoms seem to be 
dependent on the patients’ ApoE genotype. Cognitive improvements are more marked in or 
even limited to patients without ApoE4 allele in many studies (see Reger et al., 2004; 
Henderson et al., 2009). In a retrospective study, eight AD patients on standard 
pharmacological treatment were given the medium chain triglycerid caprylic triglyceride to 
induce ketosis (Maynard and Gelblum, 2013). Caprylic triglyceride administration seemed to 
slow disease progression and some patients had cognitive improvements.  
 
It can be concluded from the above literature that ketone bodies can indeed bring about 
substantial improvement in AD-related neuropathology. KB successfully ameliorate both 
molecular disruptions and cognitive deficits present in AD. Despite the encouraging results 
demonstrated by administering ketogenic agents or diets, however, it is unknown what 
effects ketone body administration has regarding autophagic flux, mitochondrial network 
morphology and function, intracellular ATP levels and localization and the extent of 
apoptotic cell death. Furthermore, it remains unknown where intracellular ATP localizes in 
neurons and it would be beneficial to assess its association with cell compartments like 
mitochondria in order to better understand ATP demand and AD-related metabolic failure.  
1.5 Aims and hypothesis 
Aims 
Therefore our aims are to assess the effects of beta-hydroxybutyrate under basal conditions 
and in an injury-induced model. Specifically we aim to assess the following parameters: 
1. Paraquat-induced neuronal cell death 
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2. Autophagic flux 
3. Mitochondrial network morphology  
4. Intracellular ATP concentrations and localization in neurons 
Hypothesis 
We hypothesize that beta-hydroxybutyrate will protect cells from paraquat-induced 
neurotoxicity, by increasing ATP levels through increasing autophagic flux. 
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Chapter 2: MATERIALS AND METHODS 
2.1 Reagents and consumables 
2.1.1 Cell line and general consumables 
GT1-7 cells, mouse neuronal cells of hypothalamic origin, were provided by Dr. Kinnear, 
Tygerberg, University of Stellenbosch (Mellon et al., 1990). Dulbecco’s modified Eagle’s 
medium (DMEM, 41965062), PenStrep antibiotic (15140122) and trypsin (25200072) were 
purchased from Life Technologies. Fetal bovine serum (FBS, FBS-GI-12A) was supplied by 
Capricorn Scientific and 15 and 50 ml Falcon tubes were purchased from SPL Life Sciences 
(EF4661 and EF4663). 0.5 and 2 ml Eppendorf tubes were purchased from Citotest (4610-
1821) and Axygen Scientific (311-10-051), respectively. 25 cm2, 75 cm2, and 175 cm2 non-
pyrogenic polystyrene cell culture flasks were purchased from Nest Biotechnology (707001, 
708001 and 709001). 10 ml serological pipettes were acquired from Biocom Biotech 
(PN10E1) and NUNC 8-well chambered coverglass dishes (155411) were purchased from 
Thermo Scientific and 48-well plates from SPL Life Sciences (30048). 35 mm culture dishes 
were supplied by Falcon (353001). White 96-well plates (3912) for use in the ATP 
luminescence based assay were supplied by Corning Costar as well as cryogenic vials 
(430488).Dimethyl sulfoxide (DMSO) was supplied by Sigma-Aldrich (D2650).  
 
2.1.2 Treatment reagents 
DL-β-Hydroxybutyric acid sodium salt (H6501) and paraquat (methyl viologen dichloride 
hydrate, 856177) were purchased from Sigma-Aldrich and bafilomycin A1 from LKT 
Laboratories (B0025). All reagents were prepared as stock concentration using dH2O 
(paraquat) or sterile PBS (ketone bodies and bafilomycin) as a solvent.   
 
2.1.3 Western blot reagents 
Bradford reagent was made up using Brilliant Blue G (27815) from Sigma-Aldrich. Bovine 
serum albumin (BSA, 10735078001) was obtained from Sigma-Aldrich. Gels were cast using 
the TGX FastCast Acrylamide kit (12%, 50 µL wells) and Trans-Blot Turbo Transfer packs 
(Midi format, PVDF 0.2 µm) both purchased from Bio-Rad (161-0175 and 170-4157).  An ECL 
(enhanced chemiluminescence) kit containing peroxide and luminol/enhancer reagents was 
purchased from Bio-Rad (170-5061).  Tween 20 (P1379) and sodium hydroxide (NaOH, 
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S5881) were purchased from Sigma-Aldrich. The following phosphatase and protease 
inhibitors were purchased from Sigma-Aldrich: Aprotonin (A1153), Leupeptin (L2884), 
Pepstatin A (P5318), Benzamidine (B6506), PMSF (93482) and Na3VO4 (S6508). BLUeye 
prestained protein ladder was obtained from GeneDirex (PM007-0500).  
 
2.1.4 Antibodies 
Antibodies were purchased from Cell Signaling and produced in rabbit unless otherwise 
specified. Primary antibodies against BACE (55606S), APP/beta-Amyloid (anti-mouse, 
2450S), cleaved PARP (9541S), LC3B (2775) SQSTM1/p62 (ab56416) and GAPDH (5174) were 
used. The secondary antibodies anti-rabbit IgG HRP (7074S) and anti-mouse IgG HRP (7076S) 
were acquired from Abcam.  
 
2.1.5 Fluorescent probes  
The above indicated primary antibodies for BACE, APP and APP/beta-Amyloid were used for 
fluorescence microscopy. Secondary antibodies AlexaFluor 488 donkey anti-mouse (A21202) 
and AlexaFluor 568 donkey anti-rabbit (A10042) were purchased from Cell Signaling.  
Hoechst 33342 (14533) was supplied by Sigma-Aldrich.    
 
2.2 Experimental procedures  
2.2.1 Tissue culture of GT1-7 neuronal cells 
GT1-7 cells were cultured at 37 °C within a humidified atmosphere in a 5% CO2 incubator in 
1X DMEM supplemented with 10% fetal bovine serum and 1% PenStrep. Cells were stored in 
a liquid nitrogen cell tank in 1 ml cryovials containing approximately 1 X 106 cells, in 90% FBS 
with 10% DMSO.  
 
2.2.2 Thawing and culturing of cells 
Frozen cells were thawed by immersing the cryovile in a bead bath at 37 °C. Cryovile 
contents and 1 ml pre-warmed medium were transferred to a sterile 15 ml Falcon tube 
using a sterile pipette tip (P1000 micropipette) and centrifuged (Eppendorf centrifuge 
5804R) at 1500 rpm for 3 min at room temperature after which the supernatant was 
discarded. The pellet was resuspended in 1 ml pre-warmed medium using a sterile pipette 
Stellenbosch University  https://scholar.sun.ac.za
53 
 
tip (P1000 micropipette) and transferred to a sterile 25 cm2 flask containing 4 ml pre-
warmed medium. The culture medium was changed every 48 hrs for the duration of the 
culturing procedure. Cells were subcultured at 80% confluency. 
 
2.2.3 Subculturing and seeding of cells for experiments 
Medium was removed using a 5 ml serological pipette after which trypsin was added to the 
cell monolayer and the flask placed in an incubated cell shaker (MRC) for 4 min. Cells were 
viewed under an inverted microscope (Olympus CKX31) to ensure their dissociation from 
the flask surface and were transferred to a sterile 15 ml Falcon tube using a sterile 10 ml 
serological pipette. FBS-supplemented medium constituting double the volume of trypsin 
used was added using a 10 ml serological pipette to deactivate the trypsin. The cell 
suspension was centrifuged at 1500 rpm for 3 min at room temperature after which the 
supernatant was discarded and the cell pellet resuspended in 1 ml medium using a sterile 
pipette tip (P1000 micropipette). A Neubauer Improved haemocytometer (Marienfeld) was 
used to count cells for seeding into the appropriate dish or for subculturing. Cells were used 
to a maximum passage number of 24.  
 
2.2.4 WST-1 assays 
2.2.4.1 WST-1 assay to determine viability 
For determining cell viability cells were seeded at 80 X 103 cells per well in 48 well plates 
and incubated (37 °C, 5% CO2) until 80% confluency was reached (approximately 24 hrs). 
Ketone body salt (DL-β-Hydroxybutyric acid sodium salt) was diluted in medium to obtain 
concentrations of 1.5 mM, 3 mM, 6 mM and 12 mM to assess for potential toxic effects at 
high concentrations and to determine the optimal concentration to use for further 
experiments.  Cells treated with medium only served as the control. Following incubation 
with the various treatments, 10 µl WST-1 cell proliferation reagent (AB155902, Abcam) and 
190 µl fresh medium was added to each well and plates were incubated in light protected 
conditions for 2 hrs. WST-1 is an indicator of mitochondrial reductive activity of living cells, 
and is analogous to the widely used MTT assay which is accepted as a measure of cell 
survival. The assay is based on the reduction of tetrazolium salts to formazan by cellular 
enzymes (Berridge et al., 1996). After incubation, plates were placed on an oscillating 
bellydancer (Stovall Life Sciences) for 1 min to allow mixing of well contents. The 
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absorbance values of the supernatant were read at 490 nm using a microplate reader 
(EL800, Bio-Tek instruments). The relative mitochondrial reductive capacity of cells was 
calculated as a percentage of control. Three independent experiments were performed for 
each condition with a mimimum of eight technical repeats for each treatment group.  
 
2.2.4.2 WST-1 assay to determine viability following paraquat and ketone body 
treatment 
After seeding cells as described (section 2.2.4.1) cells were treated with a defined range of 
paraquat concentrations (10 µM – 5 mM) for 24 hrs to determine a suitable concentration 
that achieves approximately 50% cell death, to be used in the following experiments. 
Untreated cells served as the control.  The WST-1 assay was completed as in section 2.2.4.1. 
After determining a suitable concentration (600 µM), the following treatment groups were 
assessed: Control, paraquat, ketone bodies (6 mM), and paraquat + ketone bodies (600 µM 
and 6 mM, respectively). Cells were treated for 24 hrs after which the WST-1 assay was 
completed as described above.  
 
2.2.5 Tetramethylrhodamine ethyl ester (TMRE) treatment  
2.2.5.1 Sample preparation and TMRE treatment 
GT1-7 cells were seeded into 8-chamber plates at a density of 30 X 103 cells per well. Cells 
were allowed to adhere overnight at 37 °C and in a 5% CO2 atmosphere after which growth 
medium was refreshed. Medium was removed and replaced with medium containing 500 
nM tetramethylrhodamine ethyl ester (TMRE; Abcam ab113852) to visualize mitochondria 
in living cells. TMRE is a membrane potential-dependent fluorochrome that stains 
mitochondria with polarized, intact membranes as described by Hanley et al. (2002). 
Hoechst 33342 was added to wells (1:200 in medium) prior to imaging to counterstain 
nuclei.  
 
2.2.5.2 Live cell imaging of mitochondria  
Cells were transferred to a wide field inverted microscope (Olympus IX81, Olympus 
Corporation, Tokyo, Japan) equipped with a Xenon-Arc burner (Olympus Biosystems GMBH, 
Hamburg, Germany) light source surrounded by an incubator chamber (37 °C; 5% CO2 
atmosphere). An F-view-II cooled CCD camera (Soft Imaging Systems, Olympus Corporation, 
Stellenbosch University  https://scholar.sun.ac.za
55 
 
Tokyo, Japan) was mounted on the microscope. The TxRed excitation filter was used to 
capture images of polarized mitochondria and the DAPI excitation filter for the acquisition of 
nuclei. Emission was collected with a UBG triple-bandpass emission filter cube (Chroma) and 
images were captured and edited using Olympus Cell^R (Hamburg, Germany) software. 
 
2.2.6 Mitochondrial morphological assessment 
GT1-7 cells were stained with the mitochondrial marker TMRE and imaged as described 
above. Raw images were converted to an 8-bit format using ImageJ software. The ‘Convolve’ 
and ‘Gaussian blur’ filters were utilized and thresholds adjusted to enhance the 
mitochondrial signal suitable for image analysis. The particles were analysed and the 
average mitochondrial count per group calculated based on all the mitochondria counted in 
five different cells in five respective micrographs. The mitochondrial morphological 
characteristics were quantified according to two parameters: aspect ratio, which indicates 
the length of mitochondria (ratio between the major and minor axes of mitochondria), and 
form factor, which indicates the degree of branching (Pm2/4πAm) where ‘Pm’ is the length 
of the mitochondrial outline and ‘Am’ is the mitochondrial area (Mortiboys et al., 2008). 
 
2.2.7 FRET-based ATP indicator  
2.2.7.1 Transfection with ATeam construct 
GT1-7 cells were seeded into 8-chamber dishes at a density of 30 X 103 cells per well. Cells 
were allowed to adhere overnight at 37°C and in a 5% CO2 atmosphere after which growth 
medium was refreshed. A FRET-based ATP indicator, targeted to mitochondrial ATP, ATeam 
1.03 (Imamura et al., 2009) was used to identify the intracellular localization of 
mitochondrial ATP. The transfection procedure was performed by adding a solution 
containing 400 ng DNA, 1 µl lipofectamine (Invitrogen), 20 µl serum-free medium, and 1.6 µl 
P3000 transfection reagent (Invitrogen) to each well containing 300 µl fresh growth medium 
and incubating cells (37°C; 5% CO2 atmosphere) for 1 h. Growth medium was subsequently 
refreshed and cells incubated for 48 hrs prior to imaging. Treatment groups were exposed 
to their respective treatment solutions 24 hrs prior to imaging.  
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2.2.7.2 Fluorescence microscopy of intracellular ATP in live cells 
Cells were transferred to a wide field inverted microscope as described above (2.2.5). A 
minimum of 15 transfected cells were acquired per group using a 100X magnification. 
Micrographs were captured using the CFP and YFP excitation and emission filters. In brief, 
the donor was acquired by using CFP excitation and emission, the FRET channel was 
acquired by using CFP excitation and YFP emission, while the YFP channel was acquired by 
using YFP excitation and emission. The FRET analysis function (ratio: FRET channel and CFP 
channel) of the Cell^R program was utilized to generate the FRET image displaying ATP 
derived signal and a ‘ColdWarmHot’ lookup table (LUT) was employed to indicate emission 
intensity.   
 
2.2.8 ATP analysis 
Cells were seeded in 35 mm culture dishes at a density of 1 X 106 cells per dish and grown 
under standard culturing conditions until 90% confluent. Medium was transferred to sterile 
1 ml Eppendorf tubes (in the case of the paraquat treatment groups) and centrifuged to 
ensure non-adherent cells were included for ATP harvesting. At this stage cells were 
trypsinized by adding 1 ml trypsin per dish and by placing samples in a shaking incubator for 
4 min. Culture dish contentswere centrifuged in sterile 1 ml Eppendorf tubes at 10 000 rpm 
at 4 °C for 3 min, the supernatant discarded and the pellet resuspendedin cold PBS. The 
centrifugation step was repeated and the pellet subsequently resuspended in 50 µl ice cold 
lysis buffer containing 100 mM Tris-HCl and 4 mM EDTA (pH 7.75) as previously shown 
(Essman et al. 2003). 150 µl boiling lysis buffer was added to the cell suspension and kept at 
99 °C in a water bath for 2 min. Samples were then centrifuged for 3 min at 10 000 rpm (4 
°C) after which the supernatant containing ATP was collected in fresh Eppendorf tubes and 
stored at -20 °C until further analysis.   
 
A luminometer (Glomax, Promega) was used to measure sample luminescence. 50 μl of ATP-
containing supernatant and 50 ul of rL/L reagent (Enliten ATP assay FF2000, Promega) were 
added to white 96-well microtiter plates according to the manufacturer’s instructions and 
luminescence signal was acquired. A standard curve was produced according to the 
manufacturer’s protocol.   
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2.2.9 Flow cytometry 
2.2.9.1 Tetramethylrhodamine ethyl ester (TMRE) intensity 
Cells were seeded in T-25 flasks at a density of 2 X 106 cells per flask and grown to 
approximately 75% confluency. Following treatment with paraquat and ketone bodies, cells 
were trypsinized by incubating cells with pre-warmed trypsin for 4 min until cells detached, 
centrifuged for 3 min at 1500 rpm and then resuspended in 1 ml warm sterile PBS. Unfixed 
cells were incubated with 1 µM TMRE for 30 min at 37 °C and immediately analysed. 
Carbonyl cyanide m-chlorophenylhydrazone (CCCP, Sigma, C2759) was used as a positive 
control using a concentration of 5 µM. An unstained control sample was acquired in order to 
set the photomultiplier tube (PMT) voltages. Flow cytometry (BD FACSAria I) was used to 
analyze samples by collecting a minimum of 10 000 cells using a 488 nm laser and 610LP, 
616/23BP emission filters. Fluorescence intensity signal was obtained by using the 
geometric mean of the intensity histogram.  
 
2.2.9.2 ROS assessment  
2’,7’-Dichlorofluorescein (DCF) was used to evaluate generic ROS. Cells were seeded and 
treated as mentioned in 2.2.9. Unfixed cells were incubated with 50 µM DCF for 10 min at 
37 °C and immediately analyzed. H2O2 was used as a positive control, using 100 µl in the cell 
suspension. An unstained control sample was acquired to set the PMT voltages. A flow 
cytometer (BD FACSAria I) was used to analyze samples by collecting a minimum of 10 000 
cells using a 488 nm laser and 502LP, 530/30BP emission filters. Fluorescence intensity 
signal was obtained by using the geometric mean of the intensity histogram.  
 
2.2.10 Transmission electron microscopy (TEM) 
2.2.10.1 Sample preparation 
GT1-7 cells were seeded in T-25 flasks at a density of 1.5 X 106 cells per flask and were 
grown to approximately 90% confluency. Four groups were assessed: Control, paraquat, 
ketone bodies and paraquat + ketone bodies. Two flasks per group were seeded. Following 
24 h treatment, 2 ml trypsin was added to each flask and incubated for 4 min. Cell 
suspensions were transferred into 15 ml Falcon tubes, each containing 8 ml FBS-
supplemented growth medium, according to treatment group. Tubes were centrifuged at 
1500 rpm for 3 min at 37 °C. The supernatant was discarded and the cell pellet resuspended 
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in pre-warmed 1 X PBS to remove remaining trypsin and medium. The centrifugation step 
was repeated, the PBS discarded and the cell pellet resuspended in 1 ml 2.5% 
glutaraldehyde, after which tubes were centrifuged at 1500 rpm for 3 min at 37 °C. Samples 
were transported to Tygerberg Hospital where TEM analysis was completed by the National 
Health Laboratory Services. 
 
2.2.10.2 Processing, sectioning and imaging of samples 
Samples were sectioned into 1 mm sections using a dissecting microscope and rinsed in 
phosphate buffer. Samples were incubated in 3% osmium tetroxide for 1 h and 
subsequently kept in a 10% formalin solution to reduce the osmium tetroxide. Samples were 
then transferred to an automated tissue processer, and immersed in a sequence of 
solutions according to the following protocol: 
 
1. 15 min in 10% uranyl acetate 
2. 10 min in 70% ethanol 
3. 10 min in 70% ethanol 
4. 20 min in 10% uranyl nitrate 
5. 15 min in 100% ethanol 
6. 20 min in 100% ethanol 
7. 30 min in 100% ethanol 
8. 90 min in a 1:1 solution of 100% ethanol and Spurr’s resin 
9. 60 min in Spurr’s resin 
10. 60 min in Spurr’s resin 
 
Samples were subsequently embedded into gelatin capsules overnight at 60 °C after which 
they were cut into 200 nm sections using a Leica EM UC7 ultramicrotome. Sections were 
stretched with chloroform and placed onto copper grids. Images were captured using a JEOL 
JEM 1011 transmission electron microscope and the iTEM soft imaging analysis program. 
TEM images were qualitatively analyzed. 
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2.2.11 Bafilomycin A1 and ketone body treatment for Western blot analysis of LC3, 
p62, APP, Aβ and BACE 
Bafilomycin A1 is an antibiotic that is often used to inhibit the process of autophagy as it is a 
specific inhibitor of the H+-ATPase (V-ATPase) enzyme (Klionsky et al,. 2008). Treatment 
inhibits the acidification of lysosomes and endosomes and thereby blocks the fusion of 
lysosomes with autophagosomes. Cells were seeded into T-25 flasks at a density of 1.5 X 106 
cells per flask. Flasks were divided into four treatment groups: Control, control + 
bafilomycin, ketone bodies, ketone bodies + bafilomycin. 400 nM bafilomycin diluted in 
medium was used and cells treated after reaching 80% confluency. Respective groups were 
treated with pre-warmed supplemented medium for 24 hrs, after which fresh medium in 
the presence or absence of bafilomycin was added and cells incubated for a further 2 hrs. 
Both of the ketone body groups were treated with pre-warmed FBS-supplemented medium 
containing 6 mM dissolved β-OHB for 24 hrs. Medium was refreshed with DMEM growth 
medium in the presence or absence of bafilomycin and flasks incubated for a further 2 hrs.  
 
2.2.12 Determining intracellular distribution of APP, Aβ and BACE 
2.2.12.1 Staining of APP, Aβ and BACE 
Cells were seeded into NUNC chamber dishes and treated with bafilomycin and ketone 
bodies as described above. After treatment, growth medium was aspirated and cells were 
rinsed with pre-warmed 1X PBS. 200 µl of ice cold methanol-acetone (1:1) was added per 
well and cells incubated at 4 °C for 10 min. Fixative was removed and cells allowed to airdry 
for 20 min. Wells were rinsed with 1X PBS and cells were blocked with 100 µl FBS per well 
for 20 min at room temperature. After removing the serum, each well was incubated for 90 
min with 50 µl of a mixture of APP primary antibody (mouse; 1:50) and beta-site APP 
cleaving enzyme (BACE) primary antibody (rabbit) (1:100) made up in 1X PBS or a mixture of 
APP and beta-amyloid (Aβ) primary antibody (rabbit; 1:100) made up in PBS. Wells were 
carefully rinsed with 400 µl PBS and incubated with 50 µl of a mixture of AlexaFluor 488 
donkey anti-mouse IgG (for APP) and AlexaFluor 568 donkey anti-rabbit IgG (for BACE or Aβ) 
for 30 min at room temperature in a humidified, light-protected environment. 50 µl of 
Hoechst 33342 (1:200 in PBS) was added to wells to counterstain nuclei and incubated for a 
further 10 min at room temperature in a humidified, light-protected environment. Wells 
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were rinsed three times with 400 µl PBS and subsequently mounted by using fluorescent 
mounting medium (S302380, Dako). Cells were imaged immediately.   
 
2.2.12.2 Fluorescence microscopy of APP, Aβ and BACE 
Cells were transferred to a wide field inverted microscope as described above (2.2.5). 15 
transfected cells were imaged per group at a 100X magnification. Three excitation filters 
were used to capture images: TxRed for Aβ and BACE and FITC for APP. Emission was 
collected with a UBG triple-bandpass emission filter cube (Chroma) and images were 
captured and edited using Olympus Cell^R (Hamburg, Germany) software.  
 
2.2.13 RIPA buffer extraction of protein 
Radio-immunoprecipitation (RIPA) buffer contains various ingredients to facilitate protein 
extraction from cells and includes protease inhibitors and phosphatase inhibitors. RIPA 
buffer contains phenylmethylsulfonyl fluoride (PMSF), aprotonin, leupeptin, benzamidine, 
activated sodium orthovanadate (Na3VO4) and sodium fluoride (NaF). Each T-25 cell culture 
plate was rinsed three times with cold PBS and 50 µl cold RIPA buffer was added. The cell 
monolayer was scraped with a sterile cell scraper and lysates transferred to sterile 
Eppendorf tubes. Lysates were homogenized by sonicating at a frequency of 3 Hertz 
(Misosonix S-4000) on ice for a total of four seconds with a 2 sec interval after each second 
of sonication. Tubes were kept on ice at 4 °C for approximately 2 hrs until the lysates had a 
clear appearance. Subsequently lysates were centrifuged at 8000 rpm for 10 min at 4 °C, 
aspirated and transferred into fresh sterile Eppendorf tubes and stored at -20 °C until 
further analysis.  
 
2.2.14 Western blot analysis of APP, Aβ, BACE, LC3, p62 and cleaved PARP 
2.2.14.1 Bradford protein quantification 
Bradford reagent was prepared in a working solution by using Coomassie Brilliant Blue G-
250 (27815, Sigma), 95% ethanol, phosphoric acid and dH2O (Bradford, 1976). BSA 0.2 
mg/ml stock solution was prepared at a range of concentrations by dilution in dH2O (see 
Table 2). 5 µg of protein was added to 95 µl dH2O and vortexed. 900 µl Bradford working 
solution was added to all tubes and allowed to incubate for 5 min at room temperature in 
the dark. Standard and experimental samples were prepared in duplicates. A 
Stellenbosch University  https://scholar.sun.ac.za
61 
 
spectrophotometer (Cecil CE 2021) was used to measure absorbance at a wavelength of 595 
nm. Microsoft Excel was used to produce a standard curve of protein concentration against 
absorbance values from which the protein concentrations of experimental samples was 
determined.  
 
Concentration (μg/ml) Volume of BSA (μl) Volume of dH2O 
0 (Blank) 0 100 
2 10 90 
4 20 80 
8 40 60 
12 60 40 
16 80 20 
20 100 0 
 
2.2.14.2 Sample preparation 
A stock solution (5 ml) of Laemmli’s loading buffer was prepared by diluting 1 ml Tris-HCL 
(0.5M; pH 6.8), 0.8 ml glycerol, 1.6 ml of 10% SDS (sodium dodecyl sulfate), and 0.4 ml of 
0.05% bromophenol blue in dH2O. A working solution of Laemmli’s loading buffer was 
prepared by adding 150 μl of β-mercaptoethanol (161-0710, Bio-Rad) to 850 μl of Laemmli’s 
loading buffer followed by vortexing. The appropriate volumes of protein samples were 
added to Eppendorf tubes so as to obtain 50 μg of each protein sample per tube. The 
appropriate volume of Laemmli’s loading buffer (⅓ of the protein volume) was added to 
each sample. Samples were boiled for 5 min at 95 ˚C, vortexed, centrifuged, and placed on 
ice immediately.  
 
2.2.14.3 Sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Precast Mini-Protean SDS-PAGE gels were firmly secured onto an electrode assembly and 
placed inside a Mini-Protean Tetra cell tank. 1X running buffer was used to fill the buffer 
chamber and to rinse gel wells using a syringe. 7.5 μl of protein ladder was loaded into the 
first well and the prepared samples were loaded at their respective volumes into remaining 
Table 2: BSA preparation for Bradford standard curve. 
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wells.  The electrode assembly was connected to a power supply (Bio-Rad Power Pac 1000) 
and proteins were separated at 120 V for approximately 60 min. A Trans-Blot Turbo transfer 
pack and a Bio-Rad Trans-Blot turbo transfer system were used to transfer proteins for 10 
min from the gel to a PVDF (polyvinydilene difluoride) membrane. The membrane was 
blocked in 5% non-fat milk in 1X TBS-T (Tris-buffered saline and 1% Tween 20) for 2 hrs to 
reduce non-specific binding, rinsed 3 X 5 min in 1X TBS-T, and incubated in primary 
antibodies (1:1000 in TBS-T) overnight on a rotator at 4 ˚C. After rinsing the membrane in 1X 
TBS-T for 3 X 5 min, it was incubated in anti-rabbit HRP-linked secondary antibody (anti-
rabbit or anti-mouse; 1:5000 in TBS-T) for 60 min at room temperature on a roller mixer 
(Stuart SRT9) followed by a washing step of 3 X 5 min in 1X TBS-T. 1 ml of ECL reagent 
(peroxide buffer and enhancer solution prepared in a 1:1 ratio) was added to the membrane 
and protein signal and band intensities were detected using a Bio-Rad Chemidoc MP 
imaging system equipped with Image Lab software (version 4.1). 
 
2.2.14.4 Loading controls 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control for all 
Western blots. Membranes were stripped with 0.2 M NaOH in dH2O for 5 min and washed 3 
X 5 min with dH2O. Membranes were blocked in 5% non-fat milk for 2 hrs, incubated in 
GAPDH primary antibody (1:1000) and incubated overnight on a rotator at 4 °C. Membranes 
were incubated with HRP-linked anti-rabbit secondary antibody (1:5000) for 1 h, washed 3 X 
5 min with 1 X TBS-T and developed and imaged as described above.   
 
2.2.15 Statistical analysis 
Statistical analysis of all quantifiable data was performed using Prism 5 software utilizing a 
one-way ANOVA with a Bonferroni post-hoc test. A p-value < 0.05 was considered 
significant. Results are indicated as mean ± standard error of mean.  
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Chapter 3: RESULTS 
SECTION 1: Ketone bodies and autophagy under basal conditions 
In order to unravel the role of autophagy in neurodegeneration, two aspects were 
investigated. Firstly, autophagy and specific candidate proteins were assessed under basal 
conditions, in the presence and absence of ketone bodies, in order to assess the role of 
ketone bodies and autophagic flux on the clearance of candidate proteins that are 
implicated in proteotoxicity. Secondly, neurotoxicity was induced in order to assess the 
potential protective role of ketone body supplementation in the context of neuronal cell 
death. Accordingly, the first section of this chapter will focus on the results regarding the 
effects of ketone bodies on autophagy and amyloid processing. In the second section we will 
focus on the results that assess the role of ketone bodies on paraquat-induced neuronal 
injury.  
3.1.1 The effect of ketone body treatment and basal autophagy on ATP concentration 
A luciferase-based ATP assay was employed to measure total intracellular ATP levels 
following the treatment with bafilomycin A1, an inhibitor of lysosomal fusion, in the 
presence and absence of ketone bodies. There was no significant difference in detected ATP 
levels between treatment groups (Figure 3.1.1). Measured concentrations per group were 
indicated as control [2.62 ± 0.2 pM], control + bafilomycin [2.7 ± 0.2 pM], ketone bodies [2.8 
± 0.2 pM] and ketone bodies + bafilomycin [2.5 ± 0.1 pM]. 
 
 
 
Figure 3.1.1: Total ATP concentration under basal conditions. ATP concentration 
(pM) in GT1-7 cells indicating control (Con), treatment with bafilomycin (Con-Baf: 4 
hrs 400 nM), ketone bodies (KB: 24 hrs 6 mM) or bafilomycin and ketone bodies 
(KB-Baf: 24 hrs 6 mM + 4 hrs 400 nM), (n=6).  
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3.1.2 The effect of ketone body treatment and basal autophagy on ATP distribution 
Cells were transfected with an ATP indicator, ATeam (Imamura et al., 2009), that utilizes 
FRET allowing generation of an image of mitochondrial-targeted ATP within cells. GT1-7 cells 
were treated with bafilomycin A1 and ketone bodies to determine their effect on the 
intracellular ATP distribution profile. Here, regions with high signal intensity would indicate 
areas with a locally high ATP concentration. Micrographs display a discernible pattern of ATP 
distribution of ATP within cells (Figure 3.1.2a), with the presence of ‘hotspots’ revealed by 
using a lookup table (Figure 3.1.2b). In control cells, many small hotspots, occurring 
throughout the cytoplasm are visible, suggesting a relatively homogenous distribution of 
ATP across the cell. The distribution is diffuse in comparison to the other groups, where 
larger hotspots can be observed in different regions of the cells.  
It appears that the inhibition of autophagy leads to an increased ATP-derived emission 
(Figure 3.1.2a Con-Baf and KB-Baf), suggesting that functional autophagy is important for 
local ATP generation. The same is observed upon ketone body exposure. The image data 
suggests that exposure to ketone bodies and bafilomycin further changes the ATP 
distribution profile to a large region of localized signal.  
These data suggest that, although total ATP concentration remains unchanged, ATP 
distribution is being affected by the ketone body treatment. Inhibition of autophagy shows a 
similar pattern, indicating localized changes in ATP demand.  
The ATP distribution within the complete cellular mitochondrial network, instead of 
distribution within single mitochondria was assessed, as the ATeam construct was 
mitochondrially targeted. 
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Figure 3.1.2a: Representative fluorescent micrographs of cells transfected with the 
ATeam ATP indicator under basal conditions. Micrographs display control (Con), 
control + bafilomycin (Con-Baf: 4 hrs 400 nM), ketone bodies (KB: 24 hrs 6 mM) or 
bafilomycin and ketone bodies (KB-Baf: 24 hrs 6 mM + 4 hrs 400 nM) treatment 
groups. The panels show images of the FDonor channel, FAcceptor channel, the FRET 
channel and a lookup table of images generated by the ratio FFret/FDon. 100X 
magnification. Scale bar = 20 µm. 
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Figure 3.1.2b: Selected regions of micrographs displayed in  
Figure 3.1.2a indicating ATP distribution and distinct 
‘hotspots’ generated by the ratio of FFret and FDon and 
processed using a lookup table. Scale bars = 4 µm. 
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3.1.3 The effect of basal autophagy and ketone body treatment on APP, BACE and Aβ 
levels 
Western blot analysis was performed to assess whether protein degradation through 
autophagy under basal conditions and ketone body supplementation have an effect on the 
expression levels of three key proteins involved in amyloid processing; amyloid precursor 
protein (APP), beta-site APP-cleaving enzyme (BACE) and amyloid beta (Aβ) (O’Brien and 
Wong, 2011). Here, the utilization of bafilomycin would allow determining whether 
respective proteins are targeted and cleared by the autophagic system under basal 
conditions. A protein that is cargo for autophagy would accumulate upon bafilomycin 
treatment. No significant changes were observed in the expression levels of APP or BACE, 
however strong trends can be observed. Relative expression of APP compared to control 
(Figure 3.1.3a) was increased with bafilomycin treatment [122.6 ± 27.5%], decreased in the 
presence of ketone bodies [90.7 ± 12.6%] and appear increased when cells were co-treated 
with bafilomycin and ketone bodies [137.1 ± 49%]. BACE is the protease responsible for 
cleaving APP at the +1 and +11 sites of Aβ. BACE expression levels (Figure 3.1.3b) was 
increased with bafilomycin treatment [186 ± 63.6%], decreased with ketone body treatment 
[93.3 ± 5.6%] and remained unchanged upon co-treatment with bafilomycin and ketone 
bodies [98.3 ± 39.5%]. In contrast, Aβ expression levels were significantly decreasedwhen 
exposed to bafilomycin compared to control and cells treated with ketone bodies (Figure 
3.1.3c). This was the case for both in the Con-Baf and KB-Baf groups. Taken together, the 
results, albeit not significant in this scenario, strongly suggest that these candidate proteins 
are cleared under basal conditions through autophagy.  
These results indicate that both APP and BACE are targeted by the autophagic machinery, 
serving as substrates for protein degradation through autophagy. The significant reduction 
in Aβ levels observed when autophagy is inhibited would suggest that autophagy is involved 
in the production of amyloid beta from its precursor.  
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Figure 3.1.3: Relative expression levels of amyloid processing proteins according to the following 
groups: Control (Con), control + bafilomycin (Con-Baf: 4 hrs 400 nM), ketone bodies (KB: 24 hrs 6 
mM) or bafilomycin and ketone bodies (KB-Baf: 24 hrs 6 mM + 4 hrs 400 nM). a: No significant 
differences in APP protein levels are observed. A non-significant trend for increased APP protein with 
bafilomycin treatment in the presence and absence of ketone bodies is observed, (n=4). b: No 
significant differences in BACE protein levels are observed. A non-significant trend for increased BACE 
protein with bafilomycin treatment in the presence and absence of ketone bodies is observed, (n=3) 
c: Bafilomycin causes a decrease in Aβ in the absence (*p<0.05) and presence of ketone bodies 
(*p<0.05) compared to control and ketone bodies with bafilomycin treatment alone (*p<0.05), (n=3). 
Representative blots are displayed. 
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3.1.4 The effect of ketone body treatment on autophagic flux 
Western blot analysis of p62 and LC3 was performed to determine whether ketone body 
treatment impacts autophagic flux. p62, also known as SQSTM1, is a protein often used as a 
marker for selective autophagy, as it is involved in the targeting of poly-ubiquitinated 
proteins towards autophagolyosomes or degradation (Barth et al., 2010). LC3-II is present 
on the autophagosomal membrane and the relative expression levels of LC3-II as well as 
LC3-II levels following treatment with a lysosomal inhibitor are widely used to assess 
autophagy (Mizushima et al., 2010). No significant differences in p62 expression levels were 
observed (Figure 3.1.4a); however, a strong trend for decreased expression levels was 
observed with ketone body treatment [78 ± 17.5%], suggesting an increase in the clearance 
of p62 and hence, autophagic flux. In addition, a slight decrease with bafilomycin and 
ketone bodies co-treatment [84.8 ± 17.5%] was observed. Bafilomycin treatment had no 
effect [96.9 ± 14.1%]. No significant differences in LC3-II expression levels were observed, 
however there was a trend for increased expression in the control condition treated with 
bafilomycin, compared to control [145.6 ± 10.9%], indicating that autophagosomes indeed 
accumulate upon bafilomycin treatment. 
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Figure 3.1.4: Relative expression levels of p62 and LC3 protein levels following treatment with 
medium (Con), bafilomycin (Con-Baf: 4 hrs 400 nM), ketone bodies (KB: 24 hrs 6 mM) or bafilomycin 
and ketone bodies (KB-Baf: 24 hrs 6 mM + 4 hrs 400 nM) a: No significant differences in p62 protein 
levels are observed. A non-significant decrease in p62 protein levels with ketone body treatment is 
observed, (n=3). b: No significant differences in LC3-II protein are observed. A non-significant 
increase in LC3-II levels are observed with bafilomycin and ketone body treatment and KB-Baf 
groups, (n=3).   
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Figure 3.1.4c: Western blot data summarising 
results of amyloid processing and autophagy-
related proteins. Representative blots are 
displayed. 
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3.1.5 The effect of basal autophagy and ketone body treatment on APP, BACE and Aβ 
distribution 
Fluorescence microscopy of APP, BACE and Aβ allowed intracellular visualization of their 
localization and distribution under control conditions and following treatment. The 
micrographs indicating APP (Figure 3.1.5a), BACE (Figure 3.1.5) and Aβ (Figure 3.1.5c) 
revealed similar trends in their localization and distribution. Under control conditions it was 
observed that the proteins were primarily cytoplasmic and formed small spherical 
aggregates that are homogenously distributed throughout the cytoplasm. Nuclear signal 
was observed but no cellular membrane-derived signal. Cells also displayed nuclear signal 
upon treatment with bafilomycin. Ketone body treatment caused a loss of nuclear signal, 
while treatment with both ketone bodies and bafilomycin result in increased nuclear 
localization of APP and BACE (Figure 3.1.5a and b, KB-Baf). 
Bafilomycin treatment caused an increase in aggregated APP as evidenced by the 
appearance of larger, brighter structures (Figure 3.1.5a, Con-Baf). The same was observed in 
cells treated with both ketone bodies and bafilomycin (Figure 3.1.5a, KB-Baf). A concomitant 
decrease in the diffuse levels of APP was observed in both bafilomycin treated groups 
compared to the control and ketone body treated groups.  Ketone body treatment had no 
apparent effect on APP (Figure 3.1.5a, KB). The same was the case for BACE in cells; 
however ketone body treatment does seem to increase aggregation of Aβ in cells treated 
with ketone bodies and with both ketone bodies and bafilomycin. Bafilomycin treatment did 
not increase nuclear signal of Aβ as observed for APP and BACE (Figure 3.1.5a and b, Con-
Baf). 
Thus these results indicate that autophagy inhibition causes aggregation of APP, BACE and 
Aβ and that this aggregation extends to the nucleus in the case of APP and BACE. This 
suggests that autophagy is instrumental in controlling the local availability and, in part, 
distribution of these proteins present in cells. Our results suggest that APP processing 
occurs through autophagy and that inhibition of autophagy causes protein aggregation.  
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Figure 3.1.5: Representative micrographs of stained GT1-7 cells exposed to the 
following conditions: Control (Con), bafilomycin (Con-Baf: 4 hrs 400 nM), ketone 
bodies (KB: 24 hrs 6 mM) or bafilomycin and ketone bodies (KB-Baf: 24 hrs 6 mM + 4 
hrs 400 nM). a: Green = APP, blue = Hoechst 33342. b: Red = BACE, blue = Hoechst 
33342. c: Red = Aβ, blue = Hoechst 33342. 100X magnification. Scale bar = 20 µm. 
Arrowheads indicate aggregated protein. 
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SECTION 2: The role of ketone body supplementation under neurotoxic conditions  
In the following section we report results that assess the effect of ketone body 
supplementation in paraquat-induced neurotoxicity. Since our data in section 1 indicated a 
role for ketone bodies in ATP localization as well as autophagy and protein clearance, we 
hypothesized that they would influence ATP levels, mitochondrial dynamics, and autophagy 
in a neurotoxicity model. We further hypothesized that ketone bodies would confer 
neuroprotection due to their role in upregulating autophagy.  
3.2.1 Reductive capacity  
A WST-1 assay was performed to assess GT1-7 cells’ reductive capacity following treatment 
(Figure 3.2.1).  Paraquat caused a significant reduction in the reductive capacity compared 
to the control condition [56.9 ± 2.1% (p<0.05)] while treatment with ketone bodies alone 
had no effect on cell viability [95.9 ± 3%]. Co-treatment with both paraquat and ketone 
bodies, however, caused a significant increase in the reductive capacity compared to 
paraquat treated cells [66.5 ± 2 % (p<0.05)]. Hence, we observe a rescue effect brought 
about by ketone body exposure, decreasing paraquat induced neurotoxicity.  
 
 
 
 
  
Figure 3.2.1:  Relative reductive capacity compared to control (Con) following 
treatment with paraquat (PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or 
paraquat in the presence of ketone bodies (PQ + KB: 24 hrs 600 µM + 6 mM).  
(n=3). *p <0.05. 
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3.2.2 The effect of paraquat and ketone body treatment on autophagy and apoptosis  
LC3-II is used as an indicator of autophagy, as previously mentioned. It is associated with the 
autophagosomal membrane and in this way provides an indication of autophagosomal 
number (Mizushima et al., 2010).  PARP is cleaved during apoptosis execution, to form an 85 
kDa protein (Tewari et al., 1995). No significant differences in the expression levels of LC3-II 
or cleaved PARP was observed in the treatment groups (Figure 3.2.2). A strong trend was 
observed, however, for decreased LC3-II expression upon paraquat treatment [35.8 ± 
18.3%] and in the co-treatment group [32.6 ± 15.9%].  
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Figure 3.2.2: Relative expression levels of LC3-II and cleaved PARP proteins according to the following 
groups: Control (Con), paraquat (PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or paraquat in 
the presence of ketone bodies (PQ + KB: 24 hrs 600 µM + 6 mM). a: No significant differences in LC3-
II protein levels are observed. A non-significant trend for decreased LC3-II with paraquat treatment is 
observed, (n=3). b: No significant differences in cleaved PARP are observed, (n=3). Representative 
blots are displayed. 
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3.2.3 Mitochondrial morphology following paraquat and ketone body treatment  
Mitochondrial network morphology is an indicator of the functionality of cells. Fragmented 
mitochondria often indicate cellular stress, while a predominantly fused network is 
associated with viable cells (Chan, 2006). TMRE staining revealed that control cells displayed 
elongated mitochondria that form a highly interconnected network (Figure 3.2.3). Treating 
cells with paraquat resulted in the complete loss of network connectivity, characterized by 
numerous individual (fragmented) mitochondria. Fragmented mitochondria with very bright 
fluorescent signal were apparent in cells treated with paraquat, and with both paraquat and 
ketone bodies. Cells treated with ketone bodies displayed elongated mitochondria with a 
high degree of network connectivity, similar to control cells. Co-treated cells displayed both 
fused and fragmented mitochondria; however a greater degree of mitochondrial 
connectivity was visible compared to cells treated with paraquat only.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.3: Representative micrographs of mitochondria stained with TMRE, under control 
conditions (Con) and following treatment with paraquat (PQ: 24 hrs 600 µM), ketone bodies (KB: 
24 hrs 6 mM) or paraquat in the presence of ketone bodies (PQ + KB: 24 hrs 600 µM + 6 mM). Red 
= TMRE, blue = Hoechst 33342. 100X magnification. Scale bar = 20 µm. Arrowheads indicate 
fragmented mitochondria.  
Con PQ 
PQ + KB KB 
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3.2.4 Mitochondrial network morphology indicated by form factor and aspect ratio  
Micrographs, in this case indicating mitochondria through TMRE staining, were processed 
using ImageJ software to generate skeletonized images of the mitochondrial network 
(Figure 3.2.4a). These images were then used to calculate the average form factor (degree 
of branching) and aspect ratio (length) (Mortiboys et al., 2008) of mitochondria in cells 
treated with paraquat, ketone bodies and both paraquat and ketone bodies. A form factor 
close to one indicates a completely fragmented network, while a decrease in aspect ratio 
indicates spherical mitochondria.   
No significant differences in form factor were observed between groups, however, the 
control condition displayed the lowest form factor value (Figure 3.2.4c), indicating the most 
connected mitochondrial network of all groups. Cells treated with paraquat were 
characterized by the most fragmented mitochondrial network, as indicated by the high form 
factor. No significant differences in the aspect ratio were observed between groups(Figure 
3.2.4d).  Control cells, however, had the highest value, indicating elongated mitochondria, 
and paraquat treatment resulted in the lowest aspect ratio, indicating rounded 
mitochondria.  
A particle count of the edited images (Figure 3.2.4b) displays surprising results with ketone 
body treatment resulting in the highest count, while paraquat had the lowest count. These 
differences can be explained, however by the observation that paraquat treatment caused 
severe cell shrinkage, while this effect was not seen in the control and ketone body groups. 
Thus the effect of mitochondrial networking would be masked by the greater overall 
number of mitochondria in these groups.  
Although no statistically significant differences were observed, robust changes in 
morphology and corresponding changes in both aspect ratio and form factor were observed, 
supporting the detrimental impact of paraquat treatment as well as the beneficial effect of 
ketone body supplementation. 
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Figure 3.2.4a: Processed micrographs of mitochondria stained with TMRE, under control conditions 
(Con) and following treatment with paraquat (PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or 
paraquat in the presence of ketone bodies (PQ + KB: 24 hrs 600 µM + 6 mM).100X magnification. These 
images were used to generate the form factor and aspect ratio.  
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Figure 3.2.4b: Mitochondrial count as indicated by TMRE-stained particles according to the 
following groups: Control (Con), paraquat (PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 
mM) or paraquat in the presence of ketone bodies (PQ + KB: 24 hrs 600 µM + 6 
mM).Graph indicates mean value of counted mitochondria ± SEM, (n=3). 
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Figure 3.2.4c: Degree of branching indicated by form factor analysis of mitochondria 
stained with TMRE, under control conditions (Con), or following treatment with paraquat 
(PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or paraquat in the presence of 
ketone bodies (PQ + KB: 24 hrs 600 µM + 6 mM). Graph indicates mean values ± SEM, 
(n=3). 
Figure 3.2.4d: Length indicated by aspect ratio analysis of mitochondria stained with TMRE, 
under control conditions (Con), or following treatment with paraquat (PQ: 24 hrs 600 µM), 
ketone bodies (KB: 24 hrs 6 mM) or paraquat in the presence of ketone bodies (PQ + KB: 24 
hrs 600 µM + 6 mM). Graph indicates mean values ± SEM, (n=3). 
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3.2.5 Oxidative capacity following paraquat and ketone body treatment 
3.2.5.1 TMRE mean intensity 
Flow cytometry was performed with cells stained with TMRE to assess the mitochondrial 
polarization state of a whole cell population (Figure 3.2.5.1b). The mean intensity increased 
relative to that of control cells following treatment with paraquat, although this change was 
not statistically significant [168.2 ± 25.4%]. Intensity remained similar to that of control cells 
in the presence of ketone bodies [83.7 ± 7.1%], however, a statistically significant increase 
was revealed when cells were treated with paraquat in the presence of ketone bodies 
[180.8 ± 19.4% (p<0.05)]. A statistically significant decrease was observed between the 
paraquat and ketone bodies groups. This decrease was lost in the co-treatment group 
(Figure 3.2.5.1a).  
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Figure 3.2.5.1a: Mean fluorescence intensity of a population of GT1-7 cells stained with TMRE, 
presented as a percentage of control. Cells were untreated (Con), or treated with paraquat (PQ: 24 
hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or paraquat in the presence of ketone bodies (PQ + 
KB: 24 hrs 600 µM + 6 mM, (n= 3). Mean ± SEM. *p<0.05  
Figure 3.2.5.1c: Representative graph of fluorescence intensity of GT1-7 cells stained with 
TMRE, presented as intensity histograms. Cells were untreated (Con), or treated with paraquat 
(PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or paraquat in the presence of ketone 
bodies (PQ + KB: 24 hrs 600 µM + 6 mM). Cells treated with carbonyl cyanide 
chlorophenylhydrazone (CCCP) represent a positive control.  
* 
* * 
Figure 3.2.5.1b: Representative graph of control GT1-7 neuronal cells stained with TMRE.  
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3.2.5.2 Dichlorofluorescein mean intensity 
In order to assess generic ROS levels, mean intensity analysis was performed as well as 
micrographs captured following staining with dichlorofluorescein (DCF). DCF staining is 
visible as green punctae. Cells treated with paraquat displayed the strongest DCF signal 
(Figure 3.2.5.2a). Few small DCF-positive areas were visible in control, ketone bodies and co-
treatment groups. Flow cytometry analysis revealed no significant differences in the mean 
fluorescence intensity between groups (Figure 3.2.5.2b); however the co-treatment group 
(PQ + KB) had a much higher value compared to control, ketone body and paraquat only 
treated groups.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.5.2a: Representative micrographs of cells stained with dichlorofluorescein (DCF). Cells 
were untreated (Con), or treated with paraquat (PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 
mM) or paraquat in the presence of ketone bodies (PQ + KB: 24 hrs 600 µM + 6 mM. Green = DCF, 
blue = Hoechst 33342. 100X magnification. Scale bar = 20 µm.  Arrowheads indicate DCF-stained 
areas.  
Con PQ 
KB PQ + KB  
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Figure 3.2.5.2b: Mean fluorescence intensity values of a population of GT1-7 cells stained with 
DCF, presented as a percentage of control. Cells were untreated (Con), or treated with 
paraquat (PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or paraquat in the presence of 
ketone bodies (PQ + KB: 24 hrs 600 µM + 6 mM, (n=3).  
Figure 3.2.5.2c: Representative graph of control GT1-7 neuronal cells stained with DCF.  
Figure 3.2.5.2d: Representative graph of fluorescence intensity of GT1-7 cells stained with DCF, 
presented as intensity histograms. Cells were untreated (Con), or treated with paraquat (PQ: 
24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or paraquat in the presence of ketone bodies 
(PQ + KB: 24 hrs 600 µM + 6 mM. Cells treated with hydrogen peroxide (H2O2) represent a 
positive control.  
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3.2.6 The effect of paraquat and ketone body treatment on ATP concentration 
A luciferase-based ATP assay was used to measure total ATP levels following treatment with 
paraquat, ketone bodies and paraquat in the presence of ketone bodies (Figure 3.2.6). 
Paraquat treatment caused a statistically significant reduction in ATP concentration 
compared to the control condition with values of 2.86 ± 0.1 and 2.41 ± 0.1 pM (p<0.05) 
detected, respectively. Cells treated with ketone bodies displayed a similar concentration as 
controls [2.84 ± 0.08 pM]. Co-treatment did not cause an increase in ATP concentration 
compared to paraquat treatment [2.26 ± 0.08 pM].  
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Figure 3.2.6: Total ATP concentration in an injury model. ATP 
concentration (pM) according to the following treatment groups: 
Control (Con), paraquat (PQ: 24 hrs 600 µM), ketone bodies (KB: 24 
hrs 6 mM) or paraquat in the presence of ketone bodies (PQ + KB: 
24 hrs 600 µM + 6 mM), (n=4). Graph represents mean ± 
SEM.*p<0.05 
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3.2.7 The effect of paraquat and ketone body treatment on ATP distribution 
ATP, as previously mentioned, is indicated by the ATeam construct (Figure 3.2.7a). 
Localization was dispersed in control cells as was seen in section 1, with the presence of 
multiple small ‘hotspots’ visible (Figure 3.2.7b). Paraquat treatment resulted in a robust 
decrease of detected signal, which reflects the decreased ATP concentration seen in Figure 
3.2.6. Ketone bodies caused ATP to accumulate in a number of single hotpots and the 
overall distribution was less diffuse than in the control condition. In the co-treatment group 
less overall signal was observed than in control and ketone bodies groups; however more 
signal compared to the paraquat treatment. A small number of hotspots were observed 
which supports the ATP concentration data which suggests that ketone bodies can rescue 
from ATP depletion induced by paraquat exposure, by changing ATP localization and 
distribution. ATP localization changes are apparent in mitochondrial ATP (as we assessed) 
but this could also be true of ATP in the cytosol.  
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Figure 3.2.7a: Representative fluorescent micrographs of cells transfected with the 
ATeam ATP indicator in an injury model. Micrographs display control (Con), paraquat 
(PQ: 24 hrs 600 µM), ketone bodies (KB: 24 hrs 6 mM) or paraquat in the presence of 
ketone bodies (PQ + KB: 24 hrs 600 µM + 6 mMtreatment groups. Panel A shows 
images of the FDonor channel, panel B shows FAcceptor channel, panel C shows the 
FRET channel and panel D shows a lookup table of images generated by the ratio of 
FFret and FDon. Scale bar = 20 µm. 100X magnification. 
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Figure 3.2.7b: Selected regions of micrographs displayed in 
3.2.7a indicating ATP distribution and distinct ‘hotspots’ 
generated by the ratio of FFret and FDon and processed 
using a lookup table. Scale bars = 4 µm.  
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3.2.8 The effect of paraquat and ketone body treatment on neuronal ultrastructure 
Transmission electron microscopy (TEM) was performed to determine the effect of paraquat 
and ketone body treatment, as well as co-treatment, on the neuronal ultrastructure of cells, 
with a particular focus on mitochondria and vacuolar structures.  
Micrographs reveal that under control conditions, mitochondria are characterized by a 
predominantly elongated morphology (Figure 3.2.8b). Cristae structure ares well 
demarcated. In addition, well-defined vacuolar structures are visible (Figure 3.2.8c). Cells 
treated with paraquat display decreased mitochondrial integrity, indicated by swollen and 
disrupted mitochondrial morphology (Figure 3.2.8e). Less defined vacuolar structures are 
present (Figure 3.2.8f). In the ketone body treated group mitochondria that are similar to 
the control group can be observed (Figure 3.2.8h) as well as an increased number of 
vacuolar structures (Figure 3.2.8i). Co-treatment resulted in fewer vacuolar structures being 
observed (Figure 3.2.8l). 
Control and ketone body treated cells display intact nuclei (Figure 3.2.8a and g). Paraquat 
treatment resulted in distinct nuclear morphology, as indicated by large white areas within 
nuclei with disrupted chromatin (Figure 3.2.8d). Co-treatment resulted in nuclear 
morphology with some euchromatin integrity (Figure 3.2.8j).   
.  
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Figure 3.2.8a-l: Representative transmission electron micrographs of GT1-7 cells 
arranged according to treatment condition: control (Con), paraquat (PQ: 24 hrs 600 
µM), ketone bodies (KB: 24 hrs 6 mM) or paraquat in the presence of ketone bodies (PQ 
+ KB: 24 hrs 600 µM + 6 mM). Lower magnification images (first panel) indicate general 
cellular ultrastructure; higher magnification images reveal the presence of mitochondria 
(second panel) and vacuolar structures indicative of autophagic processes (third panel). 
Arrowheads indicate structures of interest. Scale bar for a and j = 2000 nm; b, e, h, I, k, l 
= 1000 nm; c, d, f, g = 5000 nm.  
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Chapter 4: DISCUSSION AND CONCLUSION 
Ketone bodies have been demonstrated to confer a host of beneficial effects in the context 
of neurodegenerative diseases (Paoli et al., 2013). These benefits include preventing cell 
death after exposure to an ischemic insult (Samoilova et al., 2010), decreasing Aβ deposition 
(Van der Auwera et al., 2005) and ameliorating cognitive deficits (Zhang et al., 2013). 
Importantly, these benefits extend to human subjects; significant improvement in cognitive 
performance was found in AD patients (Henderson et al., 2009) and undiagnosed individuals 
suspected of suffering from AD (Benge et al., 2009). This is supported by the comprehensive 
benefits of caloric restriction in primates demonstrated by Colman et al. (2014). Although it 
is known that ketone bodies improve the energetic state of cells, evidenced by increasing 
ATP levels in the absence of glucose (Arakawa et al., 1991), it remains unclear how this 
change in ATP is brought about and how it connects to protein aggregation. This is 
important because the cell’s energetic state is a deciding factor in the survival and activation 
of cell death pathways (Loos and Engelbrecht, 2009). 
Evidence suggests that ketone bodies favour protein degradation (Finn and Dice, 2005) and 
impact on aggregate prone species involved in AD pathology (Van der Auwera et al., 2005; 
Zhang et al., 2013). Indeed, inducing autophagy through starvation improves AD symptoms 
in its own right. Autophagy is disrupted in AD, and AD brains are characterized by the 
accumulation of undigested autophagic vacuoles (Boland et al., 2008). This is attributed to 
lysosomal dysfunction, resulting in decreased degradative capacity of neurons (Nixon and 
Yang, 2011). It has been demonstrated that inhibited autophagy can lead to Aβ deposition 
through its modulation of the APP processing pathway (Pickford et al., 2008). Conversely, 
inducing autophagy slows AD disease progression in mice (Yang et al., 2011; Spilman et al., 
2010). How ketone body availability affects neuronal autophagy and neuronal viability in the 
context of neurodegeneration remains however largely unclear (Figure 4a). 
Thus we aimed to assess the role of ketone bodies in the context of AD using two distinct 
approaches. First, we aimed to investigate the molecular link between ketone body 
exposure and amyloid processing by performing Western blot analysis, fluorescence 
microscopy as well as quantitative and qualitative assessment of neuronal ATP 
concentration and distribution in a suitable in vitro model. The latter was motivated by the 
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major role of ATP in neuronal cell survival. In this context we also aimed to assess to what 
extent ketone body exposure is able to impact on autophagic flux, i.e. the protein 
degradation rate through autophagy. Secondly, we used an injury model using paraquat 
exposure and assessed the effect of ketone body treatment by performing Western blot 
analysis, a reductive capacity assay, mitochondrial morphology assessment, transmission 
electron microscopy, ATP quantification and qualitative assessment as well as flow 
cytometry. We hypothesized that ketone body supplementation would upregulate 
autophagy and increase intracellular ATP concentration. In addition, we predicted that 
ketone bodies would play a protective role in the context of neurotoxicity, specifically by 
maintaining ATP levels, mitochondrial morphological characteristics and cellular viability.  
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4.1.1 Ketone body treatment and basal autophagy relocalizes intracellular ATP without 
affecting its total concentration  
To our surprise, neither the inhibition of autophagosomal/lysosomal fusion nor the 
exposure to ketone bodies impacted on total ATP availability (Figure 3.1.1). This may 
suggest that, in these conditions and cells, basal protein degradation through autophagy is 
not a major contributor to metabolite substrate provision and ATP synthesis. It also suggests 
that ketone bodies do not increase the ATP generation profile under control conditions.  
Others have demonstrated a similar lack of change in ATP levels when silencing a PFKFB3, an 
enzyme responsible for a rate-limiting step in the glycolytic pathway (De Bock et al., 2013). 
ATP levels remained unchanged despite other important changes that were triggered by 
silencing, such as impairing endothelial cell motility and a decrease in ATP hotspots. 
Luciferase-based assays such as the one utilized here are not always the most reliable 
method to detect ATP (Kennedy et al., 1999). ATP concentration can be misleading if it is 
considered in isolation, and using an ATP sensor as an additional assessment grants a clearer 
understanding of the energetic milieu within cells. However, some have observed a 
decrease in ATP levels upon autophagy inhibition by 3-methyladenine (Hernández–Gea et 
al., 2012).  Arakawa et al. (1991) described elevated ATP levels after two hour treatment 
with 20 mM β-OHB. We did not find observe this effect; however we used a much lower 
concentration of ketone bodies. Nevertheless, both ketone body and bafilomycin treatment 
affected ATP localization in our experiments. 
Treatment with ketone bodies and bafilomycin both caused the accumulation of ATP 
derived emission within cells (Figure 3.1.2a and b). In the control condition ATP distribution 
appeared diffuse, with many small hotspots visible. This distribution changed upon 
bafilomycin and ketone body treatment where large localized areas of signal could be seen. 
The observed increase in signal may represent an adaptive mechanism of cells to the 
alternative energetic pathways activated upon ketone body treatment, as ketone bodies are 
able to enter the TCA cycle (Prins, 2008). This is a likely scenario as it has been 
demonstrated that ketone bodies contribute a substantial amount of TCA cycle flux in rat 
neurons, and can support most, if not all of neuronal oxidative metabolism (Chowdhury et 
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al., 2014). Autophagy inhibition may cause a stress response in cells as they are forced to 
rely on other metabolic pathways apart from the catabolism of amino acids.  
Our findings are to our knowledge the first to indicate ATP relocalization changes upon 
ketone body treatment and autophagy inhibition. This deserves further attention in future 
research.  
4.1.2 Autophagy targets APP and BACE for degradation 
Bafilomycin treatment increased the levels of APP and BACE in the presence and absence of 
ketone bodies (Figure 3.1.3a and b) suggesting that autophagy is involved in targeting APP 
and BACE. However statistical significance was not obtained. We believe that the basal 
turnover rates of these specific proteins are too low to lead to more robust changes in the 
intervention time investigated. The autophagy machinery was only inhibited for two hrs, 
which may be too short to provide a large enough time window to observe protein 
accumulation. In addition, it is possible that bafilomycin is not the ideal autophagy inhibitor 
in this particular cell line and it may be beneficial to use an inhibitor of lysosomal function 
such as E64d or pepstatin A instead (Mizushima et al., 2010).   
The opposite pattern was observed with regards to Aβ expression levels (Figure 3.1.3c). A 
significant decrease was seen with bafilomycin treatment, in the presence and absence of 
ketone bodies. These data are somewhat surprising as we anticipated increased aggregation 
of the Aβ peptide when autophagy was inhibited. We speculate that the aggregate prone 
behaviour of Aβ has been affected by the equilibrium between soluble oligomeric amyloid 
species, a known phenomenon which complicates AD research when assessing particular 
protein species (Benilova et al., 2012). It could also be the case that the antibody used for 
Western blot analysis showed non-specific binding effects. 
Pickford et al. (2008) described no significant change in APP levels in AD transgenic mice 
with a beclin deficiency, while Tian et al. (2011) successfully demonstrated that autophagy 
deficient mice had a non-significant increase of 25% in full-length APP compared to wild-
type mice, supporting our findings. APP C-terminal fragment (APP-CTF) levels showed the 
same pattern with the inhibition of autophagy leading to a greater accumulation 
significantly different from controls (Tian et al., 2011). These data strengthen the notion 
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that it is important which protein fragment of APP is considered, and our data support the 
literature with regards to APP expression.  
BACE1 activity is intimately linked to Aβ levels – pharmacological inhibition decreases Aβ 
levels in the brain (Fukomoto et al., 2010) and BACE-/- mice do not present with  any cerebral 
Aβ deposition (Vassar et al., 2009). Chen et al. (2015) demonstrated that autophagy 
inhibition through 3-methyladenine increased the levels of BACE1 in a model of glucose-
oxygen deprivation.  These data support the trend of BACE protein expression levels 
increasing upon bafilomycin treatment (Figure 3.1.3b). 
The decrease in Aβ that we describe (Figure 3.1.3c) is in contrast with current literature, and 
suggests that autophagy is involved in producing Aβ. Others have found that inhibiting 
autophagy leads to Aβ accumulation (Tian et al., 2011, Pickford et al., 2008) and that 
increasing autophagy via a small molecule enhancer can decrease the levels of APP-CTF. 
Atg5, Beclin-1 and ULK-1, essential components of the autophagy pathway, are involved in 
this degradation (Tian et al., 2011). This finding suggests that autophagy is not only involved 
in the clearance of amyloid, but also in its generation (Yu et al., 2004, Yu et al., 2005) which 
further contributes to the complexity of protein clearance and warrants further 
investigation.  
4.1.3 Ketone body treatment may enhance autophagic flux 
Although no significant effect of ketone bodies on autophagy was observed (Figure 3.1.4), 
ketone body exposure decreased p62 and increased LC3-II protein levels, suggesting 
upregulation of autophagy. This is supported by the change in APP and BACE protein levels, 
which both decreased upon ketone body exposure. However, concomitant inhibition of 
autophagosomal/lysosomal fusion in the presence of ketone bodies did not consistently 
increase LC3-II and p62 levels. Additional means to assess autophagic flux are here 
recommended, such as the detection of p62 and LC3 punctae through immunofluorescence, 
or the use of autophagy specific tandem proteins, that allow discerning between the 
autophagosomal and lysosomal pool size (Mizushima et al., 2010). It is also possible that 
autophagy inhibition was not complete, although we chose the concentration and duration 
of bafilomycin treatment based on dose response experiments by others in our research 
group. This deserves further attention in the future.  
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The lack of a robust increase in LC3-II or p62 protein levels in the concomitant treatment 
with ketone bodies and bafilomycin may be due to the fact that we did not deprive cells of 
glucose during the course of ketone body treatment. However, others have found that 
ketone bodies increase autophagy with glucose deprivation,(Camberos-Luna et al., 2015). 
Such a scenario is less aligned with the physiological response to ketosis induced by 
starvation. Grey et al. (1975) demonstrated that glucose levels remained unchanged despite 
increased levels of free fatty acids and β-OHB.  Further research that dissects the 
relationship between substrate availability, such as predominantly glucose versus amino 
acids or fatty acids is required to enhance our understanding of this research question. 
 
4.1.4 Basal autophagy targets and degrades APP, BACE and Aβ 
Fluorescence microscopy of APP, BACE and Aβ revealed their intracellular localization 
pattern and allowed assessment of possible localization and distribution changes when 
exposed to bafilomycin and ketone body treatment. Autophagy inhibition had an effect on 
the aggregation of all three proteins, with the most robust changes observed in APP (Figure 
3.1.5a). These results support the results observed in the APP and BACE Western blot data, 
that autophagy is involved in the clearance of these two proteins. The fluorescence 
microscopy data for Aβ showing aggregation upon autophagy inhibition contradicts Western 
blotting data which suggests that autophagy increases its levels. Findings in the literature 
support the clearance role of autophagy here (Tian et al., 2011; Chen et al., 2015) and 
supports the notion that autophagy is involved in the clearance of these proteins.  
 
APP is found in various membrane-rich subcellular compartments including the nucleus, 
mitochondria and microsomes (Selkoe et al., 1988). Our results support this finding since 
spherical localization, which could be indicative of the latter two structures, was observed, 
and could also explain the nuclear signal. BACE is a transmembrane aspartic protease that 
occurs primarily within acidic intracellular compartments such as endosomes and the trans-
Golgi, with its active site localized at the luminal interface (Vassar et al., 2009). This could 
explain the spherical aggregations observed – these may indicate endosomes or the like, 
containing BACE. In future studies this question may be confirmed by co-staining cells for 
BACE and endosome or Golgi specific proteins. Aβ is associated with tubulovesicular 
compartments such as the ER, Golgi and endosomes as well as AV within cells (Yu et al., 
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2005). The spherical aggregates shown in our micrographs (Figure 3.1.5c) support this and 
suggest the involvement of autophagy in Aβ breakdown.  
 
We observed nuclear signal of APP, BACE and Aβ which was lost upon ketone body 
treatment but not upon autophagy inhibition (Figure 3.1.5). The nuclear localization of APP 
has been documented by Kimberly et al. (2001). They constructed a plasmid that encodes 
the APP protein intracellular domain (AICD) and reported that the majority of the 
synthesized protein localized to the nucleus, suggesting that it signals through the nucleus. 
Nuclear localization of APP, BACE and Aβ could suggest a possible role in regulating 
signalling or transcription, a compelling notion that warrants further investigation. 
  
4.2.1 Ketone body exposure rescues paraquat-induced neurotoxicity  
Paraquat is toxic to cells and exposure leads to oxidative stress-induced neuronal cell death 
(McCormack et al., 2005). Our results indicate that paraquat reduces the reductive capacity 
of cells compared to controls (Figure 3.2.1). However, this study has shown that ketone 
bodies ameliorate this effect, conferring neuronal protection in the presence of paraquat, 
and improving cell viability. This demonstrates the protective effects of ketone bodies.  
Others have found that ketone bodies have an anti-oxidant effect by acting as inhibitors of 
mitochondrial permeability, thereby decreasing production of mitochondrial ROS (Kim et al., 
2007). A similar protective effect was observed in mouse kidney (Shimazu et al., 2013). 
These researchers present evidence that β-OHB acts as an endogenous histone deacetylase 
inhibitor which confers protection against oxidative damage. This may explain the 
mechanism of action of the rescue effect we observed and deserves further study, 
especially in light of the regulatory role of acetylation status on autophagy (Mariño et al., 
2014). 
4.2.2 Ketone body supplementation and paraquat affect autophagy   
Our data indicate that paraquat itself enhances autophagy as both ketone body and 
paraquat treatment show decreased LC3-II protein levels (Figure 3.2.2), which may indicate 
enhanced clearance and fusion with lysosomes. This supports findings by González-Polo et 
al. (2007) who have demonstrated that paraquat induces several autophagy characteristics 
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in neuroblastoma cells. However, fusion inhibition is recommended for future research to 
assess autophagic flux (Rubinsztein et al., 2009). 
A trend for decreased cleaved PARP with paraquat treatment was observed (Figure 3.2.2b) 
suggesting its cleavage upon paraquat exposure. However, our data do not indicate robust 
changes in PARP activation. It has been demonstrated that paraquat induces apoptosis (Fei 
et al., 2008) and that caspase-3, -8 and -9 are increased upon paraquat exposure (Hong et 
al., 2013). It is likely that our experimental conditions did not allow the relatively far 
downstream effects of PARP activation to manifest.  
4.2.3 Ketone body exposure preserves mitochondrial morphology without affecting 
mitochondrial polarization 
The important role of mitochondrial network dynamics in cellular viability is becoming 
increasingly clear (Okamoto and Kondo-Okamoto, 2012) and mitochondrial morphology 
analysis revealed definite patterns. Our analysis of the mitochondrial network using TMRE 
reveals that paraquat-induced mitochondrial fragmentation (Figure 3.2.3), a common sign of 
cellular stress also induced by other stimuli, often as an intermediate step before cell death 
programs are activated (Ashktorab et al., 2004; Cho et al., 2009). Co-treatment conferred 
some degree of protection from unbalanced fission, as more fused mitochondria can be 
observed, however the network is still less fused than what was observed in the control and 
ketone body-exposed groups. Thus our data supports the findings in the literature that a 
steady balance between mitochondrial fission and fusion favouring fusion is found in viable 
cells (Okamoto and Kondo-Okamoto, 2012) and that it is protective (Chen et al., 2007).  
Morphological analysis was completed by calculating the form factor and aspect ratio of 
mitochondria as well as obtaining the mitochondrial count (Figure 3.2.4). Results reveal a 
strong trend towards branched, elongated, networked mitochondria in the control group 
and with ketone body treatment and fragmented, spherical mitochondria with paraquat 
treatment in the presence and absence of ketone bodies. However, the presence of ketone 
bodies seems to improve paraquat-induced mitochondrial fragmentation. Our results are in 
agreement with the literature, where mitochondrial damage and fragmentation have been 
reported following paraquat treatment (Narendra et al., 2008) and there is evidence that 
oxidative stress causes mitochondrial damage and disrupts morphology (Jendrach et al., 
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2008). Mishra et al. (2014) reported that supplementing cells with ketone bodies resulted in 
increased mitochondrial respiration within 30 min of administration, which could be a result 
of the increased fusion state seen in the paraquat and ketone body co-treatment group 
compared to cells exposed to paraquat (Figure 3.2.3).  
Flow cytometry was performed to indicate ROS in two compartments. First, TMRE, a 
mitochondrial membrane potential dependent dye which associates with the inner 
mitochondrial membrane was used to indicate mitochondrial specific oxidative stress, and 
secondly DCF was employed to indicate general intracellular ROS. The TMRE analysis (Figure 
3.2.5.1) revealed that paraquat treatment caused brighter signal emission compared to 
controls, and ketone body supplementation in the presence of paraquat further increased 
the fluorescence intensity to the highest levels. This was an unexpected result, considering 
that ketone body treatment did not change emission levels. Others have reported that 
paraquat treatment decreases detected TMRE signal over time (Huang et al., 2012; He et al., 
2012b). We believe that the increased signal is a result of the paraquat-induced 
mitochondrial damage which, at the point of assessment, manifested in fragmented but 
highly polarized mitochondria. These mitochondria would increase mean intensity signal 
and somewhat mask the overall mitochondrial polarization state. 
No significant difference in DCF mean intensity was observed (Figure 3.2.5.2); however the 
trend for the highest detected signal in the co-treatment group supports the findings of the 
TMRE analysis. Others have found increases in the DCF signal with paraquat exposure which 
we did not observe (Lee et al., 2015; Kim et al., 2011).  
4.2.4 Ketone body exposure improves localized ATP availability without affecting total 
ATP concentration  
We assessed intracellular ATP levels and found that paraquat treatment, both in the 
presence and absence of ketone bodies, caused a decrease in ATP concentration (Figure 
3.2.6). Ketone bodies did not ameliorate the decrease in ATP induced by paraquat. Yang et 
al. (2007) demonstrated decreased ATP in Parkinson’s disease transgenic mice treated with 
paraquat and Yang and Tiffany-Castiglioni (2007) reported a similar effect in neuroblastoma 
cells.  
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There are shortcomings to using the luciferase-based ATP assays, and as such visual 
methods employing ATP indicators are recommended. ATeam transfection allows for the 
detection of intracellular ATP (Imamura et al., 2009). Paraquat caused a severe decrease in 
the overall ATP signal and a complete loss in signal was detected. Ketone body exposure 
caused the formation of larger hotspots, indicating ATP accumulation. Co-treatment 
increased the detected signal, with the presence of hotspots visible. Our results are 
supported by Veech et al. (2001) who reported that ketone body supplementation increases 
the free energy of cytosolic ATP hydrolysis, ∆GATP.  
These results reflect the findings in the ATP concentration data (Figure 3.1.1 and 3.2.1) as 
well as the literature (Arakawa et al. 1991; Chowdhury et al., 2014). Increased signal 
suggests not only ATP availability but also ATP consumption. Hence, ketone bodies in the 
presence of paraquat may preserve ATP consumption to an extent.   
4.2.5 Ketone body supplementation preserves neuronal ultrastructure and increases 
vacuolar structures 
Transmission electron microscopy analysis reveals the ultrastructure of cells, and provides 
the opportunity to qualitatively assess subcellular compartments such as the nucleus, 
mitochondria as well as vacuolar structures. We observed that exposure to paraquat caused 
an increase in chromatin disruptions (Figure 3.2.8d), while ketone body co-treatment 
decreased the severity of the nuclear disruption observed (Figure 3.2.8j). Chromatin 
condensation is commonly associated with apoptotis (Yao et al., 2001), however it can also 
occur during mitosis (Hendzel et al., 1998) and what appears to be morphologically identical 
processes, are actually distinct events: mitosis-related condensed chromatin results from 
aggregated heterochromatin while euchromatin degradation is the inducing factor in the 
chromatin condensation with later collapse and aggregation of heterochromatin observed 
during apoptosis (Hendzel et al., 1998). Our results suggest apoptosis-related chromatin 
condensation, which supports the results of paraquat decreasing cell viability (Figure 3.2.1) 
and the fact that paraquat induces apoptosis (Fei et al., 2008).  
Intact mitochondria observed in the control and ketone body groups support the 
mitochondrial morphology data (Figure 3.2.3). Cells exposed to paraquat displayed 
disrupted mitochondria, an effect also reported by others (Peixoto et al., 2004; Fei et al., 
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2008), who assessed mitochondrial function, which is intimately linked to mitochondrial 
morphology (Hoppins, 2014). In the co-treatment group a number of intact mitochondria 
are visible (Figure 3.2.8k), however they show mixed morphological characteristics, 
indicating that the paraquat-induced damage is decreased upon ketone body 
supplementation. 
Vacuolar structures are visible in all of the groups; however ketone body supplementation 
caused an apparent increase in their number, while paraquat exposure resulted in less well 
defined, more disrupted vacuoles. The vacuolar structures observed may be considered 
representative of AV (Boland et al., 2008). Our observation of increased AV with ketone 
body treatment is aligned with recent findings and link it to autophagy induction (McCarty 
et al., 2015; Camberos-Luna et al., 2015), further supporting our LC3 Western blotting data 
(Figure 3.1.4). 
4.3 Summary and conclusion  
Our investigation into the benefits of ketone bodies in the context of neurotoxicity revealed 
a number of findings. We demonstrated that the intracellular ATP distribution is controlled 
by autophagy and ketone body treatment, indicating a change in ATP demand during these 
conditions. Examples of ATP-consuming processes include transport mechanisms along the 
microtubule network (Mallik and Gross, 2004) and protein synthesis (Buttgereit and Brand, 
1995). Enzymes involved in ATP generating processes are likely more active in the hotspots 
observed, such as components of the TCA cycle.  In addition, ketone body supplementation 
improved localized ATP supply during neurotoxin exposure. However, the ATP relocalization 
effect did not reflect a change intracellular in ATP concentration. More sensitive methods to 
assess ATP levels may need to be employed, such as measuring mitochondrial respiration by 
means of an oxygraph (Skemiene et al., 2013; Phielix et al., 2008). 
In addition we observed that APP and BACE, and likely Aβ, are targeted for degradation by 
the autophagic pathway. These proteins are associated with amyloid deposition, and thus 
our results suggest a beneficial role of autophagy in clearing toxic amyloid aggregates 
present in AD. Furthermore, we have shown that ketone body treatment may enhance the 
autophagic flux and in this way confer its beneficial effects. This could explain the beneficial 
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effect of ketone bodies on a host of neurodegenerative diseases, many associated with 
protein aggregation as integral to their etiology.  
We also observed that ketone body supplementation serves a protective role in neurons 
exposed to a toxic environment; ketone body administration prevented oxidant-induced 
neuronal cell death. Mitochondrial morphology analysis, an important indicator of cell 
viability and thus the energetic capacity of neurons, revealed that cells treated with 
paraquat in the presence of ketone bodies presented with a morphological state more 
similar to control conditions, while mitochondria were completely fragmented in the injury-
induced model. However, the beneficial effect on morphology did not reflect measurable 
changes in mitochondrial polarization. This may be due to the fact that changes in 
mitochondrial morphology occur early after changes in, for example, energetic substrate 
supply (Hoppins, 2014) while depolarization is a late event preceding cell death (Kroemer et 
al., 2007).  
Our hypothesis was not fully verified as no change in ATP concentration was observed and 
results of autophagy upregulation did not always reach statistical significance. However the 
changes observed upon ketone body administration cannot be ignored.Ketone body 
supplementation preserved neuronal ultrastructure and increased the presence of 
autophagic vacuoles, verifying our findings that ketone bodies stimulate autophagic flux.  
Thus to conclude, based on our results, ketone bodies display great therapeutic value to 
improve dysfunctional autophagy and energetic supply, two major etiological factors in AD. 
In addition, they confer neuroprotection, at least in part by improving mitochondrial 
parameters (Figure 4b). This is an exciting prospect that requires further investigation. 
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Figure 4a and b: Aβ aggregation disrupts autophagy, mitochondrial function and ATP production, 
activating apoptosis (a) while ketone bodies ameliorate these defects and confer neuroprotection 
(b). 
a 
b 
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4.4 Future recommendations 
Future studies assessing additional parameters are recommended, and suggestions 
regarding the experimental model and methods employed will be offered and summarized 
below.  
Firstly, the use of a murine hypothalamic neuronal cell line, GT1-7 cells, as an experimental 
model for simulating AD, could be improved by using primary isolated neurons from GFP-
LC3 mice, which would simplify measuring the autophagic flux (Mizushima et al., 2004). In 
addition transgenic APP knock-in mice harbouring Swedish and Beyreuther/Iberian 
mutations (Saito et al., 2014) would provide a more physiologically relevant model of AD. 
Moreover, autophagic flux could be measured more accurately by employing a host of 
additional methods, including the assessment of tagged autophagic vacuoles, and/or 
lysosomes. In addition, using not only an acidification inhibitor such as bafilomycin, but also 
lysosomal-specific inhibitors such as pepstatin or E64d instead is recommended. Inhibiting 
autophagy for a longer time period, or using a higher concentration, in order to ensure 
complete inhibition could be beneficial.   
The ATP concentration could be assessed more sensitively by assessing mitochondrial 
respiration, which would also better identify the biochemical pathways employed by ketone 
bodies to enhance local ATP supply. In addition, cells could be treated with inhibitors such 
as deoxyglucose to inhibit glycolysis or potassium cyanide to inhibit oxidative 
phosphorylation, and then assessed to determine how ATP supply recovers over time. The 
use of other ATeam constructs in addition to the mitochondrially targeted one employed 
here, i.e. targeted to cytoplasmic and nuclear ATP, would enhance our knowledge of whole-
cell ATP supply.  
Finally, this work has uncovered potential research avenues that warrant future research. It 
would be important to identify how ketone bodies increase autophagic flux. A possible 
meeting point between ketone body metabolism and the process of autophagy could be the 
role of intracellular transport mechanisms. One way in which to assess this is to measure the 
activity of cellular transporters such as dynein, which require ATP to transport cargo such as 
autophagic vacuoles (Iwata et al., 2005), in response to ketone body treatment. Another 
research question to investigate is how ketone bodies influence protein synthesis, a key ATP 
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consumer within cells (Buttgereit and Brand, 1995).  Expression of mTOR, a key regulator of 
protein synthesis (Green et al., 2014), could be assessed here. Such research avenues will 
enhance our understanding and may provide new insights on how to use ketone bodies 
effectively as an adjuvant therapy in the context of neurodegeneration. 
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APPENDIX 
A.1 Supplementary results 
A.1.1 Neuronal reductive capacity following ketone body treatment 
Guided by literature, a dose response was established in order to confirm that there is no 
toxicity using the desirable ketone body concentration. Treating cells with ketone bodies (β-
OHB) yielded no significant differences in the cells’ reductive capacity compared to the 
control condition. This result was seen at both 24  (Figure A.1.1a) and 48 hrs (Figure A.1.1b) 
after treatment with concentrations of 1.5 mM, 3 mM, 6 mM, and 12 mM of ketone bodies. 
6 mM was selected as the treatment concentration for all subsequent experiments as it is 
physiologically relevant (Owen et al., 1967) and found to be non-toxic.  
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Figure A.1.1: Relative reductive capacity of GT1-7 cells following 24 h treatment (a) with 
different concentrations of beta-hydroxy butyrate (1.5 mM - 12 mM) and 48 h treatment (b),   
(n=2). 
a 
b 
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A.1.2 Amyloid beta-induced toxicity 
Initial experiments were performed using an amyloid-induced toxicity model. However, a 
great degree of variability was observed, which made this model in this particular scenario 
less suitable. Amyloid beta was found to be toxic at a concentration of both 2 and 5 µM. 
Treating cells with 2 µM for 24 hrs caused a reduction in the relative reductive capacity 
compared to the control [86.9% ± 2.4% (p<0.05)] while treating cells with 5 µM for 24 hrs 
caused an even greater reduction [61.8% ± 2.5% (p<0.05)] as displayed in Figure A.1.2. It is 
important to note that it was necessary to break up larger peptide formations that the 
synthetic amyloid product used formed naturally, through water-bath sonication in order to 
see the toxic effect demonstrated in Figure A.1.2. The protocol describing this process, 
derived from a protocol by Ryan et al. (2010) can be found in section A.2. It was decided 
against using the amyloid peptide as a model for Alzheimer’s disease due to difficulty in 
gaining consistent cell death data. In addition, challenges with timely delivery of the amyloid 
peptide (we experienced a waiting period of more than four months) further favoured 
utilization of the paraquat induced toxicity model. 
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Figure A.1.2: Relative reductive capacity of GT1-7 cells following 24 h treatment with 2 µM 
and 5 µM amyloid beta peptide.*p<0.05, (n=2). 
* 
* * 
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A.1.3 Propidium iodide exclusion assay and Hoechst counterstain to assess membrane 
integrity and nuclear condensation 
Hoechst 33342 is a DNA-intercalating dye that stains nuclei. It can also indicate regions of 
DNA condensation, or pyknosis, which is visible as small, bright areas within the nucleus. 
Pyknosis is often used as an indicator for apoptosis. Propidium iodide (PI) is a DNA 
intercalating fluorochrome which can only cross permeabilized membranes, and thus is used 
as a marker for necrosis-type cell death which is characterized by a loss of membrane 
integrity. Cells were stained with both Hoechst and PI to determine the mode of cell death 
present upon amyloid-beta treatment (Figure A.1.3). Control cells show a very low presence 
of PI-positive nuclei and also less pyknotic nuclei. Amyloid beta treatment caused an 
increase in PI-positive nuclei, as well as pyknotic nuclei. Nuclei that were both PI-positive 
and pyknotic were also observed, and were in fact more common than cells stained with PI 
alone. The double signal is indicative of late apoptosis, where the membrane becomes 
permeable. The presence of late apoptotic cells suggests that apoptosis is the main 
mechanism of amyloid beta-induced cell death, which has also been found by others (Loo et 
al., 1993; Di Carlo, 2010).  
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Figure A.1.3: Representative fluorescent micrographs of nuclei stained with Hoechst 
33342 and propidium iodide. Cells were treated as control cells (Con) or with 5 µM 
amyloid beta peptide (AB). Arrowheads indicate prodidium iodide positive cells with 
pyknotic features.10X magnificationScale bar = 100 µm. 
Con 
Con 
Con 
AB 
AB 
AB 
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A.2 Protocols  
A.2.1 WST-1 assay 
 Warm WST-1 to 37 °C 
 Add WST-1 to pre-warmed complete medium so that it makes up 5% of the well volume 
 Aspirate treatment medium from experimental and control wells of 48-well plates 
 Place 200 µl of pre-warmed medium containing WST-1 in each well using a sterile P200 
pipette tip 
 Wrap the plate in foil 
 Incubate for 2 hrs at 37 °C (5% CO2) 
 Place the foil-wrapped plate on a shaker for 1 min to mix well contents 
 Read the absorbance at a wavelength of 450 nm using a microplate reader 
 
A.2.2 Transfection with ATeam indicator 
 Seed cells at a density of 30 000 cells per well in NUNC 8-well chamber dishes 
 Allow to adhere overnight 
 Refresh the medium 
 Make up Mix 1 and Mix 2 in two separate 0.5 ml eppies 
 Mix 1: Add 10 µL lipofectamine and 100 µL serum-free medium to eppie (cold reagents) 
 Mix 2: Add 1.46 µL DNA (to obtain a concentration of 400 ng DNA), 100 µL serum-free 
medium, and 16 µL P3000 reagent to Eppendorf tube 
 Briefly vortex both eppies  
 Add Mix 1 to Mix 2 and vortex 
 Incubate for 5 min at room temperature  
 Add 10 µL of the transfection medium to each well  
 Incubate for 48 hrs at 37 °C, 5% CO2, refreshing medium 1 h after addition of the 
transfection medium to minimize exposure to the toxic transfection reagent 
 Image cells 48 - 72 hrs after transfection 
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A.2.3 ATP extraction  
 Seed cells at 1 X 106 cells per petri (35 mm diameter)  
 Grow until 80-90% confluent 
 Trypsinize cells and place the cell suspension into 2 ml Eppendorf tubes 
 Centrifuge at 4 °C  (8000 rpm, 4 min) and wash (resuspend) with cold PBS 
 Centrifuge again at 4 °C 
 Resuspend in 50 µL ice cold lysis buffer (100 mM Tris-HCl and 4 mM EDTA, pH 7.75) 
 Add 150 µL boiling lysis buffer  
 Incubate samples for 2 min at 99 °C 
 Centrifuge lysates at 10 000 rpm at 4 °C for 1 min 
 Collect supernatants for ATP detection and store at -20 °C until ATP detection 
 
A.2.4 ATP detection 
 Thaw extracted ATP samples on ice 
 Make up the ATP standard provided in the ATP kit by adding 15 µl of the standard 
solution after vortexing to a labelled sterile 500 µl Eppendorf tube together with 
135 µl ATP-free water to make 150 µl of solution containing 10-8 M ATP 
 Vortex this solution, and repeat the process by adding 15 µl of this solution and 135 
µl ATP-free water to a fresh, labelled Eppendorf tube 
 Repeat this sequence seven more times until you have a total of eight Eppendorf 
tubes, thus a range of ATP solutions ranging from 10-8 M ATP to 10-16 M ATP 
 Pipette 50 µl of the ATP-free water and each of the standards in duplicate into a 
white 96-well plate, vortexing Eppendorf tubes before each addition 
 Pipette 50 µl of samples in duplicate into the plate 
 Label where each sample is in the plate on a paper template 
 Make up the provided luciferase reagent according to the manufacturer’s 
instructions in light protected conditions 
 Flush the luminometer twice using the following substances: dH2O, 70% ethanol and 
air 
 Prime the luminometer with the luciferase reagent 
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 Set the luminometer’s injector volume to 50 µl, the integration time to 10 sec and 
the delay before starting to 5 sec 
 Select the wells to be measured and start the program 
 Use the generated relative light unit measurements of the standard curve to 
calculate the sample ATP concentrations 
 
A.2.5 Western blot analysis 
A.2.5.1 Protein extraction  
 Aliquote 1 ml RIPA buffer (recipe in section) into a 2 ml Eppendorf tube and add 
protease and phosphatase inhibitors in the following concentrations an hour or less 
before extraction:  
o Aprotinin (1 µg/ml)  
o Leupeptin (1 µg/ml)  
o PMSF (1 mM) 
o Na3VO4 (1 mM) 
o NaF (1 mM) 
o Benzamidine (1 µg/ml) 
o Pepstatin A (10 µg/ml) 
 Vortex the solution and place Eppendorf tube on ice 
 Remove treatment medium from flasks 
 Rinse three times with cold PBS, removing as much as possible residual PBS after the 
last wash with a 1 ml pipette 
 Add 50 µl of modified RIPA buffer to each flask and scrape the flask surface 
thoroughly using vertical motions 
 Transfer the scraped contents to labelled 1 ml Eppendorf tubes 
 Sonicate Eppendorf tubes  4 X 2 sec at an amplitude of six with a sec pause between 
each bout of sonication 
 Place Eppendorf tubes on ice at 4 °C for approximately 2.5 hrs or until most of the 
bubble have disappeared 
 Centrifuge for 10 min at 8000 rpm  
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 Carefully decant the supernatant into labelled Eppendorf tubes, place on ice and 
proceed with the Bradford protein determination assay immediately 
A.2.5.2 Bradford assay 
 Thaw BSA solution (0.2 mg/ml in dH2O) 
 Collect protein samples and keep on ice at all times 
 Mark 2 ml Eppendorf tubes in duplicate for each concentration of BSA and each 
sample 
 Prepare the standard curve by adding the correct amount of BSA and dH2O to the 
relevant Eppendorf tubes according to the following table, making sure vortex the 
stock solution of BSA before each addition: 
Concentration (μg/ml) Volume of BSA (μl) Volume of dH2O 
0 (Blank) 0 100 
2 10 90 
4 20 80 
8 40 60 
12 60 40 
16 80 20 
20 100 0 
 
 For the samples add 95 µl dH2O and 5 µl of protein to the relevant Eppendorf tubes 
 Vortex all tubes briefly 
 Add 900 µl Bradford working solution to each Eppendorf tubes and vortex again 
 Incubate Eppendorf tubes at room temperature for at least 5 min 
 Zero spectrophotometer by using one of the ‘blank’ Eppendorf tubes containing no 
BSA 
 Read the absorbance values by using a spectrophotometer set to 595 nm, by adding 
the contents of each Eppendorf tube to 2 ml cuvettes 
 Generate the standard curve by using the average of the read absorbance values 
against the concentration of BSA 
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 Aliquote samples into fresh Eppendorf tubes according to the volumes calculated 
from the standard curve and freeze at -80 °C until use 
A.2.5.3 Making gels using Fast-Cast kit 
 Assemble the gel casting stand using spacer and short plates  
 Fill the gap between plates to the top with dH2O using a disposable pipette 
 Wait 5 min to check for leaks and readjust if necessary until watertight  
 Remove the dH2O by tipping the rig and use paper towel if necessary 
 Make up the resolving and stacking gel according to the manufacturer’s instructions 
 Resolving gel (for one gel):  
o Add 3 ml of both Buffer A and Buffer B into a small glass beaker 
o 30 µl APS 
o 3 µl TEMED 
 Stacking gel (for one gel): 
o Add 1 ml of Buffer A and Buffer B into a separate small glass beaker 
o 10 µl APS 
o 2 µl TEMED 
 Mix the contents of both beakers thoroughly by swirling their contents 
 Pour Resolver into the gel rig using a disposable pipette to approximately 1 cm from 
the top 
 Pour the Stacker to the top using a new disposable pipette 
 Insert the appropriate comb(s) gently, avoiding air bubbles 
 Allow the gel(s) to set (30 min – 1 h) 
 Use within three weeks 
 Store at 4 °C and keep moist until use 
 
A.2.5.4 Sample preparation for Western blotting 
 Make a working solution of Laemmli’s sample buffer by adding 850µl Laemmli’s 
stock buffer solution + 150 µl β-mercaptoethanol 
  Vortex thoroughly 
 Thaw the appropriate number of samples needed on ice 
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 Add the appropriate amount of working solution of Laemmli’s and RIPA buffer, as 
calculated, to each appropriate tube 
 Close tubes and punch small hole in lid with tweezers or syringe needle 
 Heat samples on heating block (95 °C) for 5 min 
 Vortex each tube, spin down contents briefly (±10 sec) and place on ice immediately 
 
A.2.5.5 Separating proteins on Western blot gels 
 Carefully remove comb from gel and place in the U-shaped adaptor with short plate 
facing inward 
 Insert assembly into the loading system and close the latches by pushing them 
inward while pushing down gently on the plates (the centre will form the buffer 
dam) 
 Place the assembly in a gel tank and fill the buffer dam with cold 1X running buffer 
until it spills into the tank, then top up the tank until the buffer is level with the 
buffer at the top of the dam  
 Wash the wells with running buffer, using an insulin syringe 
 Add 7.5 µl of protein marker to the first lane on the far left of each gel 
 Add the appropriate amount (calculated from Bradford protein quantification) of 
sample slowly into the appropriate lane, using the gel-loading tips 
 Place the green lid with appropriate leads (black to black: red to red) on top of the 
tank and connect to the powerpack 
 Run at 120 V (constant), for approximately 1 h until the sample dye front and 
smallest standard of the protein marker reaches the bottom of the gel  
 Switch off power and disconnect electrodes. Remove gel plates from the tank and 
proceed to electrotransfer step immediately  
 
A.2.5.6 Transferring proteins to membranes using Transfer Turbo and Chemi-Doc  
 Open the “transfer pack” and place one of the stacks of blotting paper on the 
Biorad Transfer Blot cassette with the PVDF membrane on top 
 Gently roll out any air bubbles 
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 Place the gel on top of the membrane with the low molecular weight protein 
side facing towards the centre of the cassette and again gently roll out any 
trapped air bubbles 
 Place the remaining stack of blotting paper on the gel and roll out air bubbles, 
making sure to align the blotting paper, membrane and gel  
 Place lid on top and lock in place 
 Place the cassette in the Biorad Transfer Blot and set to transfer for 7-12 min, 
depending on protein 
 Check that protein has transferred and then place in methanol for ±30 sec, then 
leave to dry completely. 
 Pour Ponceau stain on top and swirl until red bands appear strongly 
 Pour off the stain and rinse with dH2O until membrane is clear. 
 Rinse membrane 3 X 5 min with TBS-T 
 Block for 2 hrs in 5% milk (5 ml fat-free Parmalat long-life milk in 100 ml TBS-T)  
 Wash 3 X 5 min in TBS-T 
 Place membrane in a 50ml tube containing 5 ml of primary antibody made up in 
TBS-T (1:1000) 
  Place on rotator in 4 0C walk-in fridge overnight 
A.2.5.7 Imaging membranes 
 Remove the membrane from the primary antibody and wash 3 X 5 min in TBS-T 
 Place membrane in a 50 ml tube containing 5ml of the appropriate secondary made 
up in TBS-T (1:10 000)  
 Prepare ECL substrate in a 1:1 ratio of solution A:B in a foil covered tube 
 Pour off the TBS-T from membrane and add ECL, spreading evenly over surface of 
membrane by gentle tilting 
 Swirl gently for 2 min 
 Place membrane on tray of Biorad Chemidoc, taking care to remove bubbles 
 Image the membrane by using ImageLab software, using the ‘Custom’ slider to select 
the optimum exposure time 
 
A.2.5.8 Stripping and reprobing membranes 
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 Wash membrane 2 X 5 min with dH2O 
 Strip with 0.2 M NaOH at room temperature for 5 min on shaker 
 Wash membrane 2 X 5 min with dH2O 
 Block with 3% milk in TBS-T for 1 h at room temperature 
 Wash 3 X 5 min in TBS-T 
 Proceed as per normal Western blot technique with primary0 antibody overnight and 
then secondary antibody 
A.2.6 Staining with amyloid antibodies 
 Seed cells in NUNC 8-well chamber dishes at a density of 10 000 cells per well 
 Treat with the appropriate agents 
 Aspirate treatment medium and rinse with pre-warmed sterile PBS 
 Add 200 µl ice cold methanol/acetone (1:1) fixative per well 
 Keep on ice and incubate for 10 min at 4°C 
 Aspirate fixative, leave to airdry for 20 min at room temperature  
 Rinse each well with 400 µl S-PBS 
 Add 100 µL FBS per well and incubate for 20 min at room temperature  
 Drain the FBS without washing 
 Add 50 µL primary antibody at the correct concentration  
 Incubate for 90 min at room temperature in a humidifying chamber 
 Rinse wells carefully with 200 µl S-PBS  
 Add 50 µl secondary antibody (1:200) to wells and incubate for 30 min at room 
temperature in a light-protected humidifying chamber  
 Add 50 µl Hoechst without removing secondary antibody to counterstain nuclei and 
incubate another 10 min in a light-protected humidifying chamber  
 Wash three times with 400 µl S-PBS and mount using a small amount of fluorescent 
mounting medium  
NOTE: All antibodies and Hoechst are made up in S-PBS. Secondary antibodies were briefly 
centrifuged and the supernatant used to prevent aspirating crystals.  
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A.2.7 Imaging cells stained for APP, Aβ and BACE 
 After staining, transport the NUNC chamber dish to the fluorescent microscope, 
protected from light 
 Set the magnification to 100X and apply a small drop of lens oil to the objective 
 Search for cells using the Dapi filter at a low intensity (10-30%) to visualize nuclei 
 Optimize the focus using the appropriate filters for the stained markers: Dapi for 
nuclei, FITC for APP, and TxRed for both Aβ and BACE 
 Obtain a minimum of five random regions per treatment group for each different 
marker 
A.2.8 Flow cytometry   
 Seed cells at 2 X 106 cells per T25 flask and treat as usual, seeding an extra flask 
treated for the control condition 
 After treatment trypsinize cells, centrifuge (1500 rpm for 3 min) and resuspend in 2 
ml warm S-PBS 
 Divide the cell suspension of each treatment group between two 15 ml tubes; 1 ml  
for DCF staining and 1 ml for TMRE  
 Add the correct concentration of DCF (50 µM) and TMRE (1 µM)  to the relevant 
tubes with the lights off 
 Add CCCP (to serve as a positive control) to one of the extra control tubes at a 
concentration of 5 µM, and add 1 µM TMRE 
 Leave the final tube unstained for an unstained control 
 Keep the tubes at 37 °C and in the dark while not using them for flow cytometry  
 Perform flow cytometry on DCF-stained cells, acquiring a minimum of 10 000 cells 
and using a 488 nm laser and 610LP, 616/23BP emission filters 
 Add 100 µl hydrogen peroxide to the control DCF tube to serve as a positive control, 
incubate for 1 min and perform flow cytometry  
 Perform flow cytometry on TMRE cells, acquiring a minimum of 10 000 cells  using a 
488 nm laser and 502LP, 530/30BP emission filters 
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A.2.9 Staining and imaging mitochondria  
 Seed cells at a density of 15 000 cells per well in a NUNC 8-chamber dish and treat  
 After treatment, refresh the medium with 300 µl pre-warmed complete medium per 
well and keep the dish in an incubated chamber  
 Aspirate the medium from the first well to be imaged and replace with 200 µl of 
medium containing 100 nM (2 µl)  TMRE and 10 µl Hoechst  
 Wait five min for the fluorochromes to infiltrate cells  
 Set the magnification to 100X and apply a small drop of lens oil to the objective 
 Search for cells using the Dapi filter at a low intensity (10-30%) to visualize nuclei 
 Optimize the focus using the appropriate filters for the stained markers: Dapi for 
Hoechst-stained nuclei and Texas Red or TMRE which binds to polarized 
mitochondria  
 Obtain a minimum of five cells per treatment group  
 
A.2.10 Morphological assessment of mitochondria  
 After imaging mitochondria as described above, raw images were analysed using 
ImageJ software according to the following sequence:  
o Binarize images, apply the ‘Concolve’ and then the ‘Gaussian blur’ filters and 
adjust the threshold to distinguish mitochondria from background signal 
o Quantify mitochondrial morphological characteristics and use them to 
calculate mitochondrial length (aspect ratio) and the degree of branching 
(form factor) 
o Aspect ratio: ratio between the major and minor axes of the ellipse 
equivalent to the mitochondrion 
o Form factor: (Pm2)/4πAm. Pm is the length of the mitochondrial outline and 
Am is the area of the mitochondrion 
o A minimum of three cells on three separate micrographs were analysed in 
this manner and the obtained aspect ratio and form factor values averaged   
A.2.11 Imaging cells stained with dichlorofluorescein (DCF) 
 Seed cells at a density of 30 000 cells per well in a NUNC 8-chamber dish and treat  
Stellenbosch University  https://scholar.sun.ac.za
120 
 
 After treatment, refresh the medium with 300 µl pre-warmed complete medium 
containing 50 µM DCF dye and Hoechst (1:200) 
 Allow the dye to develop for 20 min, keeping the dish incubated and protected from 
light 
 Set the magnification to 100X and apply a small drop of lens oil to the objective 
 Search for cells using the Dapi filter at a low intensity (10-30%) to visualize nuclei 
 Optimize the focus using the appropriate filters for the stained markers: Dapi for 
Hoechst-stained nuclei and FITC for DCF 
 Capture a minimum of five images per treatment group 
A.3 Buffers and solutions 
A.3.1 RIPA buffer 
Prepare 100 ml modified RIPA buffer as follows: 
 Add 790 mg Tris base to 75 ml dH20 
 Add 900 mg NaCl and stir the solution until all solids are dissolved 
 Using HCl, adjust the pH to 7.4 
 Add 10 ml of 10% NP-40 to the solution 
 Add 2.5 ml of 10% Na-deoxycholate and stir until the solution is clear 
 Add 1 ml of 100 mM EDTA to the solution 
 Adjust the volume to 100 ml using a graduated cylinder 
 Store RIPA buffer at 2-8 °C until ready to use 
 
A.3.2 Phosphate buffered saline (PBS) 
 Dissolve the following reagents in 1 l dH20: 
o 8 g NaCl 
o 0.2 KCl 
o 1.44 g Na2HPO4 
o 0.24 g KH2PO4 
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A.3.3 Bradford stock solution 
 Dilute 500 mg Coomassie Brilliant blue G250 in 250 ml 95% ethanol 
 Add 500 ml phosphoric acid, mix thoroughly using a stirrer bar 
 Adjust the volume to 1 l with dH20 
 Filter the solution and store at 4 °C  
Working solution: 
 Dilute the stock solution in a 1:5 ratio with dH20 
 Filter with two filter papers to obtain a solution with a light brown colour (light 
sensitive) 
 
A.3.4 Laemmli’s loading buffer 
 Mix the following ingredients to make up stock solution: 
o 3.8 ml dH2O 
o 1 ml 0.5 M Tris-HCl, pH 6.8 
o 0.8 ml glycerol 
o 1.6 ml 10% (w/v) SDS 
o 0.4 ml 0.05% (w/v) Bromophenol blue 
A.3.5 Running buffer (10X) 
 Dissolve 60.6 g Tris and 288g glycine in 1.5 l dH2O  
 Add 20 g SDS 
 pH to 8.6 with concentrated HCl and then make up the volume to 2 l with dH2O 
A.3.6 Tris-buffered saline (TBS)  
 Dissolve 48.4 g Tris and 160 g NaCl in 1200 ml dH2O 
 Mix the solution using a magnetic stirrer 
 Adjust the pH to 7.6 with concentrated HCl 
 Make up to 2 l with d dH2O 
 Store at room temperature 
 To make 1 l of TBS-T working solution dilute 100 ml stock in 900 ml dH2O and add 1 
ml Tween-20 
 Mix the solution until clear 
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A.3.7 Amyloid beta preparation  
 Add 22.15 µL DMSO to the amyloid salt in the vial to make up an undiluted stock 
solution of 10 mM 
 Add 443 µL of sterile PBS to the 10 mM solution to make up a stock solution of 500 
µM   
 Make aliquots at appropriate volumes and store at -20 °C until use 
 When needed, thaw the appropriate number of Eppendorf tubes and add medium to 
gain the required concentration  
 Sonicate the solution for 10 min in a water-bath sonicator to break up existing 
peptides 
 Keep at 4 °C overnight to allow oligomers to form 
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